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This  Working  Paper  has  been  prepared  as  support  for  the  European  Commission’s 
Communication on the mid term review of the Strategy on Life Sciences and Biotechnology 
(hereinafter "the Communication"). 
1.  BACKGROUND 
In  January  2002,  the  Commission  adopted  a  Strategy  for  Europe  on  Life  Sciences  and 
Biotechnology
1.  This  was  in  response  to  the  importance  attached  to  life  sciences  and 
biotechnology by the European Council. It proposes a comprehensive roadmap up to 2010 
and puts the sector at the forefront of those leading technologies which are helping to take the 
European  Union  towards  its  long-term  strategic  goal  established  by  the  Lisbon  European 
Council in March 2000. 
The strategy set out by the Commission consists of two parts: policy orientations and a 30 
point plan to transform policy into action. It sets out what was is needed from the Commission 
and the other European Institutions, but also recommends actions for other public and private 
stakeholders.  The  strategy  therefore  provides  a  framework  and  a  reference  point  both  for 
action undertaken by the many stakeholders concerned within their own responsibilities and 
for co-operation between these stakeholders. 
The Commission has reported regularly on the progress made and adopted progress reports, 
supported  by  Staff  Working  papers  in  2003,  2004  and  2005.  The  2005  progress  report
2 
foresees that the Commission will: 
–  Carry out an independent study aimed at providing a comprehensive assessment and cost-
benefit  analysis  of  the  consequences,  opportunities  and  challenges  that  applications  of 
modern biotechnology present for Europe in terms of economic, social and environmental 
aspects, 
–  Draw on both the study and an in-depth assessment of the progress achieved since 2002 to 
update the Community Strategy on Life Sciences and Biotechnology in good time for the 
2007 Spring European Council. 
The study referred to in the first bullet point has been finalised by the European Commission 
in April 2007. It is available online
3. In order to take full account of this study, it was decided 
to  slightly  postpone  the  mid  term  review  after  the  original  deadline  of  the  2007  Spring 
Council.  
2.  OBJECTIVES 
The main objective of the mid term review, as mentioned in the 2005 progress report, is to 
reflect on the role of Life Sciences and Biotechnology in relation to the main European policy 
goals.  This  implies  in  particular  an  understanding  of  how  the  adoption  of  modern 
biotechnology  in  the  various  production  sectors  can  contribute  to  the  objectives  of  the 
                                                 
1  COM(2002)27 of 23/01/2002 
2  COM(2005) 286 final of 29/06/2005 - http://ec.europa.eu/biotechnology/pdf/com2005286final_en.pdf 
3  « BIO4EU » - http://bio4eu.jrc.es/index.html  
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European policy strategies on economic growth, sustainable development and environmental 
preservation. 
It  may  already  be  understood  that  biotechnology  goes  far  beyond  the  sole  example  of 
genetically modified organisms to be used in agro food, which actually represent only a tiny 
part of biotechnology. Modern biotechnology
4 plays an increasing role in the development of 
new  treatments  and  preventions  of  diseases  and  the  industrial  landscape  in  Europe  and 
elsewhere  is  steadily  being  transformed  by  the  penetration  of  biotechnology  into  a  large 
number of industries including food and feed, chemical, paper and pulp, textiles, and energy. 
New,  eco-efficient  and  innovative  industrial  sectors  (the  "bio-economy")  are  emerging  as 
biotechnology has introduced a new dimension to innovation in agriculture and other sectors, 
offering  eco-efficient  and  cost  effective  means  to  produce  a  diverse  array  of  novel  value 
added products and tools. It has the potential to improve qualitative and quantitative aspects 
of food, feed, fibre and fuel production, reduce the dependency on chemicals and fossil fuels, 
diminish  over-cultivation  and  erosion,  and  lower  the  cost  of  raw  materials,  all  in  an 
environmentally sustainable manner. 
To reach the present objective, and following the request of the European Parliament, the 
Commission has undertaken the “BIO4EU” study to make an assessment of the economic, 
social  and  environmental  impact  of  biotechnology  and  genetic  engineering,  including 
genetically modified organisms, in the light of major European policy goals formulated in the 
Lisbon strategy, Agenda 21, and sustainable development. Furthermore, the Commission has 
prepared a report
5 on the competitiveness of the European biotechnology industry and its 
possible contribution to growth and employment. 
It appears from the analysis of the action plan that the Commission plays a major role in the 
development  of  biotechnology  in  Europe,  in  the  field  of  research,  education,  regulation, 
finances,  enforcement  and  international  cooperation,  this  list  being  non-exhaustive.  It  is 
evident that, if all actions certainly have an interest, they do not all have the same priority in 
the current context, nor have they reached the same level of achievement (see Annex I for the 
refocused priorities). 
In  addition  to  this,  the  present  Staff  Working  Paper  presents  a  detailed  overview  of  the 
progress made in implementing the action plan set out in the Strategy, the main achievements 
being highlighted in a chart annexed to this document (Annex II). 
The present document, as well as the Communication describes how the Commission intends 
to pursue its involvement in the field of biotechnology, and the means it envisages to use. 
Nonetheless, the Commission is only one of the actors in the development of biotechnology in 
Europe, aside Member States and stakeholder who should also continue to implement the 
Strategy. The Commission intends to present the mid term review to other institutions and 
stakeholders, to explore how to maximise synergies and improve the implementation of the 
Strategy. 
                                                 
4  According  to  the  latest  OECD  definition,  modern  biotechnology  is  defined  as  "the  application  of 
science and technology to living organisms as well as parts, products and models thereof, to alter living 
or  non-living  materials  for  the  production  of  knowledge,  goods  and  services" 
http://stats.oecd.org/glossary/index.htm 
5  http://ec.europa.eu/enterprise/phabiocom/comp_biotech_comp.htm  
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3.  PROCEDURAL ISSUES AND CONSULTATION OF INTERESTED PARTIES 
3.1.  Procedure 
The aim of the present Staff Working Paper is first to take stock of progress made on 
the actions contained in the original strategy from 2002, both from the legal/political 
perspective and on the basis of concrete facts, and assess what can be developed, 
improved, continued or simplified.  
This  report  is  based  on  contributions  made  by  Commission  services,  as  well  as 
stakeholders and national authorities which were consulted in July-September 2006. 
It  also  builds  on  other  Commission  reports,  on  the  implementation  of  specific 
sectoral legislation, such as for example Regulation 1829/2003
6, and on horizontal 
issues (such as horizontal policies in the field of innovation). 
On  the  basis  of  those  elements,  the  Staff  Working  Paper  presents  an  exhaustive 
review of all actions for the 2002-2006 period and makes suggestions for a simplified 
and refocused Life Sciences and Biotechnology Strategy for the 2007-2010 period, 
which  are  further  elaborated  in  the  Communication.  To  this  extent,  the  current 
exercise  goes  beyond  a  mere  reporting  exercise  and  defines  clear  and  concrete 
political objectives, with deliverables, for the 2010 perspective.  
The Strategy was purposely large in content and actions, aiming at an initial mapping 
of the situation which would allow for identification of relevant policy areas. The 
Strategy has been successful in achieving this and most of the actions contained in 
the Strategy have been or are currently being implemented.  
The preliminary conclusion is that the achievements are consequential and call for a 
continuation of the Strategy, which nonetheless needs to be partially refocused in 
view of the changes undergone since it was designed. 
The second conclusion is that most of the actions appear to be still pertinent. This is 
somehow not a surprise given the very broad scope and long term perspective of the 
Life Sciences and Biotechnology Strategy. 
Nonetheless, the corollary of this is that some of the foreseen actions, such as in the 
field of education or regional policy, are actually so broad that they are difficult to 
evaluate,  since  the  relevant  corresponding  EC  policies  are  not  life  sciences  and 
biotechnology-specific. 
The analysis of the implementation of the action plan relies on a list of priorities, 
which  envisage  three  categories  of  action,  those  needing  to  be  reinforced,  those 
which  should  be  continued  and  finally  those  which  have  been  achieved.  This 
constitutes the backbone of the political orientations contained in the Communication  
Concrete deliverables have also been assigned for priority actions, which will permit 
a more thorough monitoring and evaluation of the current Strategy for the years to 
come, and help with reflection upon possible post 2010 initiatives. 
                                                 
6  COM(206) 626 final of 25/10/2006  
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3.2.  Consultation of interested parties 
A public consultation was launched on 5 July 2006 and was open for comments until 
30  September  2006.  It  was  addressed  to  a  very  broad  range  of  "institutional" 
stakeholders
7, identified on the basis of contact lists proposed by all Commission 
services, and put online on the Europa webpage for contribution by all citizens
8. The 
consultation was based on the 2002 Life Sciences and Biotechnology Action plan, 
complemented by emerging issues identified in the 2004 and 2005 Progress Reports. 
This consultation allows drawing upon a wide range of views with respect to both the 
positive potential and short-comings of the actions.  
The Commission received over 30 responses from individuals and organisations in 
16  countries  representing  a  wide  range  of  stakeholders  (consumer  and  patient 
organisations,  farmers,  NGOs  and  other  interest  groups,  research  organisations, 
private companies and individual citizens). The overall number of responses may 
appear very limited, but some of the answers received originated from very large 
organisations, both from the industry and NGO side, representing a very substantial 
number of companies or associations established at international level. While some 
stakeholders chose to provide only general comments assessing the Strategy, others 
chose to also submit detailed suggestions for refining specific actions. In general, the 
responses provide a positive assessment of the Strategy. 
Aside from this consultation on the Action Plan, discussions on the mid term review 
have also taken place with the contact network with Member States ministries with 
responsibility for competitiveness in biotechnology
9, the industry and NGOs within 
the  framework  of  the  "Bio4EU"  study
10,  the  Commission's  Competitiveness  in 
Biotechnology  Advisory  Group  and  the  newly  established  network  of  high  level 
officials on the Knowledge-Based Bio-Economy (KBBE-NET). Both industry and 
NGOs were satisfied to be consulted. 
The  conclusions  from  these  different  consultations  are  that  the  contributions  are 
largely in agreement with the preliminary assessment done by the Commission and 
they match the suggested way forward described in the current Staff Working Paper. 
4.  ANALYSIS OF THE IMPLEMENTATION OF THE LIFE SCIENCES AND BIOTECHNOLOGY 
ACTION PLAN 
Action 1 – Education and training  
Reference to ongoing EU education programs will need to be updated to reflect the 
evolution  of  education  programs  "The  Commission  will,  together  with  competent 
                                                 
7  Consulted stakeholders include representative from industry, environmental NGOs, consumer groups, 
ethics  organisations/National  Committees,  Member  State's  competent  authorities,  national/regional 
Research  institutes,  academia,  competent  authorities  from  third  countries,  agricultural  organisation, 
retail sector, international institutions, chambers of commerce and specialised consultants. 
8  http://ec.europa.eu/biotechnology/index_en.htm 
9  http://ec.europa.eu/enterprise/phabiocom/comp_biotech_commit.htm 
10  http://bio4eu.jrc.es/stakeholders.html  
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authorities in Member States, identify the education needs in life sciences within the 
‘Ten-year  objectives  for  learning  in  the  knowledge  society’  the  education  and 
training contribution to the Lisbon strategy and the 10-year work programme on 
Education and Training 2010 – and from 2007 on under the integrated Lifelong 
Learning Programme". After carrying out thorough research in the Compendia of 
Centralised Comenius Actions (Comenius 2.1 projects and Comenius 3 Networks) 
for the whole period of Socrates II programme (2000 to 2006 included), it appears 
that there is no project or network in the area of Biosciences and Biotechnology. 
There are many projects concerning sciences in general but none on biosciences. 
Despite the high importance of education it may prove difficult to go beyond what is 
already  contained  in  the  Action  Plan  and  a  general  political  recommendation  to 
develop and strengthen education in the field of life sciences, given the absence of 
more specific sectoral information.  
Action successfully implemented and will be further pursued 
Action 2a - Match a skilled workforce with job opportunities  
This  action  aiming  at  matching  a  skilled  workforce  with  job  opportunities  is 
particularly important in the context of the Lisbon strategy.  
The Commission established in 1993 the EURES portal in order to  facilitate the 
geographic  mobility  of  workers  as  a  means  to  match  job  opportunities  with 
appropriate and well-skilled candidates, and to contribute thereby to the development 
of a genuine labour market at the European level. The occasion of the 2006 European 
Year  of  Workers'  mobility  has  provided  considerable  impetus  to  the  portal,  by 
enabling  all  EU  citizens  to  access  directly,  in  their  own  language,  all  job 
opportunities published by the Public Employment Services, i.e. around 1 million 
jobs  at  any  given  time.  In  addition  to  the  access  to  job  vacancies,  the  EURES 
platform offers the possibility for jobseekers in all activity areas to post their CV and 
access comprehensive and up to date information on living and working conditions 
in 30 countries. Beyond information provision, the EURES portal is supported by a 
network  of  750  advisors,  located  in  all  EU  regions,  with  the  aim  of  providing 
customised assistance to workers and their families in all matters relating to their 
mobility experience.  
The EURES Job Mobility Portal
11 is a key Commission initiative in this respect. 
Action successfully implemented and will be further pursued 
Action 2b – Fight brain drain  
The  Commission  foresees  a  new  "skill  and  mobility  action  plan",  which  will 
contribute to fulfilling the objectives of this action aimed at attracting and retaining 
scientists.  The  European Charter  for  Researchers  and  a  Code  of Conduct  for  the 
recruitment  of  researchers  are  now  being  implemented  and  a  number  of  specific 
actions have been supported under the 6th Framework Programme for Research 2002 
                                                 
11  http://ec.europa.eu/eures/home.jsp?lang=en  
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– 2006 (hereinafter "FP6"). The implementation of Action 2b will need to be updated 
in light of FP7. 
In the frame of the integrated strategy the Commission has set out to enhance the 
quality  and  quantity  of  researchers  in  Europe.  In  March  2005  the  Commission 
adopted  a  Recommendation  to  Member  States  on  the  European  Charter  for 
Researchers and a Code of Conduct for the recruitment of researchers. Together with 
the  formal  launch  and  unfolding  across  Europe  of  the  ERA-MORE  network
12  of 
proximity assistance to mobile researchers in 2004, as well as the Directive on the 
entry and stay in the EU of third country researchers
13, these are highlights of key 
steps towards the creation of a real European researchers’ labour market.  
The  European  Charter  for  Researchers  addresses  the  roles,  responsibilities  and 
entitlements  of  researchers  as  professionals  and  those  of  their  employers  or  the 
funding organisations. It aims at ensuring that the relationship between these parties 
contributes  to  successful  performance  in  the  generation,  transfer  and  sharing  of 
knowledge, and to the career development of researchers. The Code of Conduct for 
the  Recruitment  of  Researchers  aims  to  improve  recruitment,  to  make  selection 
procedures fairer and more transparent and proposes appropriate means of judging 
merit,  which  should  not  be  based  just  on  traditional  academic  criteria,  e.g.  the 
number  of  publications,  but  on  a  wider  range  of  evaluation  criteria,  including 
teaching,  supervision,  patents,  spin-offs,  other  teamwork,  knowledge  transfer, 
research management and public awareness activities.  
One  year after its adoption various initiatives to raise awareness and support the 
implementation of the Recommendation have been undertaken at European as well 
as  at  national  level.  More  than  one  hundred  organisations  all  over  Europe  have 
already signed the Charter. 
The  Marie  Curie  actions  in  FP6  were  conceived  to  give  broad  support  for  the 
development of abundant, dynamic and world class human resources in European 
Research systems. The actions comprise support for researchers at all stages of their 
careers from postgraduate researchers to senior professors with a number of aims: to 
facilitate movement between countries in Europe; to develop their careers outside 
Europe; and to attract the best researchers from around the world to come to Europe 
and undertake research. Support is on a bottom-up basis, across the entire range of 
scientific disciplines, with selection based on excellence. In all Marie Curie actions 
the life sciences are heavily represented and account for between a quarter and a third 
of the total budget. 
To date in FP6, just over €500 million has been committed in the Marie Curie actions 
across the broad spectrum of life sciences and biotechnology in FP6. This support 
has taken various forms. It has enabled approximately 1000 experienced researchers 
to apply for individual postdoctoral support at the research institution of their choice 
in  the  public  or  private  sector  in  Europe  or  in  third  countries.  It  has  funded 
institutions  to  hire  postdoctoral  researchers  to  work  on  collaborative  research 
                                                 
12  http://ec.europa.eu/eracareers/index_en.cfm 
13  Council Directive 2005/71/EC of 12 October 2005 on a specific procedure for admitting third-country 
nationals for the purposes of scientific research, OJ L 289, 3.11.2005, p. 15–22  
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projects. About 1000 full-time, three year PhD positions have been funded, allowing 
researchers  at  the  beginning  of  their  careers  to  access  excellent  foreign  doctoral 
research programmes. Nearly €10 million has been used to fund conferences and 
dissemination activities. Funding for 45 teams has been provided (€70 million) to 
allow experienced researchers to set up their own research groups for the first time in 
industry  or  academia.  Furthermore,  11  top-level  “Chair”  appointments  have  been 
made,  attracting  world-class  researchers  and  encouraging  them  to  resume  their 
careers in Europe (€6.5 million). 
The trans-national access activity of the Research Infrastructures programme has also 
provided opportunities for several thousand researchers to enjoy hands-on access to 
35 life sciences research infrastructures, with tens of thousands also able to access 
some of these resources remotely.  
Finally,  a  large  number  of  the  Network  of  Excellence  implemented  under  FP6 
include the programme “Integration and Strengthening of ERA”, which incorporates 
training and mobility activities. 
The  following  provide  a  comprehensive  overview  of  the  different  actions 
implemented in FP6 contributing to training and mobility of researchers in the area 
of Life Sciences and Biotechnology. 
–  47 Research Training networks (€130 million) funding 400 full-time, 3 year PhD 
positions alongside more than 500 years of postdoctoral support; 
–  61 Early Stage Training contracts (€90 million) funding 600 full-time, 3 year PhD 
positions; 
–  50 Transfer of Knowledge “Development” contracts (€26 million) aimed at skills 
transfer mainly to Convergence Regions; 
–  17 contracts (€7 million) to stimulate exchange and partnership between industry 
and  academia  in  all  areas  of  life  sciences  with  a  heavy  emphasis  on 
biotechnology, supporting 60 years of experienced researchers to move sectors 
temporarily; 
–  Approximately 500 individual, postdoctoral fellowships of up to 2 years duration 
for mobility within Europe (€100 million); 
–  Approximately 100 individual, postdoctoral fellowships for excellent European 
researchers  to  carry  out  research  in  a  third  country  for  up  to  2  years  and 
subsequently return to Europe (€25 million); 
–  Approximately 160 individual, postdoctoral fellowships to bring in excellent third 
country researchers to carry out research in Europe (€25 million); 
–  Approximately  200  experienced  European  researchers  have  been  given  grants 
(€16 million in total) to enable them to reintegrate in Europe following a longer 
stay in a third country;  
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–  In terms of dissemination and exploitation activities, Marie Curie actions have 
supported 4 large conferences (€ 400,000) and 18 linked conferences/workshops/ 
summer schools (€8 million); 
–  Trans-national access of researchers is supported under FP6 to 35 life sciences 
research infrastructures, such as animal repositories, synchrotron beam-lines for 
structural biology, NMR (Nuclear Magnetic Resonance) installations, sequence 
databases or natural history sample collections. A total of 3500 researchers will 
have  “hands  on”  access  and  tens  of  thousands  of  researchers  will  use  the 
infrastructures remotely. These trans-national access activities have a budget of 
€22  million  devoted  to  the  life  sciences,  plus  some  smaller  scale  funding  for 
training the infrastructure users; 
–  Projects exploring the use of e-learning on sustainable development and land use. 
The investment in human resources activities in People and Capacities programmes 
has  maintained  the  same  approximate  percentage  of  total  FP  funding  (10%  for 
People) as in FP6, which reflects the continued importance of investing in human 
resource  following  the  Lisbon  Agenda.  No  major  changes  are  needed,  the  main 
thrusts of the People programme show clear continuation from FP6. 
The strategies developed in previous Framework Programmes to attract and retain 
scientists  and  avoid  brain  drain  will  be  built  upon  and  continued.  The  Seventh 
Framework Programme (2006-2013) has an entire programme “People” dedicated to 
attracting  and  retaining  researchers  in  Europe,  and  ensuring  life-long  career 
development opportunities. Continued efforts will be undertaken to attract the best 
foreign  researchers  and  support the return of EU researchers established in other 
parts of the world. 
In  synergy  with  the  activities  proposed  under  the  Communication  "A  Mobility 
Strategy for the European Research Area", the Commission launched in 2002 the 
"Skills  and  Mobility  Action  Plan",  as  a  contribution  to  achieving  the  Lisbon 
objectives  of  more  and  better  jobs,  greater  social  cohesion  and  a  dynamic 
knowledge-based society. The Action Plan, which was adopted by the Commission 
in February 2002 and endorsed by the Barcelona European Council in March 2002, 
aims at expanding occupational mobility and skills development, by ensuring that 
education and training systems become more responsive to the labour market, that 
administrative and legal barriers to mobility are duly removed, and that information 
about existing opportunities for mobility and related support mechanisms are set up, 
covering all sectors of activity in the EU. The final report for the Action Plan will be 
presented  by  the  Commission.  A  new  Action  Plan,  involving  all  operational 
Commission  services  dealing  with  mobility,  is  foreseen  as  a  follow  up  to  the 
European Year of Workers' Mobility of 2006. 
On a very practical level the Commission is working on better co-ordination of the 
social security schemes of EU Member States and with third countries
14. This is a 
key  issue  for  persons  exercising  their  fundamental  right  to  free  movement.  This 
concerns e.g. the portability of pension rights but also the right to free movement 
                                                 
14  http://ec.europa.eu/employment_social/social_security_schemes/relations_en.htm  
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with third countries (e.g. agreement on free movement of persons with Switzerland 
which entered into force in 2002). 
Action successfully implemented and will be further pursued under FP7 
Action 3 - Research  
Under FP6 
FP6 has brought a strong impetus to Life Sciences and Biotechnology research in 
Europe,  in  particular  in terms  of  critical  mass  of  human  and  financial  resources, 
sharing  of  knowledge  and  facilities,  strengthening  of  scientific  excellence, 
coordination of national activities and support to EU policies.  
The activities undertaken in the context of FP6 illustrate the broad application of Life 
Sciences and Biotechnology research to a large number of industrial sectors (e.g. 
health, food, agriculture, chemical, energy) and its continuing evolution integrating 
new  and  emerging  disciplines  such  as  the  “omics”  technologies  (genomics, 
proteomics,  metabolomics,  glycomics…)  as  well  as  its  convergence  with  other 
technologies  (nano,  info,  cognitive  and  social  sciences).  The  importance  of 
Nanosciences and nanotechnology for underpinning the advances in life sciences 
and biotechnology was stressed in the Commission’s Communication “Towards a 
European Strategy for Nanotechnology”
15 adopted on 12 May 2004. The disciplines 
of synthetic and systems biology are gaining prominence at the embodiment of the 
future of biological sciences.
16. 
Around  €2512  million  have  been  awarded  for  "Life  sciences,  genomics  and 
biotechnology  for  health"  research.  These  funds  went  to  around  613  projects, 
involving  more  than  7600  participants.  These  projects  ranged  from  fundamental 
genomics  to  applied  genomics,  poverty  related  diseases  cancer,  cardio-vascular 
diseases, diabetes, age and brain related diseases as well as rare diseases. 
Another €756 million have been awarded under the thematic priority "Food quality 
and safety research". These funds went to 186 projects, involving more than 3032 
participants. These projects ranged from food processing and safety to nutrition and 
food related diseases as well as agriculture-related research topics including animal 
and plant production systems, forestry, plant and animal biotechnology. 
A number of projects dedicated to renewable energy based on biomass e.g. energy 
crops and agrowastes, were funded (approx. €20 million awarded) under the thematic 
priority "Sustainable development" in the specific programme "Sustainable Energy 
Systems".  
A  number  of  projects  on  innovative  bioprocesses  for  water,  water-waste,  sludge, 
sediments  and  soil  treatment/remediation  have  been  funded  under  the  priority 
"Global changes and ecosystems". 
                                                 
15  Towards a European Strategy for Nanotechnology COM(2004) 338 
16  http://ec.europa.eu/research/biotechnology/ec-us/index_en.html  
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Socio-economic research was among others funded under the priority "Citizen and 
governance" addressing issues such as the dynamics of institutions and markets in 
Europe, indicators for emerging technology sectors and regional models. 
Industrial biotechnology was a research area which during the implementation of 
FP6  emerged  as  an  important  eco-efficient  innovative  industrial  sector.  Industrial 
biotechnology refers to its use in manufacturing (chemicals, pharmaceutical, food 
and drinks, pulp and paper, textile, energy) at every stage in the process, from supply 
of raw materials to end-of-pipe and clean-up. It is seen as a key technology for the 
sustainable  development  of  societies  worldwide.  Biological  processes  offer  the 
prospect  of  cheap  and  renewable  resources,  lower  energy  and  less  waste 
consumption,  reduction  of  greenhouse  gas  emissions,  reduced  dependence  on 
(imported)  petroleum  and  new  markets  for  European  agriculture.  Examples  of 
products already on the market include one of the most widely used fibrous polymers 
for  household  applications  such  as  carpeting,  a  biodegradable  plastic  or  use  of 
enzymes  in  the  manufacture  of  chemicals.  This  is  a  field  in  which  European 
companies take a world lead. Industrial biotechnology is expected to contribute to a 
smooth transition from a fossil-fuel-based economy to a bio-based economy. Recent 
reports  predict  annual  growth  rates  of  5%  for  fermentation  products  and  a  10% 
market share of bio-based products within the chemical industry (around €100 billion 
value)
17. Although numbers may differ, all reports agree that industrial biotech will 
play a significant role the future. 
Several  Member  States  (e.g.  UK,  Belgium,  Germany,  The  Netherlands,  Sweden, 
France…)  have  launched  their  own  initiatives  and  additional  public–private 
partnerships  on  Industrial  Biotechnology  have  been  set  up  recently  in  the 
Netherlands and Belgium. Australia, USA, Canada, and Japan and many emerging 
countries  such  as  China,  India,  Brazil,  and  South  Africa  are  stepping  up  their 
financial and strategic efforts to remain in the scene. An international dialogue is also 
taking place at the level of the OECD
18.  
The  Commission,  recognising  Industrial  Biotechnology  as  a  key  industrial 
technology  with  great  potential  for  sustainability  (in  line  with  the  Environmental 
Technology Action Plan
19) and cost efficiency, integrating different fields of research 
from nano-scale to engineering and production and with many sectoral applications, 
has for its part: 
–  Supported  research  in  the  area  of  industrial  biotechnology  for  a  total  of  €61 
million (under the thematic priority "Nanotechnologies and Materials"; 
–  Supported the launch of the “Industrial Biotechnology Platform” as part of the 
wider Sustainable Chemistry Technology Platform in order to boost this area in 
Europe; 
–  Ensured that Industrial Biotechnology becomes one of the priorities in FP7 under 
the theme “Food, Agriculture, Fisheries, and Biotechnology” as well as under the 
                                                 
17  http://ec.europa.eu/enterprise/phabiocom/docs/cbag_2006_final_version.pdf 
18  http://www.oecd.org/topic/0,2686,en_2649_37437_1_1_1_1_37437,00.html 
19  http://ec.europa.eu/environment/etap/index_en.htm  
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themes  "Nanosciences,  nanotechnologies,  materials  and  new  production 
technologies and "Energy". It will form an important pillar of the “Knowledge 
Based Bioeconomy”. 
Industry,  and  in  particular Small  &  Medium  Enterprises  (SME)  have  benefited 
from the FP6 .In the Health Research Priority 17% of all participating partners in 
projects funded are SMEs (representing around 14 % of the budget). As expected, the 
area  “Application  of  knowledge  and  technologies  in  the  field  of  genomics  and 
biotechnology for health" attracted the highest number of industrial partners within 
Health Research Priority. The participation of SME's was in particular high in the 
diagnostic sector (42% of the proposals received in the specific SME call). Indeed 
the diagnostic sector is closer, its products are faster to the market and the risk is 
lower both financially and scientifically, compared to the drug and therapies sector. 
This situation is shared by investors and active owners of SMEs, such as venture 
capitalists.  
Under  the  thematic  priority  “Food  Quality  and  Safety"  19%  of  all  participating 
partners in projects funded are SMEs (representing around 12 % of the budget). 
In  addition  to  the  participation  in  the  activities  implemented  under  the  priority 
thematic areas, two specific schemes for SMEs having a potential to innovate but 
with limited research capacity have been implemented. Within these schemes, SMEs 
or groupings dominated by SMEs may entrust research work to solve their particular 
problems to research performers (research institutes, universities etc.) About 23% of 
the  budget  allocated  to  these  specific  activities  for  SME’s has  been  attributed  to 
research in the field of Life Sciences and Biotechnology. 
Three  main  actions  supporting  Research  Infrastructures  in  Europe  were  taken 
under FP6, with some focus on the Life Sciences and Biotechnologies: 
–  20 projects dedicated to Life Sciences have been awarded an EU contribution of 
€66 million. Life Sciences will also benefit indirectly from a number of large 
multidisciplinary infrastructure projects such as access to synchrotrons, to neutron 
sources or to natural history museum collections, as well as use of the GEANT 
high  capacity  academic  network,  of  the  DEISA  distributed  infrastructure  for 
supercomputing applications, and of the network enabling grids for e-science in 
Europe; 
–  The  European  Commission  services  initiated  an exercise  for  mapping  existing 
Research Infrastructures in Europe, in collaboration with the European Science 
Foundation and the EUROHORCs. This will assist in the gaining of an up-to-date 
picture about the current pattern, and will go towards understanding the needs for 
future Research Infrastructures; 
–  The Council of Ministers in its meetings of 1-3 July and 25-26 November 2004 
also proposed to develop a strategic roadmap for new Research Infrastructures in 
Europe over the next 10 to 20 years. The European Strategy Forum for Research 
Infrastructures (ESFRI) endorsed this work and is now preparing a roadmap that 
will in particular cover several major projects for the "Biological and Medical 
Sciences".  
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In addition to this, the Commission is in the process of developing core competences 
in bioinformatics (including bioinformatics infrastructure). It has been accepted as a 
member of the European Molecular Biology Network (EMBnet)
20 which is the only 
organisation world-wide bringing bioinformatics professionals to work together. The 
combined expertise of the nodes allows EMBnet to provide services to the European 
molecular biology community which encompasses more than can be provided by a 
single node. 
Concrete progress has been made in structuring the European Research Area and 
the active participation of all Member States has been achieved. The coordination of 
national  policies  has  been  initiated  in  the  context  of  the  Standing Committee  on 
Agriculture Research (SCAR) and of the Member States Network on the Knowledge 
Based Bio-Economy (KBBE-NET). As announced in the 3
rd progress report on the 
implementation of the strategy on Life Sciences and Biotechnology
21, the KBBE-
NET has been established, bringing together high level officials from Member States, 
acceding  and  candidate  countries  to  support  the  European  Commission  and  the 
Member  States  to  achieve  a  coordinated  effort  in  the  development  and 
implementation of a European research policy for a knowledge-based bio-economy. 
This involves: 
–  Strategic discussion and recommendations for establishing a European Research 
Agenda in the long term (FP7, and beyond) which should allow the building of a 
European Knowledge Based Bio-Economy. The work should also contribute to 
the midterm review of the EU Life Sciences and Biotechnology Strategy in 2006-
2007; 
–  Enhancing exchange of information between Member States regarding national 
research policies and mapping of activities including international cooperation; 
–  Enhancing  cooperation  between  Member  States  (joint  research  programmes, 
common infrastructures, training programmes, etc). 
A number of projects have been funded through the Specific measures in support of 
international co-operation - Developing countries on "Bio-diverse, bio-safe and 
value added crops" and on “Health of livestock populations” largely focused on the 
livestock health protection through the development and use of diagnostic tools and 
vaccines. This research area of the 'food security' priority makes use of advanced 
biotechnological techniques.  
Coordination of national and regional research programmes has been achieved 
through  the  ERA-NET  scheme
22  in  which  programme  owners  and  programme 
managers identify national and regional programmes they subsequently coordinate or 
open up mutually. 15 ERA-NET actions relating to Life Sciences biotechnology are 
now implemented: 
                                                 
20  http://www.es.embnet.org/ 
21  http://ec.europa.eu/biotechnology/progress_reports_en.htm 
22  http://cordis.europa.eu/coordination/era-net.htm  
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–  Four  ERA-  NETS  on  Plant  genomics,  Biotech  for  SMEs,  Pathogenomics  and 
Systems  Biology,  have  already  launched  joint  calls  for  trans-national  research 
projects using national funding. Together these projects have already committed 
some €80 million to these calls for 2007 and at least €50 million more for 2008. 
–  In  the  medical  sector  Era-Nets  in  the  area  of  Organ  transplantation,  Health 
emergencies, and Health technology assessment have been implemented. 
The establishment of technology platforms
23, an innovation in EU research policy, 
have continued to develop and foster public-private partnerships at European level. 
They represent a mobilising force by bringing together all relevant stakeholders in a 
given sector to develop a strategic, long-term research agenda and to implement the 
research agenda through public and private investments at European, national and 
regional level. They are expected to contribute to the effort to boost research and 
technological  development  in  Europe  and  to  leverage  knowledge  for  economic 
growth and competitiveness. Industry’s lead role in the platforms is crucial in this 
regard.  The  industrial  leadership  of  platforms  ensures  that  they  are  focussed  on 
potential  future  markets  for  key  technologies.  This  leadership  can  provide  the 
necessary impulse to realise Europe’s potential in leading-edge technologies and help 
to build the capacity to transform scientific excellence into commercial success and 
economic  growth.  It  can  also  stimulate  the  emergence  of  first-mover  markets  in 
Europe. They provide a framework for industrial, scientific and financial worlds to 
come  together  and  make  viable  projects  that  can  only  be  conceived  at  European 
level. This in turn will boost research performance and investment.  
So far 8 technology platforms in life sciences and biotechnology have now been 
launched:  Innovative  Medicines  Initiatives,  Nanomedicine  -  Nanotechnologies  for 
Medical Applications, Plant genomics and Biotechnology, Industrial biotechnology 
under  the  sustainable  Chemistry  technology  platform,  Food  for  Life,  Sustainable 
animal breading and reproduction, global Animal Health, Forestry and Biofuels. The 
last 6 technology platforms have established a virtual KBBE- Net in order to ensure a 
coherent  and  coordinated  approach  to  the  implementation  of  a  Knowledge-Based 
Bio-Economy.  Close  collaboration  between  technology  platforms  and  the  KBBE 
related ERA Nets has been initiated. 
Under FP7 
The  Seventh  Framework  Programme  (2007-2013)  will  continue  to  provide  a 
strong impetus to Life Sciences and Biotechnology research in Europe.  
Life Sciences and Biotechnology research for medical applications will remain an 
important priority in FP7 in particular under the "Health" theme in the "Cooperation 
Programme". This theme will promote research to improve the health of European 
citizens and increase the competitiveness of the European health related industries 
and businesses. It will support both basic and applied collaborative research. This 
includes discovery activities, translational research and early clinical trials (normally 
only phase I and II). Activities will be structured in 3 main areas: 
                                                 
23  http://www.cordis.lu/technology-platforms/home.html  
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–  Biotechnology, generic tools and technologies for human health; 
–  Translating research for human health; 
–  Optimising the delivery of healthcare. 
The Health Theme emphasises the importance of innovation and the integration of 
SMEs in health research projects in order to reach the  Lisbon  goal,  with special 
attention on the inclusion of 'high-tech' SMEs in projects. To that aim, in addition to 
appropriate work programme formulation of topics and calls, an articulated strategy 
is  ongoing  to  improve  visibility  and  awareness  among  the  Healthcare  SMEs 
community,  through  participation  in  international  meetings  relevant  to  SMEs 
including Trade Fairs, enhancing communication, supporting information multipliers 
and developing additional appropriate support structures. 
As in FP6, and in addition to the activities implemented under the Themes of the 
Cooperation  programme,  a  specific  scheme  is  being  developed  to  strengthen  the 
competitiveness  of  SMEs,  including  Life  Sciences  SMEs,  by  enhancing  their 
investment  in  RTD-activities  (supporting  SMEs  or  SME  associations  in  need  of 
outsourcing  research  to  research  services  providers  such  as  universities,  research 
centres or research performing SMEs) and acquisition of intellectual property rights 
and knowledge. 
The Innovative Medicines Initiative (IMI)
  24 is expected to be established as a 
Joint  Technology  Initiative  under  FP7,  forming  a  public-private  partnership 
between  the  European  Commission  and  the  European  Federation  of 
Pharmaceutical  Industries  Associations  (EFPIA).  IMI  aims  at  increasing  the 
competitiveness of the European biopharmaceutical industry and is therefore a direct 
answer to the objectives of the Lisbon's Strategy. Industry will invest in research by 
co-funding  collaborative  research  projects  taking  place  in  Europe,  together  with 
academia, SMEs, and patients associations supported by public funds. IMI research 
objectives are to provide new tools for accelerating the development of safer and 
more  effective  medicines  for  patients,  by  overcoming  four  key  pre-competitive 
research  bottlenecks  in  the  drug  development  process:  prediction  of  safety, 
prediction of efficacy, knowledge management, and education & training.  
"The European Technology Platform on NanoMedicine
25 aims at strengthening 
the  competitive  situation  for  nanomedicine  at  global  level.  Its  strategic  research 
agenda puts forward a sound basis for decision making processes for policy makers 
and  funding  agencies,  providing  an  overview  of  needs  and  challenges,  existing 
technologies  and  future  opportunities  in  nanomedicine.  It  also  takes  into  account 
education  and  training,  ethical  requirements,  benefit/risk  assessment,  public 
acceptance,  regulatory  framework  and  intellectual  property  issues.  The  initiative 
concentrates  on  three  key  areas:  Targeted  drug  delivery,  nano-diagnostics  and 
regenerative  medicine.  The  Platform  delivered  a  sound  basis  for  the  work 
programme of FP7 in this area. Industry is ready to invest considerable funds in 
                                                 
24  www.europa.eu.int/comm/research/imi.html 
25  www.cordis.europa.eu/nanotechnology/nanomedicine.htm  
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European nanomedicine research projects together with the European Commission 
and other stakeholders." 
FP7 is also expected to contribute to building a European Knowledge-Based Bio-
Economy,
 by bringing together research, industry and relevant stakeholders under the 
theme “Food,  Agriculture  and  Fisheries,  and  Biotechnology”  to  exploit  the  new 
opportunities  that  life  sciences  and  biotechnology  offer  to  create  added  value  in 
society, to enhance sustainability through the optimal use of renewable biological 
resources, to mitigate the emission of greenhouse gases, to provide new eco-efficient 
and competitive products and to reduce the adverse impact on the environment of 
agriculture, industry and aquaculture.  
Three main areas of research will be addressed: 
–  Sustainable production and management of biological resources from land, forest 
and aquatic environments; 
–  “Fork to Farm”: Food, health and well being; 
–  Life Sciences and biotechnology for sustainable non-food products and processes. 
This progress in science and research strongly contributes to the implementation of 
the objectives of the revised Lisbon strategy, as outlined in the "Kok report"
26. Life 
Sciences  and  biotechnology  will  help  to  move  towards  a  European  Knowledge-
Based Bio-Economy, where not only food and feed, but also other industrial goods 
are produced in a more sophisticated and sustainable manner by incorporating life 
sciences and biotechnology innovations. As an example, the chemical industries may 
undergo  transformation  at  several  levels:  Firstly  the  industry  may  undergo  raw 
material conversion from fossil feedstock to biological resources. Secondly, it may 
undergo process conversion from using chemical processes to using bioprocess.  
These  knowledge-intensive  and  eco-efficient  bio-products  include  among  others 
biofuels, bioplastics, green chemicals, lubricants, biopharmaceuticals, food and feed, 
as well as other bio-products.  
The move towards a bio-based economy is not only taking place in Europe, but is 
emerging  globally  and  our  main  competitors  are  now  strongly  investing in  these 
areas of research. 
As stressed in the recent "Aho report"
27, research, technology and innovation can 
only  be  powerful  vectors  of  sustainable  growth,  if  supply-side  measures  (public 
investment  in  research)  are  rebalanced  with  demand-side  policies  (public 
procurement, standards, regulation, ….) in order to stimulate private investment into 
research and product development. As expressed in the report, "simultaneous and 
synchronous efforts are needed at all levels in three areas": 
–  Creation of a market for innovative products and services; 
                                                 
26  http://ec.europa.eu/growthandjobs/pdf/kok_report_en.pdf 
27  http://ec.europa.eu/invest-in-research/action/2006_ahogroup_en.htm  
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–  Providing sufficient resources for R&D and innovation and; 
–  Improving the structural mobility and adaptability of Europe.  
A number of supply-side policies are already in place to support the emergence of a 
European bio-economy, in particular R&D support through national and Community 
research framework programmes. The KBBE-NET network was established in 2005 
to  exchange  information  on  national  research  policies  and  programmes  and  to 
enhance cooperation between Member States (joint research programmes, common 
infrastructures, training programmes, etc) with a view to develop and implement a 
European Research Agenda for the knowledge-based bio-economy.  
However, if Europe wants to explore the full potential of the “Knowledge Based 
Bioeconomy" it needs to engage in demand side policies to create dynamic market 
conditions. ("lead markets"). "Bio-based products" could be a prominent example of 
a European lead market given that Europe has some key strategic advances: 
–  A strong, world-class biotechnology R&D base;  
–  Key-enzymes producers being located in the EU;  
–  A strong chemical industry, which are leaders in the development and production 
of bio-specialities (food ingredients, pharmaceuticals and fine chemicals); 
–  The availability of renewable resources, in particular agricultural biomass through 
the recent EU enlargements;  
–  Strong  political  support  for  and  more  advanced  concepts  of  sustainable 
development  
–  Strong  public  support  for  industrial  biotechnology  (according  to  the  2005 
Eurobarometer on public perception of Biotechnology
28 70% of the respondents 
supported bioplastic and biofuels and are willing to pay more for these products). 
Such  a  lead  market  initiative  for  eco-efficient  bio-based  products  should 
stimulate  private  investments  and  lead  to  more  demanding  and  novelty-seeking 
customers, and potential higher returns on investment will act as a strong incentive to 
private research and innovation. 
Several actions could be considered, both from the supply and the demand sides, to 
provide a push for eco-efficient biobased products. The list below takes into account 
the discussion at the Presidencies Biotech Policy Round Table in Helsinki in June 
2006
29  and  the  work  of  the  network  with  high  level  officials  on  the  Knowledge 
Based  bio  Economy.  The  Commission  will  further  reflect  on  these  actions,  in 
cooperation with the concerned stakeholder, bearing in mind that some proposals 
may need to be subject to an impact assessment, including an evaluation of possible 
administrative burden, and compatible with EC rules in the field of competition and 
internal market. 
                                                 
28  http://www.ec.europa.eu/research/press/2006/pdf/pr1906_eb_64_3_final_report-may2006_en.pdf 
29  http://www.ktm.fi/index.phtml?l=en&s=1741  
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(1)  Providing sufficient resources for R&D and innovation 
(a)  Mobilise national research funding (e.g. re-enforcement of ERA-Nets) 
and reinforce the coordination of national research activities amongst 
others through the Member State network on KBBE. Special attention 
should be made to:  
–  Launching  of  demonstration  projects/pilot  plants  at 
European/National/regional  levels  e.g.  integrated  diversified 
biorefinery; 
–  Implementation of the strategic research agendas developed by 
the Technology Platforms at European, national and regional 
levels. 
(2)  Creation of a market for eco-efficient bio-based products  
(a)  Establishment  of  standards/minimum  requirements  to  claim  a  bio-
based  product  is  eco-efficient  (bio-products  that  leads  to  less 
pollution,  less  resource-intensive  production  and  more  effective 
management of biological resources); 
(b)  Help convert conventional industrial processes into eco-efficient bio-
based products by developing faster regulatory approval system for 
eco-efficient bio-based products; 
(c)  Secure  affordable  supply  of  biomass  feedstock  through  supportive 
innovation programmes, agriculture policies and price incentives; 
(d)  Provide market incentives to stimulate the commercialisation of bio-
based products: 
–  Include the issue of eco-efficient bio-based products in the EU 
green Public Procurement Policy in order to stimulate public 
procurement of eco-efficient bio-based products. The French 
Environment  Agency  Bioproducts  guidebook  for  Greener 
Procurements may serve as a model; 
–  Establish  EU  labelling  of  eco-efficient  bio-based  products 
compatible with EC rules on eco-labelling.  
–  Temporary pricing measures. 
(3)  Improving the structural mobility and adaptability of Europe 
(a)  Enhance coordination and coherence of the various policy initiatives 
at EU level e.g. biomass action plan, ETAP, sustainable development 
strategy, implementation of the biofuel directive30 etc; 
                                                 
30  Directive 2003/30/EC of the European Parliament and of the Council of 8 May 2003 on the promotion 
of the use of biofuels or other renewable fuels for transport, OJEU L 123, 17/05/2003, p. 42-46  
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(b)  Enhance  cooperation  between  the  Commission  and  Member  States 
among  others  through  the  Member  States  network  on  Knowledge 
Based  Bio-  Economy  (KBBE-NET)  in  cooperation  with  Council 
Presidency; 
(c)  Continue to elaborate the KBBE concept, assess its potential impact 
and make practical steps to ensure its implementation. Developments 
inside and outside the EU should be monitored through, amongst other 
methods,  the  Member  States  network  on  Knowledge  Based  Bio-
Economy (KBBE-NET) and interaction with the OECD; 
(d)  Enhance  the  collaboration  with  industry  and  other  stakeholders 
through the technology platforms amongst other mechanisms. 
(4)  Create awareness amongst stakeholders  
(a)  Launch information campaign on eco-efficient bio-based products and 
the  potential  of  the  “Knowledge  Based  Bio-Economy”  including 
interactions with civil society, NGOs, investors, policy makers etc; 
(5)  Promote interdisciplinary education and training programmes.  
(6)  Improve investment in eco-efficient bio-based SME's  
(a)  Attract new public and private investors 
(b)  Increase availability of seed funding for Eco-efficient bio-based start-
ups by reassuring investors through the involvement of public funding 
bodies (EIF,EIB etc); 
(c)  Put incentives in place to motivate private individuals and foundations 
to invest in "green" investment funds. 
(d)  Better target the available funding at new technology projects. 
Support for life sciences and biotechnology research under FP 7 clearly appears as a 
top priority. Hence the original "Action 3", which has already been achieved, needs 
to be revised to take into account the objective and structure of FP7. In addition to 
this, new sub-actions should be envisaged in order to provide a push for eco-efficient 
bio-based products and the implementation of the Knowledge based bio-economy. 
Such actions would certainly be relevant in a perspective of sustainable development. 
They may nonetheless require an impact assessment (i.e. as far as they foresee for 
example  the  establishment  of  standards  to  assess  the  eco-efficiency  of  bio-based 
products,  of  incentives  for  the  marketing  of  such  products  or  of  specific  eco-
labelling).  
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The  Commission  will  enhance  its  support  for  life  sciences  and  biotechnology 
research, technological development, demonstration and training activities under the 
next Framework Programme 2007-2013 aimed at contributing to the creation of a 
knowledge  society  and  to  provide  a  more  stable  foundation  for  the  European 
Research Area. 
Life  Sciences  and  Biotechnology  research  will  mainly  be  supported  under  the 
"Health" and the "Food, agriculture and Fisheries, and biotechnology" thematic areas 
under  the  Cooperation  programme.  The  following  thematic  areas  under  the 
Cooperation programme will also contribute to the implementation of the strategy: 
(1)  Information and Communication Technologies; 
(2)  Nanosciences,  nanotechnologies,  Materials  and  new  Production 
Technologies; 
(3)  Energy; 
(4)  Environment; 
(5)  Socio-economic Sciences and Humanities; 
(6)  Security and Space, notably biosecurity. 
Specific measures will be provided to encourage "investigator-driven research" in 
relation to the establishment of the European Research Council, mobility and training 
of  researchers,  coordination  of  national  and  regional  programmes,  SME 
participation, regional research driven clusters, research infrastructures, international 
cooperation and science and society issues.  
In the course of the mid-term review of FP7 in 2009 an assessment will be carried 
out regarding the accomplishment of creating a "European Knowledge Based Bio-
Economy".  The  contribution  in  terms  of  human  and  financial  resources  from,  in 
particular  theme  2  "Food,  agriculture,  fisheries  and  biotechnology",  theme  4 
"Nanosciences,  Nanotechnologies,  Materials  and  new  Production  Technologies", 
theme 5 "Energy" and theme 6 " Environment, as well as the need for new strategic 
research  priorities.  The  contribution  from  Member  States,  industry  and  other 
stakeholders will also be assessed. 
Action 3 remains of strategic importance, in particular in view of the emerging 
of industrial, environmental and marine biotechnologies as important sectors 
not only in Europe but globally. It needs to be refocused in light of the new FP7 
and of emerging issues  
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Action 4 - Management and legal services  
The two actions aiming at creating networks of biotechnology company managers 
and  at  developing  specific  legal  competence  in  this  field  do  not  have  triggered 
interest  from  the  concerned  audience.  The  two  actions  do  not  have  any  strategic 
importance at European level and do not need to be pursued further to the review. 
The idea to create networks of biotechnology company managers has been probed 
but the Commission has found that there is no interest for this action at European 
level. The existing biotech clusters/regional organisations seem to fill the needs. 
A reinforced collaboration between law schools, law firms and companies has not 
raised any interest at European level.  
The needs to improve biotech companies’ business models, acquire legal competence 
and recruit competent leaders are often cited in various reports. As the European 
biotech  sector  gradually  matures,  these  needs  will  be  more  accentuated,  and  the 
existing clusters and networks (including the recently created CEBR; see action 9) 
can provide the demanded services and networking possibilities.  
Action 4 does not need to be pursued as a specific action 
Action 5 - Patenting of new research findings  
Intellectual property rights (IPR) have a special role to play in the life sciences and 
biotechnology sector. Biotechnology requires huge levels of R&D investment and in 
many cases it takes a long time to obtain legal approval for products to enter the 
market. The patents registered by a biotech company constitute a large part of that 
company’s  value,  being  the  company’s  main  asset  to  generate  future  revenues. 
Intellectual property may even be the one and only collateral to obtain financing for 
the  company’s  research  and  development  activities.  Therefore  the  acquisition  of 
patents, a legal mechanism that ensures a return on investments is crucial to life 
sciences. IPR instruments such as trademarks, commercial names, domain names, 
know-how and licensing agreements secure the commercial interest of entrepreneurs 
in this sector. 
While  the  patenting  of  new  research  findings  in  the  field  of  biotechnology  has 
economical and ethical implications, this action should be considered in the global 
context  of  research  in  general.  Given  its  importance,  which  has  been  clearly 
confirmed by stakeholders, this action should be continued and remains a political 
priority.  In  particular,  the  economic  consequences  of  not  having  a  cost  effective 
Community Patent should be studied. Ultimately, efforts should continue to agree 
and  introduce  a  Community  Patent,  whilst  it  should  be  clear  that  this  is  not  a 
biotechnology–specific  issue  and  that  only  limited  action  can  be  taken  for  this 
purpose in the context of the Strategy.  
Action 5 (a) has been achieved and all Member States have now implemented in 
their national laws Directive 98/44/EC
31 on the legal protection of biotechnological 
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inventions. The Directive aims to clarify certain principles of patent law applied to 
biotechnological  inventions  whilst  ensuring  that  strict  ethical  rules  are  respected. 
Such  clarifications  have  proved  essential  in  order  to  fully  exploit  the  medical, 
environmental  and  economic  potential  of  biotechnology  in  line  with  high  ethical 
standards. 
For its part, the Commission has considered two questions identified in the annual 
report
32  of  the  Commission  to  the  European  Parliament  and  the  Council  on  the 
development and implications of patent law in the field of biotechnology and genetic 
engineering provided for by Article 16(c) of Directive 98/44/EC. Namely the scope 
of patents relating to sequences or part-sequences of genes isolated from the 
human body, and the patentability of human stem cells and cell lines obtained 
from them. These two topics have been addressed in the last Commission report
33. 
The Commission is financing two studies. One on the impact of human DNA patents 
in research and innovation
34 that is expected to provide an evidence-based analysis of 
the features and dynamics of patent applications. The second study, which has also 
been launched in the beginning of 2005, will analyse the EU patent system as applied 
to  human  embryonic  stem  cell  related  technologies
35.  Results  of  studies  will  be 
analysed by the Commission and discussed with Member States. 
Regarding action 5(b), after receiving the opinion of the European Parliament, the 
Commission  proposal  for  a  Regulation  on  the  Community  Patent
36  has  been 
discussed in the Council, where, on 3 March 2003, a common political approach was 
agreed on a number of issues. Following this, there was significant progress in the 
Council  in  incorporating  the  common  political  approach  in  the  text  of  the 
Community Patent Regulation and the text was practically finalised in November 
2003.  However,  since  then  the  Council  has  repeatedly  failed  to  reach  final 
agreement. In the meantime, the Commission has on 23 December 2003 presented 
proposals  for  Council  decisions  on  the  setting  up  of  the  Community  patent 
jurisdiction
37.  The  Economic  and  Social  Committee  has  issued  its,  overall,  very 
positive opinion on 31 March 2004
38 and the European Court of Justice has delivered 
its opinion on these proposals on 29 October 2004
39. 
In view of the difficulties to achieve progress in the field of patents in Europe, the 
Commission has in 2006 carried out a broad consultation of all interested parties on 
the future patent policy in Europe. The consultation focused on the structure of the 
patent system rather than on substantive patent law. One of the main issues in the 
consultation concerned the Community patent but it covered also issues such as basic 
principles of the patent system, the draft “European Patent Litigation Agreement” 
                                                 
32  COM(2002)545 final, 7.10.2002 
33  COM(2005)312 final, 14.07.2005 
34  The  Patenting  of  Human  DNA:  Global  trends  in  commercial  and  public  sector  activity 
http://www.sussex.ac.uk/spru/1-4-14-1.html 
35  Stem  Cell  Patents:  European  Patent  Law  and  Ethics 
http://www.nottingham.ac.uk/law/StemCellProject/summary.htm 
36  COM(2000)412 
37  COM (2003) 827 and COM (2003) 828 
38  OJ 2004, C 112/76 and C 112/81 
39  Council document n° 14349/04  
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and  approximation  of  Member  States'  national  laws  and  mutual  recognition  of 
Member States' patents
40. The consultation ended with a public hearing in July 2006. 
Following this consultation, the Commission is now preparing its position on the way 
forward. 
Action 5(c) has been partially achieved from the Commission side. An expert group 
on  technology  transfer  and  legal  specialists  finalised  in  2004  a  report  on 
“Management  of  Intellectual  Property  in  publicly  funded  research 
organisations – towards European Guidelines”
41 . 
A Commission study providing a detailed comparative analysis of the Intellectual 
Property Research (IPR) rules applicable to publicly-funded research, their evolution 
and their effects, in the "old" 15 EU Member States, in 2 "new" Member States, as 
well as in the US and Japan was launched in December 2005. The study focuses on 
legislative aspects and gives recommendations in order to improve the coherence of 
the IPR regimes applicable to publicly funded research in the European Union.  
Regarding action 5(d), the Commission has encouraged research organisations in the 
life  sciences  and  biotechnology  area  participating  in  the  EU  R&D  Framework 
programmes to actively protect, disseminate and exploit their research results. It 
has  supported  the  BioBIZ  project,  which  provides  entrepreneurship  training,  in 
particular in the New Member States, and has recently published a brochure with 
"100 Technology Offers"
42 collected from results of EU funded R&D projects. 
The Commission has supported a number of support actions to raise awareness for 
and provide training on IPR issues, such as the "ScanBalt IP Knowledge Network" 
project
43, which aims to spread awareness and competence development in the field 
of  strategic  IP  management  in  biosciences.  The  EPIPAGRI  project,  starting  in 
September  2006,  will  bring  together  major  EU  research  and  technology  transfer 
organisations  to  collectively  manage  public  intellectual  property  in  Agricultural 
Biotechnologies, both to support better access to IP for developing countries and 
SMEs. 
Regarding action 5(e), Member States and the Commission took part actively in an 
OECD  exercise  to  develop  licensing  guidelines  for  genetic  inventions.  On  23 
February 2006, the OECD Council adopted the Recommendation
44 , which presents 
Guidelines for the Licensing of Genetic Inventions. These set out principles and best 
practices  for  the  licensing  of  genetic  inventions  used  for  purposes  of  human 
healthcare. 
As  a  conclusion,  the  Commission,  the  Council  and  the  Member  States  should 
continue to support the objective of the action.  
                                                 
40  The  public  consultation  was  closed  on  12  April  2006.  See: 
http://europa.eu.int/comm/internal_market/indprop/patent/consultation_en.htm 
41  http://europa.eu.int/comm/research/era/pdf/iprmanagementguidelines-report.pdf 
42  Brochure can be downloaded from http://www.cordis.europa.eu.int/lifescihealth/src/leaflet.htm 
43  http://www.scanbaltipkn.org/ 
44  C(2005)149/Rev1 
http://www.oecd.org/document/26/0,2340,en_2649_34537_34317658_1_1_1_1,00.html  
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In the biotechnology sector, patenting of new research findings needs to be done at 
an early stage to secure further investments and to realise its full economic value. 
Economic consequences of not having a cost-effective Community Patent should be 
studied,  in  particular  for  the  realisation  of  European  inventions  originating  from 
academia and young innovative companies 
Developments in biotechnology may raise important ethical and legal questions with 
respect  to  their  protection  through  patents,  in  particular  in  the  area  of  human 
embryonic  stem  cells  or  the  newly  emerging  area  of  synthetic  biotechnology. 
Therefore  special  consideration  needs  to  be  given  to  the  development  of  best 
practices for IPR taking into account ethical and societal concerns while encouraging 
patenting, licensing and spin-off creation. 
With the increasing number of biotech patents, held both by the public and private 
sector, transaction costs will likely rise. To maintain the competitiveness of the EU 
industry, issues such as patent pools, research exemption and new models for the 
use of IP in public-private research partnerships are becoming important. The 
Commission, in cooperation with Members States and relevant stakeholders, should 
take a proactive role in initiating discussions on these important issues. In a first step 
the Commission is preparing guidelines on knowledge transfer between the public 
research base and industry across Europe (with an emphasis on the trans-national 
dimension)  The  guidelines  which  are  expected  to  be  adopted  in  2007  will  be 
addressed to public authorities and stakeholders. 
Action 5 remains of strategic importance and needs to be continued in the 
appropriate fora. Biotech-specific aspects of this action also need to be 
refocused 
Action 6 – Capital base 
Regarding  action  6a,  the  EIB's  Innovation  2010  Initiative  (i2i)  aims  to  help 
increasing  the  spending  on  research,  development  &  innovation  in  Europe  by 
providing €10 billion in loans until 2010. More than €750 million in loans has been 
granted to the biotech & pharmaceutical sector.  
The EIB loan facility has been strengthened by the introduction under FP7 of a new 
financing instrument, the “risk-sharing finance facility”, which will provide loans 
for  larger  research  and  infrastructure  projects.  It  also  aims  to  fund  projects  with 
higher risks. This facility, a joint loan instrument between the European Commission 
and the EIB, is managed by the EIB, and can provide finance for research in high 
technology areas by private companies and institutions, for which the risk cannot 
properly be assessed by classical banks and are therefore considered too risky.  
FP7  funds  will  be  used  in  addition  to  EIB  and  as  a  reserve  to  cover  the  risk 
associated with the EIB lending operation, thereby providing a leverage effect (factor 
of 3-4). This instrument can in particular be useful for financing high-risk biotech 
R&D  drug  development  projects,  large  scale  collaborative  research  projects 
(technology initiatives, Eureka projects) or new research infrastructures.  
The  Commission  also  supports  the  AFIBIO  project  ("Access  to  FInance  in  the 
BIOtech sector), a network of financing experts, including the EIF, to develop novel  
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and  innovate  ideas  related  to  innovation  financing  and  providing  policy 
recommendations. 
Regarding  Action  6b,  the  venture  capital  (VC)  instruments  of  the  European 
Investment Fund (EIF) consist of equity investments in venture capital funds that 
support SMEs, particularly those that are in their early stages of development and 
those that are technology-oriented. The EIF's venture capital activity is backed by 
two sources of funding: (a) capital from the EIB Group (EIB and EIF) that forms the 
bulk of the EIF's investments, and (b) capital from the European Commission that is 
allocated under three different programmes:  
–  The ETF Start-up Facility is intended to adopt a higher risk profile than the EIB 
Group operations. It aims to invest in venture capital funds such as seed capital 
funds, business incubators, smaller or newly established funds, funds focused on 
specific industries or technologies and funds financing the exploitation of R&D 
results (i.e. funds linked to research centres and science parks); 
–  The  EIF-ERP  "Dachfonds"  was  started  jointly  by  Germany  and  the  EIF  to 
encourage venture capital providers to invest in German high-technology firms, 
but  also  elsewhere  in  the  EU.  The  €500  million  fund  is  expected  to  raise  an 
additional €1,7 billion through commercial VC investments; 
–  A  new  Commission  framework  programme  called  the  Competitiveness  and 
Innovation Programme (CIP) will operate from 2007. It brings together several 
separate programmes and aims to strengthen the funding available to stimulate 
investments  in  research  and  technological  innovation,  especially  in  SMEs.  An 
increase of €1 billion of the EIB reserves from CIP has been decided; 
–  Fully  achieved.  A  “Technology  Transfer  Accelerator”  (TTA)  was  launched  in 
2006 after the Commission and the European Investment Fund (EIF) had carried 
out  a  feasibility  study  on  a  new  type  of  risk  capital  and  technology  transfer 
investment vehicle. It aims to link different centres of excellence and universities 
in  European  countries.  The  TTA  should  bridge  the  finance  gap  between 
university/spin-off  research  and  early  stage  investment,  a  sector  currently  not 
favoured by VC investors. The Commission is also financing entrepreneurship 
training courses with particular focus on scientists in the New Member States.  
Regarding action 6d, the EIB commissioned an external study in 2005 to find out 
how many European biotechnology companies are creditworthy, i.e. actually able to 
take  debt  for  their  product  development.  The  study  estimates  that  only  very  few 
European biotech companies qualify for debt financing (according to the strictest 
criteria). The main factors for debt financing are the maturity of the company and a 
steady flow of revenues.  
In September 2005, the Commission produced a report on “Best practices of public 
support for early-stage equity finance”
45. This document analyses the demand and 
supply-side of early-stage finance,  gives examples of funds operating in Member 
States, and provides recommendations for improvement of early-stage finance.  
                                                 
45  http://ec.europa.eu/enterprise/entrepreneurship/financing/docs/report_early-stage_equity_finance.pdf  
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An analysis of the European biotechnology industry’s competitiveness stance
46 was 
performed by the Commission early 2007. Europe's biotech companies are mostly 
SMEs with limited resources and they often depend on external investment capital to 
be able to follow through with their research and development projects. It is evident 
that in terms of research expenditure and number of employees European companies 
grow at a slower rate than their American counterparts. This can be attributed to 
three main constraints: Europe's fragmented patent system, the insufficient supply of 
risk capital and the not yet fully developed scientific and business cooperation. To 
remedy  the  under-funding  problem  a  combination  of  demand  and  supply  side 
measures are recommended.  
Action 6 needs to be continued and highlighted as a political priority  
Action 7: Biotechnology and Finance Forum 
The Biotech and Finance Forum Advisory Board has been renewed and strengthened 
in 2002 to include all relevant stakeholders in Europe in the field of biotechnology 
and finance (EuropaBio, EFB, EVCA, EIB, EIF, etc.), as well as representatives of 
major bio-clusters, venture capital firms, consultants, etc. in the biotech sector. It has 
made  important  recommendations  and  initiated  activities  to  improve  access  to 
finance,  in  particular  for  later  stage  companies  and  for  the  emerging  sector  of 
industrial biotechnology. Roundtable and investment conferences are organised twice 
a  year  (in  December  and  May),  bringing  together  industry,  small  companies, 
investors and policy makers. Recommendations of the Biotech and Finance Forum 
working group delivered in 2002 on "Financing of biotech companies" have led the 
EIB  to  provide  an  additional  €500  million  to  the  EIF  to  provide  further  venture 
capital to innovative SMEs, including for later stage biotech investments. 
The European biotechnology industry has seen considerable growth during the late 
1990s, in part due to strong policy initiatives to support university spin-offs, bio-
cluster development, etc. While Europe has many biotech start-ups, there are still 
problems with getting adequate funding and making the European companies grow 
(US companies are on average better staffed and funded). Further growth seems to be 
hampered; possible reasons being the lack of access to early- and late-stage finance, 
and/or the small size of national markets and actual access to markets. An in-depth 
study of the factors hampering the growth of EU biotech companies is necessary in 
order to develop appropriate policy measures that could counteract a possible "value 
drain", i.e. an increased relocation of mid-stage EU companies to the US. 
The biotechnology and finance forum to be established under this action is now 
established and operational, action 7 is thus achieved 
                                                 
46  http://ec.europa.eu/enterprise/phabiocom/comp_biotech_comp.htm  
EN  27    EN 
Action 8a - Creation of a commercial biotechnology web portal 
The  creation  of  a  commercial  biotechnology  web  portal  for  Europe  is  near 
completion. An evaluation of the setup and the long term sustainability of the web 
portal should be made and the potential stakeholders should be mapped. 
Action is near completion. An assessment of sustainability is required 
Action 8b - Commission's central biotech web site 
The  Commission's  central  biotech  web  site  is  operational
47.  It  will  be  regularly 
updated  and  provide  necessary  links  to  the  Commission's  different  Directorate 
Generals' specific biotechnology related web pages. 
The website is now established and operational, action 8b is thus achieved  
Action 9a - Networking activities between biotechnology regions  
The funding of a number of networking activities between biotechnology regions has 
facilitated the liaison between scientists and business, improving competitiveness.  
The Commission has offered funding for a number of networking activities, either 
through  the  R&D  Framework  Programme  (specific  support  actions  through  the 
Specific Programmes, and the Regions of Knowledge and  INNOVA schemes) or 
through  EU  cohesion  policy's  INTERREG  programmes.  The  Commission  has 
recently launched a project, aimed at establishing a Council of European Bio Regions 
(CEBR). The aim of CEBR is to establish a long lasting network of bio-clusters and 
regional  associations  at  the  European  level,  thus  facilitating  better  networking 
between  scientists  and  business  in  the  biotechnology  area  and  improving 
competitiveness of the EU biotech industry. The inaugural meeting took place in 
June 2006 
The INTERREG III cooperation programmes which are part of EU cohesion policy 
have  supported  projects  to  network  biotechnology/life  science  regions  in  the 
framework of cross-border and trans-national co-operation programmes (INTERREG 
III A and B). Examples are set out below.  
–  Scanbalt Campus: This project, developed in the framework of IIIB Baltic Sea 
Region  programme  and  in  cooperation  with  the  ScanBalt  Bioregion  umbrella 
initiative of the Nordic Innovation Centre, was founded with the aim of creating a 
model  for  trans-national  and  trans-sectoral  institution-building  in  education, 
research and development. It includes 31 partners, most of them universities from 
the countries surrounding the Baltic Sea. The scope of this pilot project includes 
formulating  the  concept  and  structure  of  a  virtual  academy,  establishing 
knowledge  networks,  identifying  examples  of  shared  curricula  and  creation  of 
media  services  and  visibility.  The  lead  partner  is  the  Chalmers/Göteborgs 
universitet, Centre for environment and sustainability (SE). The contribution of 
the European Regional Development Fund (ERDF) amounted to €462 405; 
                                                 
47  http://ec.europa.eu/biotechnology/index_en.htm  
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–  Reducing  the  environmental  impact  of  aquaculture:  This  cross-border  co-
operation project developed in the FYN-K.E.R.N programme between Denmark 
and Germany aims at supporting the sustainable development of maricultures and 
to increase the market share of edible fish in refined fish production. The project 
combines German expertise in land-based fish breeding with Danish knowledge 
of the management of algae growth to reduce the harmful effects of nitrogen in 
fish  production.  The  lead  partnersare  Leibniz-Institut  für  Meereskunde  an  der 
Christian-Albrechts-Universität, Kiel (DE) and the Institute for biochemistry and 
molecular  biology  at  the  University  of  Southern Denmark,  Odense  (DK).  The 
contribution of the ERDF is €298,561; 
–  Creation of a university cross-border study course on biological oceanography: 
Bio-Ocean is a joint study programme in the FYN-K.E.R.N programme between 
Denmark  and  Germany  in  the  sector  of  Biological  Oceanography  offering  an 
interdisciplinary  combination  of  lectures,  seminars,  practices.  The  programme 
covers  Physical  Oceanography,  Chemical  Oceanography,  Biological 
Oceanography, Marine Geology, Experimental Design and Data Reporting and 
Cost-Benefit Analysis. During the first term students follow courses covering the 
basics of physical, chemical, biological and geological oceanography. In addition 
students follow elective courses relevant to biological oceanography. During the 
second term, at the University of Southern Denmark, the focus is on advanced 
biological  oceanography  and  the  management  of  natural  resources  and 
environmental  economics.  In  the  third  and  fourth  terms  students  carry  out 
independent project work in biological oceanography under the supervision of an 
academic  advisor  from  Kiel  and/or  Odense.  At  the  University  of  Southern 
Denmark  in  Odense,  the  students  will  attain  a  M.Sc.  degree  in  Biology, 
specialized  in  Biological  Oceanography.  At  the  University  of  Kiel,  this 
programme will lead to a Diploma degree. The lead partners are the Christian-
Albrechts-Universität, Kiel (DE) and the Institute for biology at the University of 
Southern Denmark, Odense (DK). The contribution of the ERDF is €728,760. 
–  Harmonisation  and  upgrading  of  diagnostic  and  therapeutic  strategies  on 
osteoporosis. This project is developed in the framework of the cross-border co-
operation  programme  between  Denmark  and  Germany  INTERREG  IIIA  Fyn-
K.E.R.N. and comprises population-based patient studies and development and 
validation of a diagnosis instrument. The lead partners are Kiel Polytechnic (DE) 
and  University  Hospital  of  Odense  (DK).  The  contribution  of  the  ERDF  is 
€267,056.  
–  Helsinki-Tallinn Science Twin City. Developed in the context of the cross-border 
co-operation programme between Finland and Estonia, the core concept of this 
project is to foster co-operation between players in the science park environment 
in  the  Helsinki  (Uusimaa)  and  Tallinn  (Harju)  regions.  Activities  of  the 
programme can be divided into three categories: 1) common curricula, graduate 
schools  and  research  facilities;  2)  exchange/mobility  of  undergraduate  and 
graduate  students  and  scientists;  and  3)  high-tech  business  development  (e.g. 
networking, infrastructural development, start-up, growth and internationalisation 
phase programmes and other support measures, spin-off mechanisms, incubators, 
licensing  and  commercialisation  of  scientific  research  results  etc.).  In  order  to 
implement the 3rd item, an INTERREG IIIA Finland-Estonia project was run in 
2002-2005. Three fields of science were addressed in the project. These were:  
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biomedicine and biotechnology; ICT; and material sciences and new technologies. 
The  scope  of  the  programme  can  be  expanded  later  as  new  relevant  fields  of 
science and the need to foster cooperation within these fields arise. Interest has 
already  been  shown  in  including  areas  such  as  environmental,  ecological  and 
social sciences and urban studies in the project. The part of the project financed by 
Interreg IIIA was coordinated by Culminatum Ltd Oy (FI). The contribution of the 
ERDF was €81,400. 
–  RETSA. The objective of the project developed in the context of the cross-border 
co-operation programme between France and Spain is the creation of a food safety 
network. This network will answer needs and questions at scientific, technical and 
industrial level in the field of food safety. It will enable the development, the 
testing and the evaluation of new methods, as well as the exchange and transfer of 
experience and know-how between participants. This will permit to maintain a 
level of monitoring and information on food safety which can answer the needs of 
interested  parties,  in  particular  public  administrations  and  enterprises  from  the 
food  sector.  Another  objective  of  this  network  is  to  create  a  virtual  centre  of 
competence on food safety: competences of all participants will gather in a single 
place,  decentralised  geographically  but  unified  from  the  point  of  view  of  the 
potential  user.  This  centre  will  have  a  sufficient  critical  mass  to  launch 
cooperative research programmes between the different partners within already 
existing European Programmes (FP6, Eureka, bilateral programmes,…) The lead 
partner is the Centro Tecnico de Conservas Vegetales - Laboratorio del Ebro (E). 
The contribution of the ERDF is €537.844,80. 
–  Utilisation of adult stem cells in cardiologic diseases by regenerative cell therapy. 
The underlying idea of this project, developed within the framework of the cross-
border  programme  between  France  and  Spain,  is  based  on  the  following 
hypothesis: mother cells taken on adult tissues (muscle, marrow and fat) have the 
capacity to regenerate cardiac muscular tissue damaged by an Acute Myocardial 
Infarction and can also contribute to the heart's contractile function. Stem cells 
have  to  be  differentiated  in  vivo  or  in  vitro  from  cells  having  the  same 
characteristics as cardiac tissues. The demonstration of the functional capacity of 
the mother cells requires the use of an adequate animal model. The lead partner is 
the University of Navarra (E). The contribution of the ERDF is €974.396. 
–  Repartir – "REseau de Prospective et d’Animation visant à Renforcer les pôles 
Technologiques, d’Innovation et de Recherche et organiser leur complémentarité 
dans le Sud-Ouest Européen". The objective of this project developed within the 
framework of the trans-national programme "South West Europe (SUDOE)" is to 
lead a future-orientated reflection enabling coherent and complementary policies 
in the field of research and innovation, taking into account regional specificities. 
As a first step, a mapping of excellence in research and technology transfer will be 
done  for  the  "SUDOE"  region.  This  will  permit  the  partners  to  present 
perspectives for each regional scientific and technological centre as part of the 
European Research Area and to propose a strategy for each region, and for the 
"SUDOE" as a whole, on areas of emerging new competences. A pilot action will 
be  developed  in  the  field  of  biotechnology.  This  action  will  lead  partners  to 
elaborate  and  draft  research  programmes  for  each  network  and  to  answer 
European calls for tender. Partners of REPARTIR + will contribute to ensuring 
the follow-up of collaboration and set up a research and development observatory  
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in the SUDOE region. The lead partner is the Réseau universitaire Toulouse Midi-
Pyrénées (F).The contribution of the ERDF is €468.458,97.The network will be 
composed of the following participating regions: 
(a)  Cataluña : Biotechnology networks; 
(b)  País Vasco: Nano-materials networks; 
(c)  Midi-Pyrénées : Aeronautic network; 
(d)  Galicia  and  Aquitaine:  Economical  and  societal  working  group 
aeronautics, nano-material and biotechnology. 
–  BioValley: Bio Valley is a tri-national project located between Alsace in France, 
South Baden in Germany and north-west Switzerland. It already received support 
during the  INTERREG  II  programme (1997-1999), when support  was  used to 
identify the region's principal competences in biotechnology. The new project, 
supported through INTERREG III, has the objective of developing, on the basis of 
work  undertaken  during  the  INTERREG  II  period,  a  real  profile  as  "biotech 
region"  by  determining  areas  of  excellence  and  putting  in  place  appropriate 
measures. Areas of activity include:  
(a)  Establishment  of  the  BioValley  profile  (determination  upper-Rhine 
areas of excellence in the field of biotechnology); 
(b)  Economic measures (creation of a network of biotech parks, transfer 
of technology between universities and enterprises); 
(c)  Communication activities towards scientists, business operators and 
the general public; 
(d)  Call for tenders programmes. 
The aim is to reach, at the end of the INTERREG III project, self funding via a 
private structure. The lead partner is the Association Alsace Bio Valley (Illkirch). 
The contribution of the ERDF is €858.750
48. 
The  European  Territorial  Co-operation  Objective  replaces  the  INTERREG  III 
initiative for the period 2007-2013. It will continue to provide support for cross-
border,  trans-national  and  inter-regional  co-operation,  including  in  the  area  of 
biotechnology. 
Action to be continued as such: the funding of a number of networking activities 
has facilitated the liaison between scientists and business, improving 
competitiveness 
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Action 9b - Biotechnology clusters 
The implementation of action 9b should be refocused in order to identify and exploit 
the added value of specific cooperation actions between company clusters and bio-
regions. Such actions could be supported through FP7 or the Competitiveness and 
Innovation framework Programme (CIP)
49. While previous networks have largely 
focused on the exchange of best practise on regional development (i.e. of cluster 
management, incubator development, factors for attracting investment, etc), only a 
few  strategic  initiatives  (such  as  the  "ScanBalt  Competence  Region"
50,  a  project 
aimed at mapping competences within the ScanBalt region
51, identifying strengths 
and  weaknesses,  and  developing  a  common  strategy  for  improving  overall 
competitiveness and attractiveness of the ScanBalt Network) exist which develop 
common strategies and activities within a network of bioregions/clusters with the 
objective of increasing overall competitiveness of the network. Another interesting 
initiative has been the creation by the BioValley region
52, supported by the cohesion 
policy's  INTERREG  II  and  III  programmes  (described  further  under  action  9a 
above), of a One-Stop portal for the region which provides access to a large pool of 
Life  Science-related  jobs  that  range  from  research,  marketing,  management  or 
communications
53. The need for networking "people" such as young biotechnologists 
has also been  recognised as important  for  ensuring the future  competitiveness of 
Europe's biotech sector. 
The role of biotechnology clusters remains important but action 9b should be 
re-focused to identify and exploit cooperation between bio-regions to increase 
competitiveness 
Action 10 – Competitiveness monitoring  
A  contact  network  with  Member  States  ministries  and  an  Advisory  Board  in 
Competitiveness  in  Biotechnology  Group  have  been  created  and  are  fully 
operational.  
Action  10a  has  been  fully  achieved.  The  contact  network  with  Member  States 
ministries  with  responsibility  for  competitiveness  in  biotechnology  was  set  up  in 
2003. The network has  representatives from 20 Member States  and meetings are 
organised at least twice per year. In 2006 the co-operation has intensified and four 
meetings have been held during the first semester. In preparation of the mid-term 
review of the Strategy on Life Sciences and Biotechnology and its Action Plan, the 
network has produced a set of concrete recommendations in four thematic fields: 
regulation, access to finance, plant science and the knowledge-based bio-economy, 
and  communication  with  the  public
54:  A  summary  of  these  recommendations  is 
found in Annex III. 
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The  contact  network  with  Member  States  will  continue  to  monitor  the 
implementation of biotechnology regulation, the level of harmonisation at national 
level, and the effects of possible deficiencies. 
Action 10b has been fully achieved. The Competitiveness in Biotechnology Advisory 
Group (CBAG) with industry and academia
55 was set up in 2003. It has delivered 
three reports in 2004, 2005 and 2006 with relevant policy advice on competitiveness 
issues that have served as input for the mid term review. The advisory group's reports 
were  prepared  for  the  use  of  the  European  Commission,  but  do  not  necessarily 
represent the Commission's official position. The 2006 report of the CBAG and its 
summary can be downloaded
56. 
Action 10 has been fully achieved 
Action 11 - Transparency in the administrative process for applicants 
With  the  2005  reform  of  the  European  Medicines  Agency  (EMEA),  the  drug 
development process has been simplified, facilitating the role of SMEs. Together 
with the recently published User Guide to European Regulation in Biotechnology, 
transparency in the way this area is regulated has been improved. 
In the field of pharmaceuticals, action 11a has been fully achieved. The reform of 
EMEA  (Regulation  (EC)  No  726/2004  and  Regulation  (EC)  No  2049/2005)  has 
meant a number of improvements:  
–  reinforced scientific advice as early as possible in the drug development process; 
–  an SME office to help SME applicants find their way more easily, and to provide 
administrative assistance such as translations; 
–  SMEs may also benefit from fee waivers and deferrals. 
–  In other fields of biotechnology, the Commission is in close contact with operators 
to help them with the notification procedures. 
Action 11b has been fully achieved. The Commission has in collaboration with a 
consultant developed a User Guide to European Regulation in Biotechnology, which 
was  finalised  and  published  in  2006
57.  It  has  been  conceived  to  help  companies 
identify  routes  to  regulatory  compliance  for  their  products  and  processes.  At  the 
same time, it will help all EU citizens to improve their understanding of the way 
regulation balances the benefits, risks and ethical issues arising from biotechnology. 
Action 11 has been fully achieved 
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Action 12 - Benchmarking of clusters and business incubators 
Benchmarking clusters and business incubators have not met the interest that would 
make it worthwhile to go further with this action.  
By contrast, a programme for benchmarking biotechnology policies has been started 
by the Commission. A first round of benchmarking of national policies took place in 
2004 in close collaboration between the Commission and MS governments and was 
published in 2005. A second round is planned at a later stage to evaluate how far 
policies have evolved and what impact it has had on the biotech community.  
Since 2002, new studies on the role and development of clusters have been made and 
improved our understanding of their importance. The  action does not  need to be 
pursued at the current time. 
The benchmarking of clusters and business incubators in view of the current 
understanding and available studies does not seem necessary. Action 12 does not 
need to be pursued further  
Action 13 - Societal scrutiny and dialogue  
In the 2005 Eurobarometer survey on biotechnology
58, 52% of those polled indicated 
a belief that biotechnology will improve their  quality of life. The Eurobarometer 
“Europeans and biotechnology in 2005” shows that most Europeans are in favour of 
medical  applications  of  biotechnology  when  there  are  clear  benefits  for  human 
health. They are also in favour of industrial applications, but they are still generally 
sceptical about agricultural biotech, and will continue to be so unless new crops and 
products are seen to have societal benefits. Confidence has increased in the European 
Union's regulation of biotechnology but there is no evidence that this has influenced 
the  public's  reported  purchasing  intentions,  especially  for  GM  foods.  Overall, 
optimism  about  biotechnology's  contribution  to  improving  society  has  grown 
significantly since 1999. There is also support for research using stem cells, provided 
this is tightly regulated.  
A structured framework for the dialogue with stakeholders to make the regulatory 
oversight of biotechnology more open and transparent is still only partially achieved. 
Ongoing efforts to reassure rigour of the scientific risk assessment in the protection 
of human health and the environment should continue as a high priority. More efforts 
are  also  needed  to  assess  and  demonstrate  how  biotechnology  can  contribute  to 
addressing global challenges. Nonetheless, a substantial number of actions have been 
implemented by Commission services to achieve the objectives of action 13. There 
exists a recognised need for the establishment of international quantitative impact 
indicators  for  all  aspects  of  life  sciences  and  biotechnology  and  to  conduct  a 
systematic impact analysis on the benefits and risks of biotechnology in order to 
support a structured and evidence based societal dialogue and policy making process. 
A close collaboration between the Commission, Eurostat, Industry, Member States 
and the OECD is needed. 
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The Commission has set up the Pharmaceutical Forum, a senior platform which is 
designed to provide a broad political mandate to discuss and agree ways forward on 
key  non-legislative  issues  that  have  an  impact  on  European  competitiveness  and 
related health policies. Working groups set up under the Forum will treat three major, 
controversial and long-standing issues, namely pricing and reimbursement, relative 
effectiveness assessments and information to patients. The Pharmaceutical Forum is 
of strategic importance and the activity will continue. Depending on the outcome it 
may become possible to achieve common understanding at European level on several 
of the topics discussed.  
The  Commission  has  organised  various  scientific  meetings  and  workshops
59  to 
raise  awareness  for  the  state  of  the  art  and  existing  challenges  regarding 
measurements in life sciences and biotechnology. Particular topics such as reliability 
and comparability of bioanalytical measurement data, the evaluation of measurement 
uncertainties and their consideration for decision making processes as well as the full 
range  of  standardization  and  metrology  for  bioanalysis  have  been  addressed. 
Measurements  of  biological  molecules  and  other  entities  can  still  impose 
considerable challenges and international harmonisation is ongoing. The activities 
have to be continued at the various levels of the international technical measurement 
infrastructure and between scientists, industry and regulators. 
In December 2003 the Commission organised the first stakeholder conference with 
the objective of exploring the effect of human perception on risk assessment and its 
significance  and  implications  in  promoting  key  scientific  paradigms  underlying 
regulatory  oversight  and  governance.  In  particular,  the  conference  addressed  the 
issue  of  risk  assessment  and  risk  analysis,  and  how  these  processed  could  be 
improved. 
Ever since, the European Commission has continued to take action to reassure the 
general public, stakeholders and Member States that Community decisions on GMOs 
are based on rigorous scientific assessments which deliver a high level of protection 
of both human health and the environment. To this end, the Commission has adopted 
a  series  of  actions  in  its  orientation  debate  of  12  April  2006.  The  Commission 
presented these actions to the Environment Council in June 2006 and Member States 
welcomed  the  Commission's  proposal.  The  Commission  will  continue  to  work 
together with Member States EFSA, and stakeholders in the coming months with the 
objective of building greater consensus and transparency in this area of Community 
policy. Some steps have already been taken to ensure greater transparency in the risk 
assessment procedures, such as the recent public consultation organised by EFSA on 
GMO feeding trials
60. However, more actions probably need to be undertaken to 
assess the current as well as the potential future benefits of agriculture biotechnology 
and therefore enhance society acceptance and confidence. 
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By  Commission  Decision  2004/613/EC  of  6  August  2004,  the  Commission  has 
created an advisory group on the food chain and animal and plant health. The 
advisory  group  comprises  36  members  representing  different  economic  sectors, 
consumers and animal welfare organisations. These stakeholder representatives are 
consulted on health and consumer protection work programmes and measures in the 
areas of food safety, labelling, human nutrition, animal health and welfare and plants 
and pesticides. If there was need, a focus group on biotechnology could be set up 
within this advisory group 
In the field of Community research and development policies, the Commission has 
developed a number of activities in the field of governance, notably regarding the 
participation of civil society in decision making processes, the collection and use of 
expertise and scientific advice. 
At  programme  level,  Civil  Society  Organizations  and  NGOs  are  increasingly 
becoming members of the advisory groups for the implementation of the various 
thematic priorities under Research Framework Programmes. Actions have been taken 
to launch public consultations in relation to the preparation of the research priorities 
including under the thematic priority on Sustainable development
61.  
At project level, initiatives have been taken to involve for example consumer and 
patient organisations in research projects from the very beginning of a new project, 
rather than at the final stage, for instance, in relation to the acceptance of new food 
products.  Behavioural  studies  and  food  choice  aspects  have  been  incorporated 
particularly  in  Integrated  Projects.  Examples  of  this  approach  are  those  projects 
aimed  at  developing  new  food  products  for  reducing  the  prevalence  of  chronic 
diseases  or  networks  that  started  under  the  initiative  of  patient  associations
62. 
Furthermore,  in  drawing up  the  work  programme  for  the  final  Food  Quality  and 
Safety Programme Call for Proposals, specific efforts have been made to include 
consumer interests in research projects by making consumer aspects a requirement in 
specified programme areas. 
Specific projects regarding the process of governance were supported, addressing 
issues  of  scientific  advice,  risk  governance  and  the  participation  of  civil  society, 
notably in the field of GMOs, stem cells and so forth
63.  
As a conclusion, a continuation of the effort made by the European Union – and its 
Member States – in recent years to draw together the "innovation triangle" (science, 
society and the economy) remains a priority. 
One of the main conclusions which can be drawn from current experience is the need 
to  involve  Civil  Society  Organisations  early  in  the  research  process  and  on  a 
permanent  basis  and  not  only  launching  individual  actions  in  relation  to  the 
implementation  of  programmes  or  projects.  The  experience  gained  may  also 
contribute to the development of a framework for dialogue as proposed under action 
13a. 
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This  could  imply  a  more  systematic  involvement  of  Civil  Society  Organizations, 
NGO's and other interest groups, such as networks of young biotechnologists, in the 
implementation of the strategy and should be encouraged. This could include: 
–  The establishment of a Civil Society Organization forum to assist the Commission 
in  the  implementation  of  the  strategy.  Initial  steps  have  already  been  taken 
through announcement of the creation of this new forum on the revised Biosociety 
and KBBE Website and the invitation to Civil Society Organization and others, 
including individuals, to register for further information and to become involved 
in  the  broad  based  debate  on  the  future  of  life  sciences  (particularly  in  food, 
agriculture and biotechnology); 
–  A more systematic involvement of Civil Society Organization and NGOs in, for 
example, technology platforms, research projects or conferences at community as 
well  as  at  national  level  to  discuss  amongst  other  things  research  agendas,  to 
assess research findings and to make the regulatory oversights of biotechnology 
more open and transparent. For example Civil Society Organizations were co-
organising a EC conference on Stem Cells and their Therapeutic Applications in 
2005  and  CSOs  will  be  invited  to  take  part  in  the  forthcoming  foresight 
conference  to  be  held  early  2007  to  consider  the  future  of  food  and  the  food 
industry in 2030; 
–  Promote  initiatives  lead  by  Civil  Society  Organisations  e.g.  organisation  of 
conferences or support the outsourcing of research in relation to the activities of 
this typt of organisations, including the dissemination of results to the public. FP7 
will support such activities along with other mechanisms; 
–  Encourage research institutions to support innovative governance experiences. 
The need to undertake impact assessment studies as one of the tools to inform the 
public and structure the debate should be highlighted. The inclusion of sustainable 
consumption and production among the priorities of the Sustainable Development 
Strategy will require enhancing the consideration of impact assessment in relation to 
policy  dialogue.  There  is  a  need  to  develop  new  and  better  assessment  tools 
regarding the economic, social and environmental impact of biotechnology. These 
aspects will be addressed in FP7. 
The Commission as well as many Member States have called for an engagement of 
scientists with the public, at different levels. However scientists and in particular 
young scientists are faced with a paradigm, since going out of the laboratory and the 
need to communicate more actively with society in the early stage of a scientific 
career is not being emphasised. If we do not target directly early stage researchers, it 
will  be  impossible  to  develop  a  future  scientific  community  integrating  public 
engagement and interaction within its structural values and public duties. There is a 
need to take into account non-scientific experiences, in particular communication and 
engagement with public. 
Action 13 should continue to encourage societal debates on the benefits and risk 
of life sciences and biotechnology  
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Action 14 - Better integration of socio-economic and ethical issues  
This action aiming at better integration of socio-economic and ethical issues has been 
successfully implemented in FP6 and it is the Commission intention to continue to 
apply these tools for governance of research under FP7 (2007-2013). This action 
should be refocused to better reflect the intention of the Commission to define and 
apply ethical framework and standards for FP7, so as to reinforce the ethical review 
as  well  as  encourage  the  participation  of  ethicists,  lawyers, patient  organisations, 
farmers, animal welfare organizations, and other stakeholders in research projects 
thereby active engagement in public dialogue could be envisaged. 
In order to ensure that fundamental ethical principles are respected and the ethical, 
legal, social and wider cultural aspects are taken into account at the earliest possible 
stage of Community–funded research in Life Sciences and Biotechnology, involving 
the  general  public  to  the  greatest  extent  possible,  the  Commission  has  taken  a 
number of actions, under FP6 including: 
–  Defining an ethical framework and ethical standards for FP6
64;  
–  Reinforcement  of  the  ethical  review  of  project  proposals  that  raise  sensitive 
ethical issues or where ethical issues have not been properly addressed as part of 
the  funding  evaluation  process,  which  is  carried  out  by  independent  external 
experts.  This  additional  assessment  aims  to  make  sure  that  the  EU  is  not 
supporting research which might violate fundamental ethical principles; 
–  Encouraging the participation of social scientists and ethicists in research projects 
as well as integration of the analyses of the ethical, legal and social aspects into 
research  projects  funded  under  Priority  1  "Life  sciences,  genomics  and 
biotechnology for health" and Priority 5 “ Food quality and safety”; 
–  Encouraging participation of stakeholders, including NGOs, in research projects 
and dialogue with the wider public in the research strategy; 
–  Supporting specific actions to promote the debate on ethical, legal, social and 
wider cultural aspects of Life Sciences and Biotechnology, as well as monitoring 
and evaluating consequences
65.  
In summary, this action remains of strategic importance and it is the Commission's 
intention to continue to apply these tools for governance of research funded under 
FP7. Governance of research, in particular at project level, should also be encouraged 
at national level.  
Action 14 should continue to promote the integration of socio-economic and 
ethical issues 
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Action 15 - European Group on Ethics –EGE and related activities 
The  European  Group  on  Ethics  (EGE)
66  is  an  independent,  pluralist  and 
multidisciplinary  body  which  has  the  institutional  role  of  advising  the  European 
Commission on ethical aspects of science and new technologies.  
Following the Communication from the Commission (COM(2005) 243 final), and a 
request  from  the  President,  the  EGE  issued  in  January  2007,  an  Opinion  on  the 
Ethics  of  nanomedicine
67.  During  2006,  the  EGE  has  had  hearings  with  relevant 
experts on a bi-monthly basis, met the Austrian National Ethics Council (NEC) in 
May 2006 -under the Austrian Presidency-, met both the FI NEC under the Finnish 
Presidency and, also on that occasion, the National Ethics Councils Forum (EU 25 
NEC) in September 2006. The EGE also organised a public round table on ethics and 
nanomedicine in March 2006.  
The  Global  dimension  of  science  and  technology  and  the  intention  of  the 
Commission  to  take  an  active  role  in  discussions  on  ethical,  legal  and  social 
implications of biotechnology are not news but the main challenge is the relevance 
the Commission is attributing to it by promoting and actively participating in debates 
on  ethics  in  the  EU  and  beyond.  Therefore,  actions  focusing  on  international 
dimensions will be carried out (networking between relevant ethics bodies and the 
creation of an International discussion platforms on ethics and science) as well as 
actions to reinforce the role of the EGE in current debates on ethics of science and 
new technologies. 
An  International  Platform  clustering  National  Ethics  Councils  of  several  non-
European  Countries  will  be  established  by  the  EGE  Secretariat,  and  a  platform 
between  the  Commission  services  dealing  with  ethics  and  bioethics  has  been 
established in the second half of 2006. The platform will be chaired by the Bureau of 
the European Policy Advisors (BEPA) to the President and will discuss the European 
Union's actions in the fields of ethics and European policies.  
Networking  of  ethical  bodies  will  remain  an  important  task  of  the  Commission. 
Some examples of networking activities promoted and supported by the Commission 
include: a) A Forum of National Ethics Councils (NEC Forum) established in 2003 
now  involving  all  27  Member  States
68.  It  consists  of  the  chairpersons  and  the 
secretaries of the national ethics councils; b) a European Network of Research Ethics 
Committees  (EUREC)  which  will  consist  of  almost  all  national  associations  of 
research ethics committees in Europe. 
Action 15 should continue 
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Action  16  -  Ethical  guidance  for  best  practice  in  the  context  of  EC  funded 
research projects  
The need for the development of ethical guidance for best practice in the context of 
EC funded research projects has been highlighted in the area of Life Sciences and 
Biotechnology during FP6 and should be pursued. Many emerging issues (cloning of 
animals,  use  of  non  human  primates  for  non-medical  research…)  and  the  high 
importance  of  ethical  issues  for  public  acceptance  of  biotechnology  justify  a 
particular priority being given to action in the field of ethics.  
The Commission is closely following the regulatory developments in Member States 
regarding biobanks, stem cell research and genetic testing
69. 
The development of guidelines on ethics which go beyond guidance for EC funded 
research  is  not  likely  to  be  achievable.  However  the  experience  from  the  ethical 
review and the implementation of research projects in the areas of Life Sciences and 
Biotechnology  under  FP6  have  underlined  the  need  to  develop  guidance  for  EC 
funded projects and an educational package is currently being prepared and should 
be available in early 2007. This will be the core curriculum to enable the research 
community to address ethical issues throughout an EC funded project lifecycle. 
Action 16 should continue under FP7 
Action 17 – Coexistence of GM crop with conventional and organic farming 
Coexistence remains a key issue for the development of green biotechnology in the 
EU. The adoption of legislation on co-existence is under the competence of Member 
States.  In  2003  the  Commission  adopted  Recommendation  2003/556/EC  on 
guidelines for the development of national strategies and best practices to ensure the 
co-existence of genetically modified crops with conventional and organic farming, 
which  is  intended  to  help  Member  States  develop  national  legislative  or  other 
strategies for coexistence. 
Actions will continue to be undertaken by the Commission in this field, in particular 
further to the conclusions of the April 2006 co-existence conference in Vienna and 
the May 2006 Agriculture Council conclusions. The emerging non-food/feed uses of 
GM crops (biofuel, industrial raw materials and pharmaceuticals) will require further 
action.  These  new  types  of  GMOs  provide  challenges  with  respect  to  the  risk 
assessment, but also with respect to co-existence, given the possible need for specific 
thresholds. There is currently much interest in non-food GMOs, so this emerging 
issue needs to be tackled. 
Significant progress has been made in the field of co-existence. The Commission 
continued  to  assess  national  co-existence  measures  that  were  notified  to  the 
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Commission under the procedure of Directive 98/34/EC laying down a procedure for 
the provision of information in the field of technical standards and regulations
70. 
New  case  studies  on  the  co-existence  of  GM  and  non-GM  crops  in  European 
agriculture were published by the Commission in January 2006
71. 
On  9  March  2006  the  Commission  adopted  a  report  on  the  implementation  of 
national  measures  on  the  co-existence  of  genetically  modified  crops  with 
conventional  and  organic  farming
72.  This  provides  an  overview  of  national  co-
existence measures adopted or being discussed in the Member States. In the report 
the Commission proposes a number of future actions to be taken in relation to co-
existence.  
In March 2006 the Commission also launched a study on liability in cases of damage 
resulting from the presence of GMOs in non-GM crops, which is aimed at providing 
an overview of the present legal situation in the Member States on this issue. 
On 4-6 April 2006 the Commission jointly organised with the Austrian Presidency of 
the Council the conference "Co-existence of genetically modified, conventional and 
organic crops – freedom of choice"
73, which took place in Vienna. This conference 
allowed  an  exchange  of information  and  positions  on  co-existence  among  policy 
makers, scientists, and a broad range of stakeholders, such as farmers and consumers' 
associations, NGOs, seed producers, importers, food and feed processors, etc. 
On 9 May 2006 the Council adopted conclusions on co-existence, which include 
general considerations on this issue as well as proposals for future actions by the 
Commission. 
The coordination network on co-existence, COEX-NET, has continued its activities, 
which are aimed at enhancing the exchange of information among Member States on 
regulatory approaches and practical experiences of co-existence. Future activities of 
this  network  group  will  be  of  particular  importance  to  further  the  exchange  of 
information among Member States on co-existence. 
The increased use of stacked GM events poses new challenges to the development of 
quality assurance tools for the measurement of individual and combined GM events 
in crops. 
The Commission has developed 9 new sets of certified reference materials for the 
identification and quantification of genetically modified crops. This supports also the 
reliable differentiation between conventional/organic farming and GM crops. Further 
research activities in relation to co-existence are funded under FP6, notably the large 
research projects SIGMEA, CO-EXTRA and TRANSCONTAINER with a total joint 
budget of €17 million in which the Commission also participates. Following the two 
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calls for proposals, 17 actions were selected for co-funding, and the corresponding 
grant agreements, involving 17 coordinators and 162 partners in 25 Member States 
and 12 countries outside the EU have been signed. 
Concerning the conservation of genetic resources in agriculture, the Commission put 
forward a proposal for the establishment of a new Community Programme, which 
was adopted by Council on 24 April 2004 (Council Regulation (EC) No 870/2004). 
The Community Programme, which covers the period 2004-2006, has a total budget 
of  €10  million.  It  applies  to  the  conservation,  characterisation,  collection  and 
utilisation of plant, animal and microbial genetic resources that are or could be of use 
in agriculture. A corresponding work programme was adopted by the Commission on 
28 December 2004
74. The first call for proposals was launched on 26 July 2005
75 and 
a second call on 28 April 2006
76.  
The  actions  that  will  be  co-funded  have  a  maximum  duration  of  4  years.  The 
implementation of the Community Programme will cover the period until 2010. 
The  stated  objective  of  launching  a  new  action  programme  for  the  conservation, 
characterisation, collection and utilisation of genetic resources in agriculture in the 
Community has thus been fully achieved.  
Scientific support for the implementation of co-existence, as well as the agricultural, 
environmental  and  economic  assessment  of  policies  remains  important.  FP7  will 
continue  to  support  this  area  of  research  including  the  development  of  new 
assessment tools. 
As a conclusion, co-existence will remain an important issue to be addressed in the 
future.  Only  a  few  Member  States  have  already  adopted  national  co-existence 
measures. Many Member States have not yet developed a legislative framework for 
coexistence or good farming practices for technical field measures in relation to crop 
segregation.  Practical  experience  with  commercial  GM  crop  cultivation  is  still 
limited in most Member States. Amongst other measures, a need for guidelines with 
crop specific segregation measures, guidance in relation to cross-border issues, and 
sustainable solutions in cases, where co-existence is difficult to establish at local 
level,  have  been  identified.  In  this  context,  research  will  continue  to  play  an 
important role. Furthermore, the Council invited the Commission to explore whether 
further steps towards common principles regarding co-existence should be taken and 
to adopt labelling thresholds for the adventitious presence of GMOs in conventional 
seed lots. Based on an impact assessment which will be carried out in 2007, the 
Commission will consider whether it is necessary to establish these thresholds and 
for which products. 
The Commission will continue its activities in relation to co-existence. It will carry 
on to assess national co-existence measures and to support research activities under 
the Framework Programme as well as via direct research conducted by the Joint 
Research Centre (JRC) in relation to co-existence. It will continue work on suitable 
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approaches to implement the mandate for further work on co-existence provided by 
the Commission's co-existence report and the Council conclusions. In particular, the 
Commission will establish a Bureau for the elaboration of crop-specific guidance 
documents for co-existence measures, including, where appropriate, measures aimed 
at  preventing  cross-border  problems  and  recommendations  for  regions,  where 
farming conditions make farm-level co-existence difficult to achieve. 
Concerning the conservation, characterisation, collection and utilisation of genetic 
resources  in  agriculture,  Council  Regulation  (EC)  No  870/2004  foresees  an 
evaluation of the Community Programme by independent experts at the end of the 
Programme.  The  evaluation  report  shall  assess the  results  of  the  Programme  and 
make  appropriate  recommendations,  and  it  shall  be  submitted  to  the  European 
Parliament,  the  Council and  the  European  Economic  and  Social  Committee.  The 
discussion  on  the  need  for  revising  the  current  policy,  considering  also  new  and 
emerging challenges, will take place in this context.  
The objective stated in Action 17 regarding co-existence was met, but further 
activities in this area are required 
Action 18 – Legislative development in the field of pharmaceuticals  
The aim of this action was to speed up the adoption of three legislative proposals in 
the field of pharmaceutical.  
Regarding action 18a, scientific advice has been reinforced and made easier in the 
2004 revision of the Pharmaceutical legislation. Each committee of the EMEA has 
now established a standing working party with the sole remit of providing scientific 
advice to undertakings. The EMEA has also put in place a ‘New Framework for 
Scientific Advice & Protocol Assistance’
77, which introduces significant changes to 
the way the Agency provides scientific advice on the research and development of 
new medicines. The main aspects of the new framework include:  
–  earlier and greater systematic involvement of internal and external experts from 
the pre-submission phase to the final adoption of scientific advice;  
–  faster  delivery  of  the  advice  to  sponsors  to  allow  finalisation  within  40  to  a 
maximum of 70 days;  
–  increased transparency and communication with stakeholders. 
Regarding  action  18b,  an  accelerated  procedure  has  been  introduced  in  the  2005 
revision of the Pharmaceutical legislation. When an application is submitted for a 
medicinal product that is of major public health interest and in particular from the 
viewpoint of therapeutic innovation, the assessment time may be reduced from 210 
to 150 days.  
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Regarding action 18c, a Regulation on the conditional marketing authorisation for 
medicinal  products  for  human  use  falling  within  the  scope  of  the  'centralised 
procedure' (e.g. biotech products) has been adopted in March 2006
78. 
The action can now be considered as achieved with objectives completed 
Action  19  -  New  legislation  on  GM  food  and  feed,  and  on  the  labelling  and 
traceability of GMOs 
The aim of this action was the adoption of new legislation on GM food and feed, and 
on the labelling and traceability of GMOs.  
On 10 May 2006 the Commission issued to the Council and the European Parliament 
a report on the implementation of Regulation(EC) No. 1830/2003, based on the input 
from all involved stakeholders
79. The majority of stakeholders have pointed to the 
fact that the Regulation has only been operational for a limited period of time and 
that experience in terms of its implementation is extremely limited. Therefore the 
Commission will draw up a second report, following a further period of 24 months to 
enable a more complete picture of implementation to be obtained. 
Furthermore, on 25 October 2006, the Commission adopted a report to the Council 
and  the  European  Parliament  on  the  implementation  of  Regulation  (EC)  No 
1829/2003 of the European Parliament and of the Council on genetically modified 
food and feed
80. 
The objective has been fulfilled and action 19 can now be considered as achieved  
Action  20  -  GM  plant  propagating  material,  environmental  liability  and  the 
implementation of the Biosafety Protocol 
This action can be considered as achieved, since the Biosafety Protocol
81 has been 
ratified and implemented by the EC, the final piece of legislation adopted to this 
extent  being  Regulation  1946/2003
82.  Directive  2004/35/EC  on  environmental 
liability
83 has also been adopted, and there is no planned legislation on GM plant 
propagating material on top of GMO legislation. 
The objective has been fulfilled and action 20 can now be considered as achieved  
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Action 21 - Implementation and enforcement activities 
As far as the adoption of implementing measures under Regulation 1829/2003 and 
Directive 2001/18/EC are concerned this action should be considered as achieved. 
An  updated  list  of  the  implementing  measure  of  Directive  2001/18/EC  and 
Regulation (EC) No. 1830/2003 can be found on the Europa webpage
84. Reports on 
the implementation of the above mentioned legislation are published on a regular 
basis.  Complementing  this  strictly  regulatory  approach,  detailed  information  and 
further guidance is provided by the Commission on reference materials, validation 
processes and activities of the Community Reference Laboratory for GM Food and 
Feed
85. Given the huge importance of reference material and detection methods for 
the enforcement of EC legislation, and in light of the recent Bt10, LL601 and Chine 
rice scandals, this action needs to be refocused and continued. 
As far as the legal framework on GMOs is concerned, all Member States apart from 
France  have  notified  the  Commission  of  their  transposition  acts  of  Directive 
2001/18/EC.  The  conformity  check  on  these  acts  is  currently  ongoing.  Two 
infringement procedures are currently open: one against France for non transposition 
of Directive 2001/18/EC and one against Poland for a general ban of GM seeds. 
Furthermore, there is one pending case  at the  ECJ regarding the imposition of a 
general ban on GMOs in the region of Upper Austria. 
The  Commission  is  also  checking  the  legality  of  the  co-existence  measures  of 
Member States as notified under the procedure of Directive 98/34/EC. 
In addition to the regulatory work on GM Food and Feed (Regulation 1829/2003) 
and on traceability and labelling (Regulation 1830/2003), the Commission has issued 
Commission Recommendation 2004/787/EC on technical guidance for sampling and 
detection of genetically modified organisms and material produced from genetically 
modified  organisms  as  or  in  products  in  the  context  of  Regulation  1830/2003
86. 
These  guidelines  also  provide  principles  for  expressing  percentages  of  GMOs. 
Moreover,  Commission  Regulation  65/2004,  establishing  a  system  for  the 
development  and  assignment  of  unique  identifiers  for  GMOs,  was  adopted  as 
implementing measure of Regulation 1830/2003 on traceability and labelling. 
The uniform implementation and monitoring of the EU legislation on GMOs has 
been supported by the development, production and distribution of new generations 
of matrix reference materials. Since 2002, the following GMO Certified Reference 
Materials,  each  consisting  of  sets  of  different  GMO  concentrations,  have  been 
released:  RoundupReady®soybean,  Bt-176  maize,  Bt-11  maize,  GA21  maize, 
NK603 maize, MON 863 maize, MON 863 x MON 810 maize, 1507 maize, and 
MIR604  maize.  These  reference  materials  are  widely  used  by  Member  State 
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laboratories and worldwide for calibration and quality assurance to fulfil regulations 
EC 1829/2003 and EC 1830/2003. 
A Regulation on detailed rules for the implementation of Article 32 of Regulation 
(EC)  No  1829/2003  as  regards  the  CRL  for  GMOs,  settling  the  issue  of  the 
contribution of applicants to the costs of the CRL and defining tasks and duties of 
CRL and of the European Network of GMO Laboratories has been adopted by the 
Commission on 22 December 2006
87. 
The  development  of  independent  calibration  standards  for  the  quantification  of  a 
wide range of GM products in the  frame of the labelling regulation represents  a 
considerable scientific challenge. Moreover, the creation of quality assurance tools 
which mimic closely the status of various commercial food products with respect to 
their  analytical  measurement  behaviour  poses  additional  challenges  to  reference 
material developers. 
As far as the adoption of implementing measures under Regulation 1829/2003 
and Directive 2001/18/EC are concerned, this action should be considered as 
achieved. Nonetheless, activities on reference materials and validation processes 
of detection methods are of key importance and need to be pursued 
Action 22 – Further improve the consistency of the legal framework on GMOs  
The action to improve the consistency and efficiency of the regulatory framework for 
the deliberate release of GMOs into the environment has been partially implemented 
with  the  entry  into  force  of  the  so  called  "one  door  one  key"  procedure  under 
Regulation 1829/2003. The Commission has issued its report on the implementation 
of Directive 2001/18/EC on 5 March 2007
88. As shown by the April 2006 College 
orientation  debate,  work  to  improve  the  consistency  and  the  efficiency  of  the 
regulatory framework is still needed. 
Action 22 needs to be continued 
Action 23 – Long term environmental impact of GMOs  
How to assess the potential long term positive and negative effects of GMOs on the 
environment  and  health  remains  a  key  issue,  both  scientifically,  technically  and 
politically, in particular with the arrival of so-called second and third generation of 
GMOs  Currently  commercially  available  GM  crops  (first  generation)  concern 
agronomic  input  (production)  traits  and  emerging  GM  crops  (second  and  third 
generation)  include  more  complex  traits  and  the  production  of  novel  products 
through molecular farming. There is clearly a need for further improvement in risk 
assessment  practices  as  regards  long  term  effects  on  the  environment  and 
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biodiversity  for  reasons  of  substance  (experience  with  import  and  cultivation  of 
GMOs  in  Europe  somewhat  limited)  and  in  order  to  increase  confidence  in  the 
scientific  basis  of  the  decision-making  process  on  GMOs.  This  action  should  be 
given high priority given its key role in restoring confidence in the regulatory process 
and  in  preparing  methods  to  address  forthcoming  challenges.  In  particular  it  is 
important to further address the potential contributions of GMOs to address global 
challenges. European agriculture faces major challenges related to climate change, 
for instance regarding water management. Biotechnology could contribute towards 
helping EU agriculture to address some of these challenges while maintaining its 
competitiveness. 
New and emerging issues on GM crops for non-food uses, such as in agricultural 
production of biofuels, biomass, industrial raw materials and pharmaceuticals will 
require  further  attention.  The  development  of  molecular  farming  raises  new 
opportunities but poses also new challenges and makes the development of quality 
assurance  tools  a  high  priority.  Consideration  should  be  given  to  regarding  how 
future GMOs for non-food applications (e.g. for producing vaccines or monoclonal 
antibodies) could be produced in a way which does not compromise the safety of 
food production and biodiversity. There may therefore be a need to adapt existing 
guidance on the environmental risk assessment and monitoring of potential adverse 
effects on the environment, including the long-term effects, of particular types of 
GMOs, like animals, or for particular uses of GMOs, such as non-food applications. 
Under FP6 several research projects have started on GM traceability and safety of 
which the most important ones are SAFEFOODS and NOFORISK. On a regular base 
EFSA and Commission services are informed about the progress of these projects. 
How to assess long term effects on the environment and health of GMOs at the pre- 
and  post-market  assessment  stage  remains  a  scientific  challenge  that  will  be 
addressed under FP7. 
EFSA has established a self-tasking working group to study requirements for Post 
Market Environmental Monitoring (PMEM WG) in order to produce guidance for 
both applicants and regulatory authorities. Based on its mandate, the PMEM WG 
initiated a series of consultation workshops with different stakeholders (applicants, 
environmental  NGOs  and  scientific  institutes,  experts  from  Member  States)  to 
establish a rationale and general framework for General Surveillance as a component 
of Post Market Environmental Monitoring
89. EFSA's PMEM Working Group intends 
to publish a new version for the chapter 11.4 "General Surveillance of the Impacts of 
the GM Plants" of the "Guidance Document for the Risk Assessment of GM Plants 
and Derived Food and Feed". 
The  Commission  has  also  established  a  Working  Group  with  the  Competent 
Authorities designated under Directive 2001/18/EC, to examine these issues. It is 
expected to finalise its work in 2007. 
The Commission and EFSA will endeavour to define how monitoring plans should 
be tailored to address potential long-term effects taking into account the work of the 
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Member  State  Monitoring  Working  Group  which  has  been  established  under 
Directive 2001/18/EC (c.f. Annex VII) and the implementing measure adopted under 
Directive 2001/18/EC which addresses the objective, general principles and design of 
the  monitoring  plan
90.  Moreover,  in  view  of  the  outcome  of  the  risk  assessment, 
further consideration will be given as to the extent of risk management measures 
required to address potential long-term effects. Further consideration is also needed 
on  whether  and  how  relevant  representative  geographical  areas  in  relation  to  the 
release of the GMO in question could be taken into account in the context of the 
above exercise. 
Action 23 should be given a high priority as further assessment of the long term 
positive/negative effects of GMOs on the environment and health is key to the 
implementation of the relevant legislation 
Action 24 – Development of international standards in the field of biotechnology  
The  recent  incidents  with  the  transboundary  movement  of  unapproved  GMOs 
demonstrate that there is an urgent need to further develop the framework for the 
international governance of GMOs. The EU should continue to play a leading role in 
developing  international  guidelines,  standards  and  recommendations,  in  particular 
regarding the implementation of the Cartagena Protocol on Biosafety and activities in 
standards bodies and Codex (including the discussions on adventitious presence), 
where the Commission continues to play a key role.  
The Commission actively participates in the meetings of the Codex Task Force on 
Biotechnology.  This  Task  Force  has  produced  guidelines  for  the  food  safety 
assessment  of  plants  and  micro-organisms  derived  from  modern  biotechnology. 
Work is ongoing in order to develop a similar guidance document for the food safety 
assessment  of  recombinant  DNA  animals  and  plants  modified  for  nutritional  or 
health benefit. The Task Force has agreed in its 6
th session to commence work on the 
low  level  presence  of  recombinant-DNA  plant  material  in  food  resulting  from 
asynchronous authorisation. The focus of this work will be two-fold; on developing 
guidelines on the risk assessment of this low-level presence and on the data and 
information mechanisms necessary to facilitate this assessment. 
The Commission plays a lead technical role in a number of international bodies that 
are responsible for setting the standards such as: 
–  CEN: the European Committee for Standardisation
91; 
–  ISO: the International Organization for Standardization
92; 
–  Codex Alimentarius
93. 
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The Commission has contributed significantly to the development of international 
guidelines and standards for bioanalysis. For instance, the revision of ISO Standards 
(such  as  15193  'reference  measurement  procedures  for  in  vitro  diagnostics'  and 
15194 'reference materials for in vitro diagnostic measurements') and ISO Guides 
(such as Guide 35 'certification of reference materials') and the development of new 
standards  for  GMO  analysis  (such  as  EN  ISO  21570  'quantitative  DNA-based 
detection  standard',  EN  ISO  24276  'general  document',  EN  ISO  21571  'DNA 
extraction standard', EN ISO 21572 'protein based method standard', EN ISO 21569 
'qualitative  DNA-based  standard')  were  performed  with  the  support  of  the 
Commission's Joint Research Centre.  
Scientific  advice,  recommendations  and  measurement  standards  are  regularly 
provided to international metrology, standardization and accreditation bodies such as 
CIPM/CCQM,  CEN,  ISO,  AOAC,  EA  and  ILAC.  By  that  the  international 
measurement system and infrastructure is further developed and supported to allow 
the obtaining of reliable and harmonised measurement results in life sciences and 
biotechnology.  The  Commission  is  also  involved  in  the  Joint  Committee  for 
Traceability  in  Laboratory  Medicine  (JCTLM).  It  co-chairs  the  WG  'Reference 
materials and reference methods' for the evaluation of corresponding applications for 
inclusion in the JCTLM/BIPM database of materials and methods of higher order for 
in vitro diagnostics. 
The Commission chairs the European Network of GMO Laboratories, which is a 
consortium of all 25 EU enforcement laboratories (plus Norway, Switzerland). In 
addition to providing support to the Community Reference Laboratory for GM Food 
and Feed, this network contributes to the harmonisation and standardisation of GMO 
detection  protocols.  In  this  context  the  Commission  is  developing  a  guidance 
document  on  the  evaluation  of  the  measurement  uncertainty  during  GM 
quantification.  In  2004  The  Commission's  DG  JRC/IRMM  pioneered  to  become 
worldwide the first institution to be accredited for the production of GM reference 
materials. 
In the context of nanobiotechnology, the Commission contributes to the planning and 
performance  of  research  for  new  testing  methodologies  for  risk  assessment  of 
engineered nanomaterials and the development of new biosensors. The Commission 
participates  in  CEN  and  ISO  Technical  Committees  for  the  development  of 
international  standards  in  the  field  of  nanotechnologies.  A  strategy  for  the 
Commission's  activities  with  regard  to  nanotechnology,  in  particular 
nanobiotechnology, is currently being prepared on the basis of a Commission action 
plan from 2005
94. 
The  further  development  of  international  guidelines  and  standards,  including 
measurement standards, for harmonised and reliable measurements of a large range 
of  parameters  relevant  to  life  sciences  and  biotechnology  continues  to  make 
necessary major scientific challenges. 
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Information on recent developments under the Cartagena Protocol on Biosafety is 
available online
95. The Cartagena Protocol has now been ratified by 138 countries. 
For 2007, work is continuing in particular on liability and redress (Article 27 of the 
Protocol),  identification  of  living  modified  organisms  (Article  18.2(a)  of  the 
Protocol)  as  well  as  on  capacity  building,  the  Biosafety  Clearing  House,  risk 
assessment and further development of the Roster of Biosafety Experts. 
Action 24 needs to be continued 
Action 25 - Cooperation with the developing world in the field of agricultural 
biotechnology 
Biotechnology  has  also  a  potential  to  contribute  to  the  objective  of  the  EU's 
Development Cooperation Policy Framework, which emphasises that the EU will 
promote  the  integration  of  development  objectives  into  its  R&D  and  innovation 
policies, and that the EU will continue to assist developing countries in enhancing 
their domestic capacities in the area of Sciences and Technology. Indeed, the EU 
already supports global, regional and national efforts in research and development to 
address the special needs of developing countries in the areas of health, including 
prevention and treatment of HIV/AIDS, agriculture, natural resource, environmental 
management, energy, and climate. 
The  Strategy  is  highly  relevant  to  three  of  the  12  of  the  Policy  Coherence  for 
Development
96  thematic  priorities  (Environment,  Agriculture,  and  Science  and 
Innovation),  and  development  issues  should  continue  to  be  taken  into  account, 
special attention being given to: 
–  Engaging in scientific partnerships with developing countries so that they benefit 
from technological development, amongst others, in the field of agricultural and 
environmental research; 
–  Addressing  specific  problems  that  third  countries  face  or  that  have  a  global 
character, and where biotechnology can contribute to finding solutions; 
–  Pursuing  the  EU  commitment  to  a  strengthening  and  implementation  of  the 
Cartagena Protocol on Biosafety
97, of the Bonn Guidelines on Access and Benefit 
Sharing and of the FAO International Treaty on Plant Genetic Resources for Food 
and Agriculture. 
Thus, this action aiming at enhancing cooperation with the developing world in the 
field of agricultural biotechnology still remains important and should possibly be 
reviewed in the context of the UN Millennium Development Goals
98.  
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The Commission has played a key role in the elaboration and entry into force of the 
Cartagena Protocol on Biosafety
99, and continues to be one of the driving forces in its 
further  development  (for  example  in  the  field  of  identification  of  GMOs  or  in 
reflection on possible liability regimes). The Cartagena Protocol is a key element of 
cooperation with the developing world in the field of agricultural biotechnology. 
The  INCO  programme  has  launched  two  calls  aiming  at  promoting  international 
research with the Developing Countries on "Bio-diverse, bio-safe and value added 
crops" which is a research area of the 'food security' priority. The area deals with 
research to increase the sustainable use and productivity of annual and perennial 
under-utilised  tropical  and  sub-tropical  crops  and  species  important  for  the 
livelihoods of local populations. This means crops with a potential for wider use 
contributing to food security, agricultural diversification and income generation. The 
calls  emphasized  the  need  for  innovative  tools  and  techniques  for  the 
characterisation, development and use of crops with enhanced tolerance to abiotic 
stress,  particularly  'Tolerance  to  drought,  salinity,  heat,  cold';  'Enhanced  nutrient 
uptake' and 'Enhanced tolerance to heavy metals and acid soil'. INCO teams are set 
up on the principle of equitable partnership building (3+3). Calls were also launched 
on “Health of livestock populations” largely focused on livestock health protection 
through the development and use of diagnostic tools and vaccines.  
The Commission is also engaged in the selection of research proposals from the 
CGIAR
100  and  in  particular  of  co-funding  the  Generation  Challenge  Programme 
(GCP).  This  programme  aims  to  unlock  the  genetic  diversity  of  crops  for  the 
resource-poor. The activities of the GCP are centred on identifying genetic diversity 
of the genetic resource collections of the CGIAR, comparative genomics, improving 
plant traits, bio-informatics and capacity building. 
A number of projects involving partners from developing and "emerging" countries 
have been implemented under the thematic priority "Food quality and safety". These 
projects cover a large range of issues including: 
–  Adaptation  to  European  food  quality  and  safety standards  of  food  products  in 
exporting countries, including food traceability and food-chain approach; 
–  Establishment of scientific fora fostering bilateral dialogues in the area of food, 
agriculture and biotechnology research (including trade-related issues) between 
the EU and other regions in the world; 
–  Global issues interesting Europe and different regions in the world like sustainable 
use of water in agriculture, mycotoxins in food products, food allergies, food born 
diseases, the use of microbial resources, agricultural biodiversity, food processing 
wastes, diet and health, epizootics and zoonotic diseases. 
As a conclusion, this action remains important and should be reviewed in the context 
of the UN Millenium Development Goals.  
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International cooperation will be addressed in all programs under FP7 and priorities 
will be defined according to the principle of mutual benefits and shared interests 
between the EU and the targeted region, taking into account local needs and socio-
economic contexts. Special attention will be given to the achievement of the UN 
Millenium Development Goals in the case of "Specific International Co-operation 
Actions" dealing with the poorest countries. 
Any research agenda on biotech should take into account the negotiations/outcomes 
of various inter-governmental fora in this domain.  
The EC Strategy on Agricultural Research for Development (ARD) has been updated 
in  2004  in  cooperation  with  Member  States,  through  the  European  Initiative  for 
Agricultural  Research  for  Development  (EIARD).  The  updated  strategy  includes 
giving  support  to  the  global,  continental  and  regional  ARD  multi-stakeholders 
networks and platforms in order to: 
–  actively include farmers and other stakeholders in the development and setting of 
ARD priorities; 
–  Develop a more integrated approach to ARD, including the integration of new and 
traditional techniques. 
The Commission has supported the development of research partnerships at national, 
sub-regional, regional and at global level through the implementation of Competitive 
Regional  Research  Programmes  and  through  the  CGIAR  Global  Challenge 
Programmes, in collaboration with Member States through EIARD. 
Capacity building and physical infrastructure have been supported through various 
financial instruments.  
The Commission has launched the European Technology Platforms with Strategic 
Research Agenda adopted in 2006. Main stakeholders contribute to the promotion of 
the European knowledge dissemination, through Private Public Partnership.  
The EC support to sub-regional, regional and international research organisations has 
been provided in consultation with Member States through EIARD. 
EC  provides  support  to  ARD  at  regional  level  through  EDF  regional  envelopes. 
Examples include the support given to sub  regional organisations (SRO) such as 
ASARECA for East and Central Africa, CORAF for Western and Central Africa and 
SADC for Southern Africa. 
The EC support to the International Agricultural Research Centres of the CGIAR for 
the period 2002-2006 has been provided, for an average amount of €22 million per 
year.  Member  States  through  EIARD  regularly  collaborate  in  the  allocation  and 
monitoring process. 
For the future, the new Thematic Programme on Food Security 2007-210 (FSTP) is 
being  finalised  and  will  become  operational  in  2007.  The  FSTP  will  support  the 
delivery  of  international  public  goods  contributing  to  food  security:  research  and 
technology. The FSTP aims at contributing to the delivery of scientific, technological  
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innovations and policies responding to beneficiaries’ needs and the enhancing of the 
active role of low-income smallholder farmers in research programmes. 
The  FSTP  will  include  support  for  continental,  regional  and  sub-regional 
programmes  and  institutions,  which  coordinate  and  support  national  agricultural 
research systems. 
Research Partnerships will be further supported through the incoming FSTP. The 
FSTP will support the exchange of information, experience and knowledge, through 
scientific networks and (multi)stakeholder platforms to strengthen Institutions and 
capacities of developing countries. 
Funds from FP7 will be allocated to support SRA activities. 
The EC support for the sub-regional, regional and international organisations and to 
the International Agricultural Research Centres of the CGIAR for the period 2007-
2010 will be included in the Multi-Annual Indicative Programme of the new FSTP. 
The EC ARD strategy will be updated in early 2007, in collaboration with Member 
States through EIARD, taking into account the new EC/EU development policies, the 
evolution  of  the  international  ARD  actors,  the  state  of  attainment  of  MDGs,  the 
global  drivers  for  ARD  (e.g.  trade  liberalization,  climate  change,  emerging 
economies, decentralization processes), the emerging of new ARD paradigms (rural 
innovation systems, knowledge systems), the evolution of Science and Technology, 
trends in ARD financing (public and private). 
Action 25 needs to be continued 
Action  26  -  Cooperation  with  the  developing  world  in  the  field  of  genetic 
resources 
This action aiming at enhancing cooperation with the developing world in the field of 
genetic resources should be pursued and Commission and Member States should 
continue their active engagement in the relevant international fora. 
The Commission and the Member States have been actively engaged in the relevant 
different international fora (TRIPs
101, CBD
102, WIPO
103 and FAO
104). 
At the WTO, the Commission actively participated in the review of Article 27.3.b of 
the TRIPs and examination of the relationship between the TRIPS Agreement and 
the CBD. In 2002 the Commission presented a submission that was well received by 
developing  countries.  The  Commission  continues  its  active  participation  in  the 
debate on TRIPS and Biodiversity.  
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In the CBD, the Commission and the Member States were active negotiators of the 
Bonn Guidelines on Access and Benefit Sharing adopted in 2002. The Commission 
is  actively  engaged  in  negotiations  of  an  International  Regime  on  Access  and 
Benefit-sharing. The negotiations are supposed to be completed at the latest in 2010. 
At WIPO, in 2004 the EU submitted a proposal that if accepted would introduce a 
mandatory  requirement  to  disclose  the  country  of  origin  or  source  of  genetic 
resources in patent applications.  
At  the  FAO,  the  European  Community  and  22  Member  States  ratified  the 
International Treaty on Plant Genetic Resources. The Commission and the Member 
States  have  been  active  negotiators  in  its  implementation,  including  the  recently 
adopted standard Material Transfer Agreement  
International discussions on the issues within the different relevant forum continue. 
The Commission and the Member States should continue to support the objective of 
the action. 
There  is  no  need  to  revise  the  policy  or  actions.  But,  the  Commission  and  the 
Member States should continue their active engagement in international discussions/ 
negotiations  in  the  appropriate  fora  for  the  development  or  the  enforcement  of 
effective measures to provide access to genetic resources and to share equitably the 
benefits arising from the utilization of genetic resources and associated traditional 
knowledge. This implies the following actions: 
–  Continue to support mandatory disclosure of the country of origin or source of 
genetic resources and associated traditional knowledge in patent applications in 
WIPO; 
–  Continue  to  actively  participate  in  the  debate  on  TRIPS  and  CBD  in  the 
WTO/TRIPS; 
–  Completion of the negotiations of an International Regime on Access and Benefit-
sharing in the CBD framework; 
–  Implementation of the International Treaty on Plant Genetic Resources for Food 
and Agriculture. 
Furthermore,  in  2007,  the  Commission  will  support  part  of  an  international 
conference  about  Animal  Genetic  resources.  A  deep  inventory  of  indigenous 
resources has been carried out worldwide under the FAO coordination. Main results 
and next steps will be presented during the Conference in Switzerland. 
Action 26 needs to be continued 
Action 27 – Combat poverty related diseases 
The EU's commitment to research to combat HIV, Malaria, TB and other poverty 
related diseases has been concretised under FP6 and shall be pursued. Issues such as 
food, health, malnutrition and the influence of global environmental changes should 
also be added.  
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Under  FP6  poverty  related  diseases  section,  numerous  projects  focused  on 
developing  promising  and  innovative  interventions  (vaccines,  drugs  and 
microbicides)  against  HIV/AIDS,  TB  and  malaria  have  been  funded.  The  total 
budget allocated for this area in FP6 under the thematic priority 1 is estimated at 
€221.5 million (1st call: €73 million, 2nd call €27.5million, 3rd call: €54 million, 4th 
call:  €67  million).  Most  of  the  projects  are  based  on  the  collaboration  with 
developing countries. Further support under FP6 was provided during 2004 by means 
of a special call for high risk and innovative projects (STREP/SSA) in drug and 
vaccine development for HIV/AIDS, TB and malaria. The total budget was €27.5 
million. There were 16 STREPs selected (€14.2 million: for 7 projects in the field of 
HIV/AIDS, 5 in the field of malaria, 4 in the field of TB) and 5 SSAs (€1.3 million: 
for 2 projects in the field of HIV/AIDS and 3 in the field of TB). 
A project looking at the redistribution and spread of malaria in Europe and North 
Africa as a result of global environmental changes was supported under the thematic 
priority "Sustainable development". 
The  European  and  Developing  Countries  Clinical  Trials  Partnership  (EDCTP) 
initiative
105,  with  its  Head  Office  located  in  The  Hague  (The  Netherlands)  was 
officially launched at the beginning of 2004 and an African Office of the EDCTP 
was opened in Cape-Town (South Africa) in July 2004. A balanced North/South 
partnership  and  the  networking/coordination  of  participating  European  States' 
national programmes have been widely considered in the setting-up of the structure 
of  this  pilot  EU  initiative  which  now  operates  within  its  own  implementation 
structures, calls for proposals, evaluation and selection procedures. 
In the first EDCTP call, 9 projects on phase II /phase III clinical trials in the field of 
HIV/AIDS,  tuberculosis and  malaria  drugs  have  been  selected  for  funding  and  6 
senior fellowships were granted to African scientists. A total volume of about €20 
million  is  committed  and  31  partners  are  concerned  from  African  institutions 
representing 16 sub-Saharan African countries.  
Following  the  second  EDCTP  call,  final  negotiations  with  the  selected  proposals 
should start shortly. It is worth noting that for the first time participating European 
States  co-fund  EDCTP  projects  in  through  contributing  to  a  total  budget  of  €25 
million (to be equally funded/devoted by the EC budget and by the participating 
European  States).  The  projects  cover  research  on  microbicides  against  sexual 
transmission of HIV, capacity building and site development for TB vaccines as well 
as combination therapies against double-infected HIV/TB patients. 
Referring to the third EDCTP call, clinical trials for the three diseases and capacity 
building activities will be considered. The call is expected to be launched during the 
second half of 2006. 
The  South  African  Cochran  database  (A  Clinical  Trial  Registry)  has  also  been 
selected.  
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In  2004,  the  operational  basis  for  the  networking  and  coordination  of  National 
Programmes  was  set  up  through  the  establishment  of  the  European  Network  of 
National Programmes (ENNP) 
In the annual “Work Programme 2005” for grants issued by the Commission in April 
2005,  a  restrain  call  in  support  of  clinical  trials  sites  in  Africa,  selected  by  the 
EDCTP  programme  was  earmarked.  The  implementation  of  the  three  projects 
selected, following this call (for a total of € 15 million) is expected during the second 
half of 2006. 
Under  the  same  conditions  and  funding  scheme,  the  Commission's  support  to 
EDCTP has been recently renewed, according to the "Work Programme 2006" for 
grants. 
A project supporting the construction of new infrastructures of bio-safety level 3 and 
4  laboratories  for  studying  highly  contagious  diseases  (“EUTRICOD”)  including 
viral hemorrhagic fevers was initiated involving the Republic of Ghana and Uganda. 
During  2004,  additional  funds  were  also  made  available  to  support  North/South 
collaborative  research  projects  on  further  “neglected  tropical  diseases”,  on  child 
survival, on reproductive health and on “health systems research”. 
A number of initiatives on capacity building on ethics in developing and emerging 
countries are being supported by the Commission. Four African institutions together 
with  two  European  organizations  and  the  World  Health  Organization  have  come 
together to foster the networking of medical research ethics committees in Africa: 
Networking for Ethics on Biomedical Research in Africa (NEBRA). As a first step, 
the  project  will  identify  existing  ethics  review  capacity  and  needs  in  15  African 
countries. A series of training and capacity building workshops on ethical review of 
clinical trials has been launched in several developing countries through the project 
“European and Developing Countries Ethics Partnership”. 
The  European  Group  on  Ethics  issued  Opinion  (N°17)  on  the  ethics  of  clinical 
research in developing countries which has been published and is available online
106. 
The  Forum  of  National  Ethics  Councils  discussed  capacity  building  for  ethics 
committees  in  developing  countries  during  its  March  2006  meeting  in  Vienna, 
Austria. A presentation was made by the NEBRA project. Plans for an upcoming 
conference on this subject were welcomed. 
A project has been launched addressing the issue of genomics and benefit sharing 
with developing countries. 
From the above it is advisable that, in the future, the cooperation and exchange of 
information between projects like EUTRICOD or Committees like NEBRA with the 
EDCTP programme on clinical trials in Africa should be encouraged.  
As a conclusion, action 27 remains an important action. The issue of food, health and 
malnutrition should be addressed as well. These issues are important in the combat 
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against these diseases as the general health status and nutrition of the patients affect 
the outcome of treatments and prevention of diseases as well as mothers' nutrition 
during pregnancy and infancy. 
Consideration  should  also  be  given  to  the  influence  of  global  environmental 
changes
107,  and  the  action  should  include  food,  health  and  malnutrition  issues as 
policy actions as well as the influence of global environmental changes. 
There are also new and emerging challenges. Although the EDCTP is now operating, 
major issues still need to be addressed such as the necessity to attract further funds 
not earmarked for research (e.g. the private sector, in particular the pharma sector 
and biotech companies), the need to consolidate the global dimension of the EDCTP 
(e.g.  through  international  partnerships  with  the  New  Partnership  for  Africa’s 
Development (NEPAD), the International AIDS Vaccine Initiative (IAVI), the World 
Health Organisation (WHO), Glaxo Smith & Kline (GSK), Medicines for Malaria 
Venture (MMV) or the recently founded Global HIV Vaccine Enterprise (GVE)), the 
African  participation  and  ownership  within  the  EDCTP  and  finally  the  questions 
related to participating Member States’ medium and long term commitments vis-à 
vis EDCTP. It should do the same for more impact and visibility of the EDCTP at the 
global  level,  in  particular  through  the  G8,  where  the  EC  is  holding  an  observer 
position  and  participates/may  contribute  to  the  various  preparatory  documents  as 
well  to  the  final  statement.  Significant  efforts  are  currently  being  put  in  by  the 
Commission to that end. 
The  strong  implication  of  the  Commission  and  member  states  into  the  Global 
partnership to fight against Avian Flu and prevent an Influenza Pandemic includes 
support  to  developing  countries  and  their  Integrated  Action  Plan  focused  on 
strengthening sanitary services. 
Action 27 needs to be continued 
Action 28: Promote a responsible and careful use of biotechnology in developing 
countries 
This action aiming at promoting a responsible and careful use of biotechnology in 
developing countries should be continued. This includes, amongst other measures, 
continuous  involvement  in  projects  in  relation  to  the  implementation  of  the 
Cartagena Protocol on Biosafety, such as those from UNEP-GEF
108. 
The Commission launched in March 2005 a study: “Guidelines for Green, White, 
Blue and Red Biotechnologies”, on the potential future of “biotechnologies” in the 
Developing Countries. As a follow up to this study, the Commission is working on a 
Biotech policy document for the Developing Countries in mid 2007 the Commission 
will  propose  a  Strategic  Paper  about  its  support  for  developing  countries  on 
biotechnologies. In response to the beneficiaries' request, the paper will highlight the 
great need for capacity building. 
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With  support  from  the  international  community,  West  African  countries  and 
Regional Economic Communities (ECOWAS, WAEMU) have identified their needs 
and gaps in dealing with biotechnologies/challenges and appreciate the opportunities 
these  technologies  afford.  The  Commission  will  co-finance  WAEMU  programme 
with the World Bank, the Global Environment Fund and Member States. 
Action 28 needs to be continued 
Action 29: Policy coordination and emerging issues 
Foresight, monitoring and coordination activities have been a key  element of the 
Commission's activities in the field of Life Sciences and Biotechnology and need to 
be pursued. Forward looking coordination on emerging technologies, both between 
services  and  with  Member  States  and/or  stakeholders  has  to  be  enhanced.  A 
reflection could possibly take place on the pertinence of a cross sector co-ordinated 
interface  for  a  dialogue  with  Member  States  on  biotechnology,  as  suggested  in 
Action 29c. 
Regarding  action  29a,  the  Commission  has  clearly  put  an  emphasis  on  the 
identification and assessment of newly emerging issues. Foresight actions are being 
planned by the Standing Committee on Agriculture (SCAR) which has established a 
working Group to prepare inputs for a European agricultural research agenda with a 
20 year perspective, based on national and EU-wide foresight initiatives. In addition 
major foresight conferences on food and on agriculture are currently being planned 
for the first half of 2007.  
Close  coordination  amongst  Commission  services  and  with  Member  States  also 
enables the mapping of emerging issues (such as the possible placing on the market 
of  GM  fish,  application  of  cloning  technology  in  animals,  and  in  particular  the 
introduction of products obtained from cloned livestock into the food chain.) and the 
early development of policy responses. Two complementary initiatives have been 
launched by the Commission in this area, at the end of 2004. A project aiming at 
stimulating an informed, public debate across Europe on farm animal cloning and to 
ensure public participation in the forming of policies has been launched under the 
thematic priority “Food quality and Safety”. The project will provide conclusions 
and possible options for policy actions covering research on farm animal cloning and 
its subsequent applications
109. A stakeholder conference has taken place in Brussels 
5-6 October 2006.  
A number of research projects funded under FP6 are developing tools for assessing 
the impact of adoption of biotechnology on land use, agriculture and forestry as well 
as tools for assessing the macro-economic impact.  
The Commission has used a number of focused expert groups both to review and to 
determine  future  research  needs  in  preparations  FP7.  In  addition  major  foresight 
conferences e.g. on food and on agriculture are currently being planned for the first 
half of 2007. 
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In addition the Commission, in response to a request by the Parliament, has carried 
out a study on the actual and potential impact of biotechnology on the economy and 
on  European  society:  "Consequences,  opportunities  and  challenges  of  modern 
biotechnology  for  Europe"  (Bio4EU  Study)
110.  The  study  evaluates  the 
consequences, opportunities and challenges of modern biotechnology for Europe, in 
terms of economic, social and environmental impacts, in particular their contribution 
to the achievement of major European policy goals. It will help to increase public 
awareness and understanding of life sciences and biotechnology. The study focuses 
on major modern biotechnologies in three main application areas: human and animal 
health,  primary  production  and  agro-food  and  industrial  processes,  energy  and 
environment. Results are available since April 2007. 
Furthermore, the work of an EC interservice group on genetic testing has allowed 
the identification of a number of emerging issues and has put forward actions in 
order  to  ensure  the  highest  quality  of  genetic  testing  in  the  EU  including  closer 
collaboration  with  Member  States  on  quality  assurance  and  networking  for  rare 
diseases, a review of Directive 98/79/EC
111 on in vitro diagnostic medical devices, 
and  the  launching  of  a  network  on  public  health  aspects  of  genetic  testing.  The 
emerging issues of genetic testing, pharmacogenetics and biobanks, identified in the 
Life  Sciences  and  Biotechnology  progress  reports,  have  been  subject  to  specific 
actions by the Commission within this interservice group. 
(1)  Genetic testing 
Genetic  testing  is  a  relevant  example  of  cutting-edge  research  and  development, 
showing  potential  for  the  benefit  of  society  and  at  the  same  time  having  policy 
implications for research, public health, regulation, fundamental rights, ethics and 
international cooperation beyond the EU. 
The need for policy actions regarding the use of genetic testing both for medical and 
non-medical purposes have been stressed in the European Parliament Report on the 
Commission communication on Life Sciences and Biotechnology- A Strategy for 
Europe  –  adopted  in  November  2002.  This  calls  on  the  Commission  to  draft  a 
legislative regulation for the introduction of a standard for genetic tests, since these 
services lie outside the scope of Council Regulation (EEC) N° 2309/93 laying down 
Community procedures for the authorisation and supervision of medicinal products 
for  human  and  veterinary  use
112  and  Directive  98/79/EC  on  in-vitro  diagnostic 
medical devices, which applies only to products to be marketed. In the draft report 
from  Temporary  Committee  on  Human  Genetics  from  November  2001  the  EP: 
“Notes that genetic testing will in many cases be used for predictive purposes and 
that  any  discussion  on  the  enormous  medical,  ethical,  psychological  and  legal 
implications  of  inaccurate  findings  raises  the  need  to  determine  a  legal  and 
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regulatory framework at European and national level to: guarantee the quality […] 
of genetic testing in Europe […].” 
A growing number of laboratories in Europe and the world are offering a wide and 
varied array of genetic testing and analysis services. These practices are becoming 
increasingly  frequent,  highly  variable  in  quality,  and  available  across  national 
boundaries and some genetic tests are becoming the subject of uncontrolled “mass 
marketing”, including via the Internet. In a statement, the European Group on Ethics 
in Science and  New Technologies (EGE) warned against the risks of  advertising 
genetic testing via the Internet, in particular due to the serious concerns raised from 
the perspective of fundamental rights and the private life of the person. The Group 
also addressed the ethical and legal issues of genetic testing in the workplace and 
adopted an Opinion on this subject on 28 July, 2003 (Opinion nr 18 on "the ethical 
aspects of genetic testing in the workplace "
113).  
The  ETAN-STRATA  high  level  group  composed  of  representatives  from 
pharmaceutical  companies,  NGOs  including  patients'  organisations,  scientists  and 
ethicists and legal experts set up by the Commission in 2003 called for actions at EU 
level and gave 25 recommendations
114. These recommendations were also discussed 
at a public conference organised in Brussels on May 6-7, 2004
115. 
In the specific case of rare diseases, the majority of which having a genetic origin, no 
EU Member State is as yet self-sufficient in testing for these, and there remains room 
for improvement in cross-border co-operation. This highlights the need to encourage 
a broader exchange of information and samples though trans-national networking, 
which is essential for ensuring the development of tests as well as for accessibility to 
genetic testing. 
Although genetics specialists and professional organisations have made many moves 
to promote quality assessment, genetic testing services are provided under widely 
varying conditions and regulatory frameworks in different countries, as well as in the 
EU.  The  2003  prospective  study  from  the  Commission’s  JRC
116  identifies 
shortcomings and measures to ensure the highest quality of such services, including: 
–  Harmonised quality control of genetic tests and the counselling that accompanies them; 
–  Development of a common range of certified reference materials; 
–  Better cross-border co-operation including the establishment of a network for genetic testing of 
rare diseases, and; 
–  The establishment of a European database of genetic testing centres. 
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Genetic  testing  and  the  use  of  genetic  information  need  to  be  seen  in  the  non-
exhaustive context of: 
–  Quality assurance of genetic tests (kits) and testing services; 
–  Use of genetic testing and genetic information in health care including for diagnosis, screening of 
newborns and adults, predictive/ pre-symptomatic testing, pharmacogenetics, selection of donors; 
–  Collection, storage transmission and analysis of personal genetic information for the purpose of 
public health and/or medical research including applications like medical registers and bio-banks; 
–  Use  of  genetic  testing  and  genetic  information  in  employment  and  obligatory  public  health 
insurance; 
–  Use of genetic testing and genetic information in private life and/or health insurance; 
–  Forensic use of genetic testing in criminal investigation (including parental…) and public security 
(including fights against terrorism)  
The Commission identified genetic testing in its second and third progress reports on 
the implementation of the Life Sciences and Biotech strategy as an emerging issue 
with important scientific, ethical, legal and social implications.  
In  the  second  progress  report  on  the  Life  Sciences  and  Biotechnology  Strategy 
(2004) the priorities identified for future actions by Commission and Member States 
were as follows: 
–  To engage in EU-wide co-ordination of efforts to ensure the highest quality of genetic testing in 
the EU and beyond EU-25; 
–  To  establish  EU-wide  networking  of  national  centres  for  exchanges  of  information  regarding 
quality assurance of genetic  testing, including training activities, and EU-wide networking  for 
genetic testing of rare diseases. 
The third progress report (June 2005) identified the following priorities: 
–  To  enhance  an  EU-wide  exchange  of  information  on  best  practice  and  cooperation  on  the 
development and use of genetic testing through the open method of coordination. In particular, an 
evaluation of the clinical validity/utility of genetic tests and the establishment of a referral system 
at EU level for genetic testing of rare and complex diseases will be addressed in 2005- 2006; 
–  To take whatever action appropriate or required, as arising from the coordination; 
–  To launch an initiative on the protection of workers' personal data in the employment context, 
taking account of the European Group on Ethics in Science and New Technologies Opinion No 18 
“Ethical  Aspects  of  Genetic  Testing  in  the  Workplace”.  The  initiative  will  also  address  the 
processing of genetic data; 
–  To analyse the possibility of setting standards on genetic testing under Article 152 or 153 of the 
Treaty and the appropriate legal instrument; 
–  To analyse the Directive 98/79/EC on in vitro diagnostic medical devices in the context of genetic 
testing and in particular regarding quality and performance assurance of genetic test devices; 
–  To launch a mapping and networking exercise on public health aspects of genetic testing.  
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The Commission will pursue the work on the action proposed in 3rd progress report: 
"Analyse the possibility of setting standards on genetic testing under Article 152 or 
153 of the EC Treaty and the appropriate legal instrument taking into account the 
result of the analyses of the Directive 98/79/EC in the context of genetic testing". 
Since these recommendations were made, the main achievements have been: 
–  Establishment of informal network on genetic testing with experts and officials 
from EU Member States in 2004, which meets each year to exchange information 
about national activities and discuss the way forward to ensure the highest quality 
of genetic testing in the EU 
–  Based on the work of the informal network a survey on national legislation and 
activities  regarding  genetic  testing  was  prepared  in  2005  and  is  now  being 
updated
117. 
On 17 March 2004, the advisory committee, "Article 29 Working Party" (National 
Data  Protection  Authorities),  adopted  a  working  document  on  the  processing  of 
genetic data. One of this opinion's main conclusions is that any use of genetic data 
for purposes other than directly safeguarding the data subject’s health and pursuing 
scientific research should require national rules to be implemented, in accordance 
with  the  data  protection  principles  provided  for  in  Directive  95/46/EC
118.  The 
processing of genetic data should be authorized in the employment and insurance 
fields only in very exceptional cases provided for by law, so as to protect individuals 
from being discriminated against on the basis of their genetic profile. The Working 
Party  may  revisit  the  working  document  in  the  light  of  experience  acquired  by 
National Data Protection Authorities and may decide to focus in detail on specific 
areas at a later stage, in order to keep in line with the technological developments 
linked  to  the  processing  of  genetic  data.  This  opinion  will  be  considered  by  the 
relevant Commission services for consistency with the current "acquis". 
The IVD, in vitro diagnostic, technical group under the Directive 98/79/EC on in 
vitro diagnostic medical devices has analysed the directive in the context of genetic 
testing and in particular regarding quality and performance assurance of genetic test 
devices.  The  Conclusions  were  endorsed  by  the  Competent  Authorities 
representatives  of  the  Medical  Devices  Expert  Group  in  spring  2006.  The 
conclusions can be summarized as follows: 
–  The current requirements for the quality and performance assurance of genetic tests are assured by 
the Directive 98/79/EC on in vitro diagnostic medical devices; 
–  But, genetic tests that do not have a medical purpose, e.g. genetic tests for forensic or predictive 
purposes, are not covered by the Directive; 
–  Also, it is recognised that a number of genetic tests are “manufactured and used only within the 
same health institution”, so-called "in-house" products, and are thus excluded from the scope of 
the current Directive;  
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–  Hence, they are covered by national rather than harmonised community legislation; 
–  Member States are encouraged to apply national controls equivalent to the community controls in 
such instances and to collaborate in the field of quality assurance programs for laboratories; 
–  The term ‘health institution’ needs elaboration or definition to clarify that commercial laboratories 
are covered by the Directive; many commercial test laboratories claim to be ‘health institutions’ 
and thus claim to be excluded from the Directive. Such a laboratory must use in vitro diagnostic 
tests  bearing  CE  marking  in  accordance  with  the  Directive,  even  where  the  tests  has  been 
manufactured and used within the same laboratory; 
–  Where considered necessary by Member States, there is already the possibility, under Article 14 
(Comitology), to introduce certain or all genetic tests currently covered by the Directive, into 
Annex II (List A or B), or, by derogation to the normal rules, to prescribe specific conformity 
assessment routes; 
–  As 'New Products' have to be notified under Article 10(4), guidance on this could be given for 
those New Genetic Tests, particularly as regards to clinical evaluation. 
A  large  network  of  excellence,  EUROGENTEST,  for  test  development, 
harmonization,  validation  and  standardization  of services  across  Europe  has  been 
launched under FP6, thematic priority “Life sciences, genomics and biotechnology 
for  health”.  Amongst  other  measures,  an  International  Symposium  on  Reference 
Materials  for  Genetic  Testing  was  organised  jointly  with  the  Commission's  Joint 
Research Centre (IRMM) in 2005. Proceedings of the symposium will be available 
on the EuroGentest website
119. 
The  Commission's  Joint  Research  Centre  (IRMM)  has  produced  three  Certified 
Reference Materials (CRMs) for the analysis of the human Factor II (prothrombin) 
gene G20210A mutation. Moreover, IRMM has launched a large EQA study among 
European  laboratories  using  these  reference  materials  in  order  to  identify  the 
problems related to molecular genetic testing.  
The Commission has contributed to the work of the OECD on guidelines on Quality 
Assurance of Molecular Genetic Testing (currently under adoption process)
120 and is 
participating in the work of the Council of Europe regarding a protocol on Genetic 
Testing issued by the Steering Committee on Bioethics (CDBI), still under internal 
consultation
121. 
Forensic use of genetic testing and genetic data in criminal investigation and public 
security (including measures taken to prevent terrorism) and the establishment of 
databases raise issues related to individual rights (including rights to privacy) and 
public  interest  (including  antiterrorism  and  security  measures).  Current  legal 
initiatives, such as the proposal for a Council Framework Decision on the protection 
of personal data processes in the framework of police and judicial co-operation in 
criminal  matters  will  lay  down  a  legal  framework  that  will  be  applied  to  these 
activities. 
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(2)  Public Health Genomics (including genetic testing) and the integration of 
genome-based knowledge and technologies into practice 
The great success of current genomic research already lead to exponential growth of 
genome  based  information  and  technologies.  The  genome  based  information  and 
technologies comprise all aspects of genetic testing. The advances in genomics and 
the underlying technologies create new challenges for researchers, policy makers and 
other stakeholders. To complement the Community research actions in genomics and 
more  narrowly  in  genetic  testing  as  described  above,  a  Public  Health  Genomics 
European Network (PHGEN)
122 was launched on 1 January 2006 co-funded by the 
Community  under  the  EU  Public  Health  Programme.  PHGEN  conjuncts  public 
health and genomics aiming at a responsible and effective translation of genome-
based  knowledge  and  technologies  into  public  policy  and  health  services  for  the 
benefit  of  population  health.  Genetic  testing  is  subsumed  under  public  health 
genomics  as  a  more  narrow  focus  resulting  from  genetic  research  prior  to  the 
Genomics  era.  Translation  in  this  area  requires  stakeholder  involvement  together 
with  the  recognition  and  integration  of  related  projects  in  genetics,  Health 
Technology Assessment, orphan diseases and cross border health services. 
Public Health must be seen as the starting point of this enterprise as it ensures the 
development  of  a  coherent,  socially  balanced  and  ethically  responsible  policy 
framework. This is reflected by the integral role of ethics and legal experts in the 
PHGEN  network.  Thus,  Public  Health  Genomics  can  be  seen  as  the  tool  which 
guarantees societal benefits from genetics / genomics and not an erratic progress 
which  neglects  the  health  needs  of  the  people  of  Europe.  The  Community 
competences  in  biotechnology  and  Public  Health  call  for  continuing  the  holistic 
approach for a coherent and integrating policy strategy. With the emerging field of 
Public Health Genomics, genome-based knowledge no longer solely belongs to the 
sphere  of  national  health  care  systems,  additionally  Fundamental  Rights,  Market 
Freedom, Consumer Rights and Consumer Protection need to be integrated. 
Consequently,  a  communication  process  with  stakeholders  and  Member  States 
should be started and facilitated as Public Health requires a gearing of competences 
and regulatory frameworks. The Community competences, e.g. in the single market, 
the  freedom  of  service  providers,  employment,  data  protection,  access  to 
information, marketing authorisation, intellectual property rights, cross border health 
services, pharmaceuticals and research supervision must be explored in relation to 
the translation of genome based information and technologies for population as well 
as individual health. Examples are Art 3 (p), 95 par. 3 and 152 par. 1 of the Treaty, 
which oblige the Community to achieve a high level of health protection in all its 
regulatory actions.  
It becomes more and more apparent that genomics requires a coherent health strategy 
which  assesses  potential  interdependences  and  unwanted  consequences.  Public 
Health Genomics is an umbrella enterprise which offers the capabilities needed by 
the Community and the Member States. With the translation from basic sciences into 
health  care,  the  framing  of  ethically  and  legally  acceptable  standards  and  the 
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empowerment  of  professionals  and  lay  people  Public  Health  Genomics  supports 
implementation and transcription of relevant Community competences into practice. 
In  conclusion, these actions remain important. One should have in mind that the 
European  Parliament  called  on  the  Commission  to  draft  legislation  for  the 
introduction of a standard for genetic tests in its report on the strategy. 
(3)  Biobanks 
Biobanks  (storage  of  genetic  material  linked  to  lifestyle,  medical  and  other 
information  of  the  individual  for  research  and  biomedical  purposes)  were  also 
identified  as  emerging  issues  in  the  context  of  the  progress  reports  on  the  Life 
Sciences and Biotech strategy. 
An  increasing  number  of  population-based  biobanks  have  been  established 
worldwide. At the same time, this has led to new ethical issues being discussed in 
ethics committees at national and international levels. New specific laws regarding 
biobanks  have  been  implemented  or  are  under  discussion  at  national  level.  The 
ability  to  optimise  the  use  of  biobanks  across  Europe  is  an  important  basis  for 
ensuring progress in European biomedical science, including in the development of 
genetic testing and pharmacogenetics. However, effective collaboration is becoming 
increasingly difficult in a complex world where the principles governing public and 
private biobanks differ from one country to another. 
Priorities for future actions for Commission and Member States are the following: 
–  To  launch  initiatives  to  establish  recommendations  for  general  principles 
governing biobanks, which will optimise data and sample-sharing methods for 
research purposes across the EU. The activities should take account of ongoing 
work at national and international level, such as the activities of the Council of 
Europe and OECD; 
–  For the Commission to consider the need for an opinion from the European Group 
on Ethics regarding the ethical implications, some of which were covered in their 
Opinion No 19 “Ethical aspects of umbilical cord blood banking”
123.  
The main achievements were: 
–  The Commission has launched a study on Biobanks in Europe - Prospects for 
Coordination and Networking (a comprehensive picture of biobanks in the EU 
(and non-EU regions) - and will explore the possibilities of networking among 
European biobanks, with the results expected in September 2007, 
–  A European initiative “EUHEALTHGEN” has been launched in 2004 to promote 
the  translation  of  the  outputs  from  research  on  population  genetics  into  direct 
health  benefits  for  European  citizens.  It  is  jointly  funded  by  the  European 
Commission, and the Wellcome Trust; 
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–  An international conference entitled 'From Biobanks to Biomarkers – Translating 
the  potential  of  human  population  genetics  research  to  improve the  quality  of 
health of the EU citizen' was held on 20–22 September 2005 to promote the aims 
of this initiative
124; 
–  The  Commission  recently  held  a  high-level  expert  workshop  on  unifying 
databases of human genetic variation
125.  
(4)  Pharmacogenetics 
Pharmacogenetics (genetic variability to drug response) is still at the research and 
development  stage,  but  its  application  in  drug  development  and  evaluation  is 
expected  soon,  and  appropriate  measures  should  be  prepared  in  time  for  this 
evolution. The potential impact of pharmacogenetics on health care and its ethical, 
legal and socio-economic implications are still uncertain. The European Medicines 
Evaluation  Agency  (EMEA)
126  organised  an  expert  meeting  in  November  2004, 
which stressed that no legislative provisions should be made before a wide-ranging 
consultation  process  with  all  the  relevant  stakeholders  has  taken  place,  and 
highlighted  the  importance  of  ensuring  high  quality  and  validation  methods  for 
pharmacogenetic  tests.  The  research  projects  funded  under  FP7  and  the  newly 
established Technology Platform for Innovative Medicines are expected to provide 
incentives  in  this  field  and  enhance  cooperation  between  all  the  stakeholders 
concerned. 
In the third progress report (June 2005) the priorities for future actions were for the 
Commission to launch initiatives on the potential benefits, risks and possible new 
policy  issues  associated  with  the  application  of  pharmacogenetics,  including  a 
prospective study, and consider the need for an opinion from the European Group on 
Ethics on the ethical implications.  
In  response  to  this,  the  Commission  has  recently  completed  a  study  on 
pharmacogenetics and pharmacogenomics in the EU. The study maps the current 
R&D status in the field, assesses its potential socio-economic impact, and finally 
provides a comparison of regulatory and quality assurance frameworks in the EU and 
the US
127. 
As  outlined  in  the  above  mentioned  study,  gathering  and  analysis  of 
pharmacogenetics data is more and more common in the conducting of clinical trials 
of medicines. In the future, use of pharmacogenetics could affect critical elements of 
an increasing number of drugs, such as dosage or target population. The strategic 
importance of pharmacogenetics has therefore increased. It is now reaching a critical 
stage where it may justify the need for policy action, in order to better regulate the 
use of pharmacogenetics in the development and monitoring of medicines. 
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The European Medicines Evaluation Agency (EMEA) is in the process of drafting 
new harmonised guideline on the terminology used in Pharmacogenomics
128. The 
goal  of  this  initiative  is  to  harmonise  at  international  level  definitions  for 
Pharmacogenomics,  Pharmacogenetics,  genomic  biomarkers,  and  relevant  sample 
and  data  coding.  Standardised  terminology  will  be  proposed  for  incorporation  in 
future regulatory documents related to pharmacogenetics and pharmacogenomics. 
The  Commission  considers  the  issue  of  personalised  medicine  and  use  of 
pharmacogenetics  in  drug  development  of  strategic  importance,  justifying  policy 
action  in  the  coming  years  through  an  appropriate  revision  of  the  existing 
Community regulatory framework on pharmaceuticals. 
Pharmacogenetics  raises  a  number  of  scientific,  ethical,  legal  and  economic 
challenges.  On  the  regulatory  side,  the  main  challenges  for  the  Commission  are 
related to: the use of pharmacogenetics data in the evaluation of medicines, licensing 
decisions and post-marketing monitoring; the harmonisation of requirements for the 
conduct of pharmacogenetics studies, in particular at clinical level; the co-evaluation 
of medicines in combination with pharmacogenetics tests (drug-test application); and 
the labelling of medicines based on pharmacogenetics data. Because of the specific 
features of pharmacogenetics it is necessary that its impact on fundamental rights and 
in  particular  protection  of  personal  data  shall  also  be  carefully  examined  and 
integrated in any study/policy that will be carried out. The Forum of National Ethics 
Councils  will  address  the  implementation  of  ethical  frameworks  for 
pharmacogenetics.  
(5)  Other prospective studies on biotechnology 
Other prospective studies carried out by the Commission on biotechnology as early 
identification activities are: 
–  "Human tissue-engineered products - Today's markets and future prospects" (EUR 
21000; 2003
129). The study provides data on products on the market and in the 
pipeline  and  the  structure  of  the  tissue  engineering  sector,  as  well  as  the 
challenges the sector is facing. 
–  "Human tissue-engineered products: Potential socio-economic impacts of a new 
European  regulatory  framework  for  authorisation,  supervision  and  vigilance" 
(EUR  21838;  2005
130).  The  study  analyses  the  potential  economic,  social  and 
environmental impacts that a future European level regulation on human tissue-
engineered products could have.  
–  “Nanobiotechnology in the medical sector – drivers for development and possible 
impacts”.  The  study  aims  to  draw  a  comprehensive  picture  of  the  R&D  and 
commercial medical nanobiotechnology landscape in Europe in comparison with 
the  US  and  Japan.  Furthermore,  the  impact  and  likely  development  of 
nanobiotechnology applications in the medical sector will be investigated and the 
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socio-economic aspects  of this development analysed. Publication of  results is 
expected for the second half of 2007. 
–  "Animal Cloning and Genetic Modification and derived products" The study aims 
to  provide  a  comprehensive  picture  of  research  and  commercial  activities 
involving  animal  cloning  and/or  genetic  modification,  to  identify  the  potential 
benefits,  risks  and  socio-economic  impacts,  as  well  as  to  assess  policy 
implications  of  the  developments  of  these  technologies  and  of  the 
commercialization of their products in the EU. Publication of results is expected 
for the second half of 2007. 
–  "Review  of  GMOs  under  Research  and  Development  and  in  the  Pipeline  in 
Europe" (EUR20680 EN; 2003
131). The report describes which agricultural GM 
plants are most likely to be developed up to the market level in the next decade. 
The results are based on an original survey on the situation of European R&D 
projects and a statistical analysis of the database of experimental GM releases in 
Europe.  
Regarding Action 29b, the Commission has already published three progress reports 
on the Life Sciences and Biotechnology Strategy
132, which have reported thoroughly 
on the implementation of the Strategy. Furthermore, several relevant reports from the 
Commission are providing  regular updates on the implementation of the relevant 
Community legislation (such as the reports on Directive 2001/18/EC or Regulation 
1829/2003). In addition to this, the College is holding regular orientation debates on 
Biotechnology, which are an opportunity to reassess the pertinence of the legislation 
and  policy  orientations,  which  have  so  far  always  been  confirmed,  sometimes 
including some fine tuning.  
With  regards  to  societal  and  economical  aspects,  the  Commission  is  supporting 
assessments  on  the  use  of  biotechnology  and  pays  the  highest  attention  to  the 
positions  expressed  by  all  stakeholders,  whether  they  represent  the  industry,  the 
environmental organisations, the consumers or any other part of civil society. The 
Commission  has  developed  a  culture  of  transparency  and  is  generally  involving 
stakeholders closely. Nonetheless, there are limits to this involvement, which quite 
often  relate  to  the  protection  of  the  Commission’s  right  of  initiative,  or  of 
confidential business information or personal data. On some occasions concerns were 
voiced  by  stakeholders  about  restrictions  to  their  access  to  information  or 
participation in the decision making process, but such restrictions are always related 
to  a  legal  obligation  by which  the  Commission is  bound.  In  conclusion,  there  is 
certainly  an  adequate  follow-up  to  policies  and  legislation  in  the  field  of 
biotechnology and proper synergies with Member States, stakeholders, but also third 
countries and international organisations. Nonetheless, it has to be pointed out that 
the implementation of the legislation in the field of biotechnology, mostly in the field 
of GMO, has proven to be quite cumbersome and that several implementation and 
enforcement  problems  have  been  encountered.  This  is  in  particular  linked  to  the 
ambivalence of European societies towards food biotechnology. According to the 
Eurobarometer 2005 58% of the respondents oppose GM food while 42% do not. 
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The Eurobarometer confirmed also that there were major differences in acceptance 
between the societies of different Member States.  
Overall, all fields of biotechnology generally enjoy a high level of public support 
with the exception of GM food. It should be noted that 50% or more say they would 
buy GM food if it is healthier, if it contains less pesticide residues, or if it is more 
environmentally friendly. Moreover, the supporters outnumber the opponents on this 
issue. This indicates that public support would rise if the benefits are demonstrated to 
the  consumers,  but  also  that  public  awareness  of  GMOs  currently  is  linked  to 
negative perceptions. 
Regarding  action  29c,  biotechnology  is  a  policy  area  under  particularly  thorough 
scrutiny and solid coordination between all involved Commission services exists, at 
an informal level and through the Biotechnology Steering Committee, a Commission 
internal coordination group composed of concerned cabinets and services. In addition 
to this, all involved Commission services have organised specific technical groups 
with  Member  States’  competent  authorities  and/or  relevant  stakeholders,  which 
enable  efficient  information  sharing  and  rapid  response  in  case  of  problems  (for 
example, the cooperation between Commission and Member States enabled swift 
reaction  further  to  the  Bt10  maize  and  LL601  rice  cases,  for  which  emergency 
safeguard measures had to be taken). 
As a conclusion, Biotechnology is a fast evolving and complex policy area, both 
from a scientific and legal point of view and the Commission should further enhance 
its foresight functions to be able to anticipate the possible future introduction of new 
applications  and  ensure  that  they  can  benefit  the  European  economy,  whilst 
respecting the highest quality and safety standards. Forward looking coordination on 
emerging  technologies,  both  between  services  and  with  Member  States  and/or 
stakeholders has to be enhanced. A reflection exercise could possibly take place on 
the pertinence of a cross sector co-ordinated interface for a dialogue with Member 
States on biotechnology, as suggested in Action 29c. 
Furthermore, biotechnology is emerging as an eco-efficient technology (as evidenced 
in the Kok report
133) which can contribute to economic growth and at the same time 
contribute to enhanced sustainability through the optimal use of renewable biological 
resources including for example production of bioproducts, to mitigate the emissions 
of  greenhouse  gases  and  reduce  the  adverse  impact  on  the  environment  of 
agriculture, industry  and aquaculture.  A better coordination and  coherence of the 
various policy initiatives at EU level e.g. biomass action plan, implementation of 
biofuel directive, ETAP, sustainable Development Strategy etc will be required in 
order to fully benefit from this emerging potential of life sciences and biotechnology. 
The  Commission  has  initiated  a  closer  collaboration  with  Member  States  on  this 
issue in the context of the network of high level officials on the Knowledge based 
Bio-Economy. Discussions with industry are taking place in, amongst other fora, the 
context of the Technology platforms and an interaction exercise with civil society is 
under development. 
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In addition to this, efforts have to be pursued to reinforce Member State’s support in 
the  GMO  decision  making  process,  in  order  to  improve  the  implementation  and 
enforcement of relevant legislation. In particular, the actions agreed by the College at 
its 12 April 2006 orientation debate have to be implemented. 
Action 29 should be given high priority as foresight, monitoring and 
coordination activities in the field of biotechnology should continue 
Action 30 - Progress reports 
Progress reports have so far been produced on a yearly basis. In the elaboration of 
the 2005 Progress Report, it appeared that they were no sufficient developments to 
produce  a  progress  report  in  2006.  It  was  therefore  decided  to  merge  the  2006 
progress  report  with  the  2007  mid  term  review.  The  frequency  of  Life  Sciences 
reports should therefore be from now on every two years.  
The next report will be published in 2009 
5.  CONCLUSIONS AND WAY FORWARD FOR THE CONTINUATION OF THE STRATEGY 
The main conclusions of this review exercise are that: 
–  The Strategy has been successful and is still relevant. The list of achievements for 
the period of reference, for example, research activities, or regional integration of 
"poles  of  excellences",  clearly  highlights  the  role  that  the  Strategy  played  to 
integrate the "biotech dimension" in other policy areas. Furthermore, the Strategy 
has always been and still is supported by the relevant stakeholders, which also 
contributes to demonstrating its pertinence; 
–  A  small  number  of  actions  have  been  achieved.  This  mainly  relates  to  the 
adoption of the new legal framework on GMOs, which has been very significantly 
revised since 2002; 
–  A few other actions have become obsolete, mainly because of lack of interest by 
the  audience  they  targeted  (e.g.  Action  aiming  at  creating  networks  of 
biotechnology company managers); 
–  A majority of actions need to be continued, in a way which is coherent with other 
horizontal  initiatives  (e.g.  education,  IPR,…)  or  in  accordance  with  the  EU's 
international  commitments  (e.g.  contribution  to  Multilateral  Environmental 
Agreements); 
–  Some actions need to be refocused and given a special priority for the coming 
years, given their importance and biotechnology-specific character. 
The original design of the Strategy was purposely large in content and actions, so as 
to aim for an initial mapping of the situation which would allow for identification of 
relevant policy areas. It has been successful in achieving this. The mid term review is 
nonetheless the occasion to reflect on how to maximise the aforementioned benefits 
of  potential  uses  of  biotechnology.  This  implies  pursuing  actions  which  are  still  
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relevant according to their original design and following the deliverables foreseen, 
reinforcing synergies with other pertinent horizontal policies and reviewing priorities 
which are specific to the sector of biotechnologies to improve the efficiency of the 
Strategy for its implementation until 2010. 
These biotech-specific priorities can be regrouped under five main themes, which are 
interdependent: 
(1)  Promote  research  and  market  development  for  life  sciences  and 
biotechnology applications and the Knowledge-Based Bio-Economy (KBBE). 
Research remains a precondition for the development of biotechnology and 
the Action Plan needs to be adapted to the new FP7. Europe's basic biotech 
research  is  advanced  but  Europe  does  not  excel  in  turning  research  into 
commercial  applications,  which  is  why  part  of  the  Action  Plan  should  be 
refocused in order to foster market development for bio-based products and 
improve the uptake of new technologies; 
(2)  Foster competitiveness, knowledge transfer and innovation from the science 
base to industry. Europe's biotech companies are mostly SMEs with limited 
resources whose growth and economic sustainability are held back by three 
main constraints: Europe's fragmented patent system, the insufficient supply 
of  risk  capital  and  the  not  yet  fully  developed  scientific  and  business 
cooperation.  As  evidenced  in  the  Communication  "An  innovation-friendly 
modern  Europe"
134,  Europe  urgently  needs  a  clear  and  coherent  legal 
framework for IPR protection. The Commission will propose concrete steps 
toward a modern and affordable framework. In addition to this, the refocusing 
of  part  of  the  Action  Plan  can  contribute  to  addressing  some  framework 
conditions relating to competitiveness which are specific to the biotech sector.  
(3)  Encourage informed societal debates on the benefits and risks of life sciences 
and biotechnology. The uptake of biotechnology  is also conditioned to its 
societal and market acceptance. Ethical concerns are also more prevalent than 
in other forefront technologies. Thus, there is a clear prerequisite for actions 
aiming at associating the public and stakeholders as closely as possible to the 
decision making process and to follow a cost-benefit approach to regulation, 
based on harmonised data and statistics and including ethical considerations.  
(4)  Ensure a sustainable contribution of modern biotechnology to agriculture. 
Biotechnology in the field of primary production and agro/food has by all 
means a huge potential for development, in particular for the replacement of 
chemical processes and fossil fuels. Nonetheless, some of the technologies 
involved  need  close  scrutiny.  This  is  why  the  legal  framework  which 
regulates the uptake of GM technology takes into account possible long-term 
effects on the environment and health, the safety of the food chain, when 
crops are used for example for the production of pharmaceutical substances, 
and respect other modes of agricultural production; 
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(5)  Improve  the  implementation  of  the  legislation  and  its  impact  on 
competitiveness. The EU has probably the most developed, and sometimes 
most  stringent,  legal  framework  on  life  sciences  and  biotechnology. 
Nonetheless,  stringent  rules  should  not  hinder  competitiveness  and 
innovation. 
The way the Commission intends to refocus its implementation of the Strategy in 
light of the above five priority themes is detailed in the annexed "Refocused Life 
Sciences and Biotechnology Action Plan" 
. 
EN  72    EN 
Annex I: Refocused Life Sciences and Biotechnology Action Plan 
(1)  Promote  research  and  market  development  for  life  sciences  and  biotechnology 
applications and the Knowledge Based Bio-Economy (KBBE).  
(a)  Research (supply–side measures) (action 3
135). Deliverables: 
–  Generation of new knowledge under FP7 in particular under the themes 
"Health",  "Food,  Agriculture  and  Fisheries,  and  Biotechnology", 
"Nanosciences",  "Energy"  and  "Environment".  Implementer: 
Commission. 
–  Mobilise national and regional public and private research funding and 
reinforce the coordination of research in the field of life sciences and 
biotechnology  Implementer:  Commission,  Industry  and  Member 
States and other funding bodies. 
–  Implementation  of  the  Joint  Technology  Initiative  on  Innovative 
Medicine  under  FP7  with  a  specific  focus  on  biotechnology. 
Implementer: Public-private partnership between the Commission and 
the  European  Federation  of  Pharmaceutical  Industries  Associations 
(EFPIA). 
(b)  Promotion, demonstration and facilitation of the uptake of eco-efficient bio-
based products and processes. (Demand-side measures.) Deliverables: 
–  Engage  schemes  to  finance/promote  the  establishment  of  multi-
functional  pilot  plants  to  demonstrate  the  potential  of  bio-based 
applications  and  facilitate  their  market  penetration.  Implementer: 
Member States, Industry and Commission through the network of high 
level  officials  on  the  KBBE  as  well  as  with  relevant  European 
Technology Platforms and the EIB. 
–  Explore in cooperation with stakeholders lead market initiatives in the 
areas  of  eco-efficient  bio-based  products,  by  facilitating  the 
development of markets in these areas through  public policy actions 
such as, standards, labelling, regulation and financial incentives, subject 
to impact assessment and compatibility with EC rules in the field of 
competition and internal market. Implementer: Commission. 
(2)  Foster competitiveness, knowledge transfer and innovation from the science base to 
industry 
(a)  Patenting of new research findings in the field of biotechnology (action 5). 
Deliverables: 
–  Development of best practices in the responsible licensing of genetic 
inventions  taking  into  account  ethical  and  societal  concerns  while 
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encouraging patenting, licensing and spin-off creation. Implementer: 
Commission, Member States. 
–  Promote  knowledge  transfer  by  improving  links  between  research 
organisations and industry (e.g. conferences, publications, funding, and 
promotion  of  best  practice).  Incentives  to  innovation  should  be 
improved  by  facilitating  patent  pools,  research  exemption  and 
promoting  new  models  for  IPR  in  public-private  partnerships. 
Implementer: Commission, Member States. 
–  Monitor  the  implementation  of  Directive  98/44/EC  on  the  legal 
protection of biotechnological inventions, particularly in terms of the 
economic  consequences  of  possible  divergences  between  Member 
States. Implementer: Commission. 
(b)  Access to finance (action 6) 
–  Encourage  Member  States  to  include  biotechnology  in  national 
schemes,  specific  rules  and/or  incentives  for  Young  Innovative 
Companies, taking into account the European framework for state aid in 
research and innovation Implementer: Commission, Member States. 
–  Promote the use of EIF/EIB instruments and the Competitiveness and 
Innovation  Framework  Programme  to  facilitate  access  to  finance  for 
biotechnology companies Implementer: Commission. 
–  Implementation  of  Risk–Sharing  Finance  Facilities  for  actors  in  the 
biotech sector (including SME's, research organisations etc) which will 
be co-funded by FP7 and the EIB. Implementer: Commission, EIB. 
(c)  Regions and clusters (action 9) 
–  Support a better integration between clusters of European companies 
into "mega clusters", the cooperation between bio-clusters and regional 
networks and the development, across Europe, of regional "research–
driven  clusters"  associating  universities,  research  centres,  enterprises 
and regional authorities, through the "Capacity Programme" under FP7. 
Implementer: Commission. 
(3)  Encourage societal debates on the benefits and risk of life sciences and biotechnology 
(a)  Structured  framework  for  the  dialogue  with  stakeholders  to  make  the 
regulatory oversight of biotechnology more open and transparent (action 13). 
Deliverables: 
–  Stimulate  the  possible  establishment  of  a  Civil  Society  Organization 
Forum,  which  would  be  an  institutionalised  interface  with  different 
stakeholders on benefits and risk of life sciences and biotechnology. A 
first  step  could  be  a  call  for  expression  of  interest  of  CSO  groups. 
Implementer: Commission.  
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–  Set up proposals on how to improve the cooperation with all relevant 
stakeholders to ensure input in Commission's activities. Implementer: 
Commission. 
(b)  Improve the indicators that are needed to monitor the impacts of life sciences 
and biotechnology 
–  Set up a proposal for establishment of international quantitative impact 
indicators (including social and economic) and structured collection of 
data for all aspects of life sciences and biotechnology. Implementer: 
Commission in collaboration with Eurostat, Industry, Member States, 
OECD. 
(c)  Continue the effort to promote the integration of socio-economic and ethical 
issues (actions 14 and 16). Deliverables: 
–  Adapt the action to the new FP7, and produce guidance for EC funded 
research projects to enable the research community to address ethical 
issues during the entire project lifecycle. Implementer: Commission 
–  Anticipate the possible ethical and socio-economic impact of emerging 
scientific  issues  by  launching  foresight  studies  and  by  encouraging 
experts  in  ethics,  social  sciences  and  economy  to  participate  in  EC 
funded  research  projects  in  life  sciences  and  biotechnology. 
Implementer: Commission. 
(4)  Ensure a sustainable contribution of modern biotechnology to agriculture 
(a)  Coexistence  between  GM,  conventional  and  organic  crops  (action  17). 
Deliverables: 
–  Assessment of notified national and regional co-existence measures and 
study of the national civil liability systems with regard to co-existence, 
including specific compensation and insurance schemes developed in 
the Member States. Implementer: Commission. 
–  In line with the Council conclusions on co-existence of May 2006, re-
evaluation  by  2008  of  the  possible  need  for  further  guidance  at  EU 
level, on the basis of practical experiences gathered with the cultivation 
of  GM  crops  in  the  Member  States  and  result  from  research. 
Implementer: Commission. 
–  Development  of  guidelines  for  crop-specific  co-existence  measures 
through  the  activity  of  a  technical  European  Co-existence  Bureau 
(ECoB)  at  the  European  Commission's  Joint  Research  Centre. 
Exchange  of  information  on  best  practices  among  Member  States, 
through  the  co-ordination  network  on  co-existence  (COEX-NET"). 
Implementer: Commission, Member States. 
–  Adoption of crop-specific labelling thresholds for seeds. Implementer: 
Commission.  
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(b)  Assessment  of  the  long  term  positive/negative  effects  of  GMOs  on  the 
environment and health (action 23). Deliverables: 
–  Conduct  studies  and  support  related  research  activities  on  potential 
positive and negative long term environmental effects of commercially 
available GMOs. Implementer: Commission. 
–  Explore  benefits  and  risks  of  GM  crops  used  for  industrial 
transformation or molecular farming. Implementer: Commission 
(5)  Improve the implementation of the legislation and its impact on competitiveness 
(a)  Foresight, monitoring and coordination activities in the field of biotechnology 
(action 29). 
–  Reinforce the existing networks with Member States (e.g. KBBE-NET, 
Biotech Competitiveness Network) to monitor the implementation of 
the Strategy, with a special emphasis on addressing regulatory obstacles 
to competitiveness Implementer: Commission 
–  Pursue foresight activities and the evaluation of the regulatory coverage 
on  emerging  issues  (genetic  testing,  biobanks,  cloning,  GM  animals, 
nano-biotechnology, non-food use of biological resources, adventitious 
presence  of  GMO  traces  in  food  and  feed,  GMOs  for  non-food 
applications …). Implementer: Commission. 
–  Improve  policy  coordination  and  on  cross  cutting  issues,  with  a 
particular  focus  on  newly  emerging  issues  (biofuel,  nano  –
biotechnology, innovative therapies…) and develop a coherent policy 
agenda for the Knowledge Based Bioeconomy (improve the collection 
of  data,  develop  indicators,  evaluate  regulatory  needs,  ensure  policy 
coherence).  Implementer:  Commission. 
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Annex II: State of implementation of the Life Sciences and Biotechnology Action Plan – Summary chart of main achievements 
N°  DESCRIPTION  ACHIEVEMENTS 
1  The Commission will, together with Member States, identify 
the  education  needs  in  life  sciences  within  the  'Ten year 
objectives for learning in the knowledge society' and  
   strengthen  a  broad  education  and  understanding  of  life 
sciences,  
   develop  and  train  a  skilled workforce  in  life  sciences  by 
issuing  recommendations  for  curricula  and  teacher  training. 
Community support can be provided under the Comenius and 
Erasmus program  
   promote  continuing  education  and  refresh  the  current 
competence  of  the  scientific  workforce,  as  set  out  in  its 
communication  on  the  European  area  of  lifelong  learning. 
Community  support  can  be  provided  under  the  Leonardo 
program  
 support discussion for specialist scientists, with the objective of 
stimulating an exchange across disciplines. Community support 
can be provided under the Erasmus program 
Funding of projects concerning sciences in general under Socrates II program (no breakdown available for biotech 
specific projects). 
2a  The  Commission  will  explore  with  Member  States  the 
opportunity  and  best  way  to  establish  efficient  methods  to 
match a skilled workforce with job opportunities, involving 
effective communication of open positions, collaboration with 
established companies and a labour force aware of available 
employment options. 
 
The EURES Job Mobility Portal (http://ec.europa.eu/eures/home.jsp?lang=en) 
The 2006 European Year of Workers' mobility has provided considerable impetus to the portal, by enabling all EU 
citizens to access directly, in their own language, all job opportunities published by the Public Employment Services, 
i.e. around 1 million jobs at any given time. 
2b  The  Commission  will  explore  with  Member  States  possible 
measures  to  attract  and  retain  scientists  and  avoid  brain 
drain. 
 
  in 2004, the ERA MORE network of proximity assistance to mobile researchers was launched  
  the Directive on the entry and stay in the EU of third country researchers  
 in  March  2005  the  Commission  adopted  a  Recommendation  to  Member  States  on  the  European  Charter  for 
Researchers and a Code of Conduct for the recruitment of researchers.  
 in  all  Marie  Curie  actions  in  FP6  the  life  sciences  are  heavily  represented  and  account  for  over  €500  million 
(postdoctoral positions, PhD, funding to allow experienced researchers to set up their own research groups for the 
first time and “Chair” appointments to attract world class researchers and encouraging them to resume their careers in 
Europe.  
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3  The  Commission  will  enhance  support  for  life  sciences  and 
biotechnology  research,  technological  development, 
demonstration  and  training  activities  under  the  Sixth 
Framework Program 2002-2006 aimed at  
- contributing towards the creation of the European Research 
Area. 
-   supporting  Biotechnology  research  under  5  thematic 
priorities 
-  to facilitate the objectives of  Europe-wide collaborations, 
attaining  critical  mass  and  simplification  of  administrative 
procedures. 
-  encouraging SME participation, international cooperation 
and mobility and training of researchers. 
The FP6 has brought a strong impetus to Life Sciences and Biotechnology research in Europe, in particular in terms 
of critical mass of human and financial resources, sharing of knowledge and facilities, strengthening of scientific 
excellence, coordination of national activities and support to EU policies.  
 Concrete progress has been made in structuring the European Research Area and an active participation of all 
Member States has been achieved. 
 Support under thematic priorities. 
-Coordination of national and regional research programmes has been achieved through the ERA NET scheme 
(http://cordis.europa.eu/coordination/era-net.htm). 
  Industry, and in particular Small & Medium Enterprises (SME) have benefited from the FP6. 
  Establishment of technology platforms. 
4  To  enhance  the  supply  of  specific  management  and  legal 
skills: 
- Member  States  and  national  biotechnology  associations 
should  examine  the  opportunity  of  creating  self sustained 
networks  of  biotechnology  company  managers  at  the 
national level. 
- Member  States  and  the  Commission  should  promote 
collaboration between law schools, law firms and companies 
for the development of specific legal competence needed 
by biotechnology companies. 
This action has not triggered interest from the concerned audience. 
5a  To finalize a strong, harmonized and affordable European 
intellectual  property  protection  system  by  d Member  States 
urgently  transposing  into  national  laws  the  Directive 
98/44/EC  on  the  Legal  Protection  of  Biotechnological 
Inventions. 
All Member States have now implemented in their national laws Directive 98/44/EC
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5b  Council adopting the Community Patent Regulation. 
 
The Commission has launched on 16 January 2006 a broad consultation of all interested parties on the future patent 
policy in Europe. One of the main issues in the consultation concerns the Community patent but the consultation 
covers also issues such as basic principles of the patent system, the draft “European Patent Litigation Agreement” 
and  approximation  of  Member  States'  national  laws  and  mutual  recognition  of  Member  States'  patents.  The 
Commission has embarked on a wide ranging review of IPR policy as a whole and will propose concrete steps 
toward a modern and affordable framework in 2007. 
http://europa.eu.int/comm/internal_market/indprop/patent/consultation_en.htm 
5c  Member  States  and  the  Commission  clarifying  rules  on 
ownership  of  intellectual  property  stemming  from  public 
research and monitoring the effect of implementation of patent 
legislation on research and innovation. 
  An expert group of technology transfer and legal specialists has finalised in 2004 a report on “Management of 
Intellectual Property in publicly funded research organisations – towards European Guidelines” 
(http://europa.eu.int/comm/research/era/pdf/iprmanagementguidelines-report.pdf) 
A Commission study providing a detailed comparative analysis of the Intellectual Property Research (IPR) rules 
applicable to publicly funded research has been launched in December 2005. 
 
5d  encouraging  awareness  training  in  the  strategic  use  of  IPR 
during the entire research and innovation process and raising 
awareness among academics of 
The  commercial  potential  of  their  research,  encouraging 
entrepreneurship  and  movement  between  academia  and 
companies. 
  the BioBIZ project   entrepreneurship training, in particular in the New Member States and a brochure with "100 
Technology  Offers"  collected  from  results  of  EU  funded  R&D  project 
(http://www.cordis.europa.eu.int/lifescihealth/src/leaflet.htm) 
  a number of support actions to raise awareness for and provide training on IPR issue, such as the "ScanBalt IP 
Knowledge Network" project (http://www.scanbaltipkn.org/) 
 The EPIPAGRI project brings together major EU research and technology transfer organisations to collectively 
manage public intellectual property in Agricultural Biotechnologies 
5e   taking  steps  to  promote  international  dialogue  and  co-
operation with a view to work towards a level playing field with 
industrialized countries in patent protection on biotechnology 
inventions,  ensuring  an  effective  level  of  protection  for 
innovation in this field. 
Member States and the Commission took an active part in an OECD exercise to develop licensing guidelines for 
genetic  inventions.  On  23  February  2006,  the  OECD  Council  adopted  the  Recommendation,  which  presents 
Guidelines for the Licensing of Genetic Inventions.  
(C(2005)149/Rev1 http://www.oecd.org/document/26/0,2340,en_2649_34537_34317658_1_1_1_1,00.html) 
6a  The  Commission  should,  together  with  the  European 
Investment  Bank  (EIB)  and  the  European  Investment  Fund 
(EIF), strengthen the capital base for the 
biotechnology industry, by: 
 Seeking  to  stimulate  investments  in  research  and 
technological innovation via complementary financing on the 
basis of the co operation agreement signed in 
June 2001 between the Commission and the EIB group 
 the EIB's Innovation 2010 Initiative (i2i) aims to help increase the spending on research, development & innovation in 
Europe by providing 10 bn € in loans until 2010. More than 750 mn € in loans has been granted to the biotech & 
pharmaceutical sector.  
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6b  Seeking  to  stimulate  investments  in  business  incubators 
through the EIF Start Up Facility 
 
Capital from the European Commission that is allocated to the European Investment Fund (EIF) under 3 different 
programmes: 
–  The ETF Start up Facility which aims to invest in venture capital funds such as seed capital funds, business 
incubators, smaller or newly established funds, funds focused on specific industries or technologies and funds 
financing the exploitation of R&D results (i.e. funds linked to research centres and science parks); 
–  The EIF ERP Dachfonds was started jointly by Germany and the EIF to encourage venture capital providers to 
invest in German high technology firms, but also elsewhere in the EU. The 500 mn € fund is expected to raise 
an additional 1,7 bn € through commercial VC investments; 
–  A new Commission framework programme called the Competitiveness and Innovation Programme (CIP) will 
operate  from  2007.  It  brings together  several separate  programmes  and  aims  at strengthening  the  funding 
available to stimulate investments in research and technological innovation, especially in SMEs.  
6c  Studying  measures  to  support  technology  transfer 
mechanisms,  such  as  financing  of  patent  pools  or  other 
methods for patent exploitation. 
 
A “Technology Transfer Accelerator” was launched in 2006 after the Commission and the European Investment Fund 
(EIF) had carried out a feasibility study on a new type of risk capital and technology transfer investment vehicle. It 
aims to link different centres of excellence and universities in European countries. 
The Commission is also financing entrepreneurship training courses with particular focus on scientists in the New 
Member States. 
6d  Studying  measures  to  encourage  commercial  financing  of 
companies based on a medium term investment perspective. 
 
The EIB commissioned an external study in 2005 to find out how many European biotechnology companies are 
creditworthy, i.e. actually able to take debt for their product development. 
In  September  2005,  Commission  produced  “Best  practices  of  public  support  for  early stage  equity  finance”. 
(http://ec.europa.eu/enterprise/entrepreneurship/financing/docs/report_early-stage_equity_finance.pdf) 
An analysis of the European biotechnology industry’s competitiveness and access to finance has been made early 
2007. 
7  To strengthen the work of the Biotechnology and Finance 
Forum  by  the  inclusion  of  relevant  major  stakeholders  to 
provide advice into policy development in the field of capital 
supply. 
The Biotech and Finance Forum Advisory Board has been renewed and strengthened in 2002 to include all relevant 
biotech stakeholders in Europe (EuropaBio, EFB, EVCA, EIB, EIF, etc.), as well as representatives of major bio 
clusters, venture capital firms, consultants, etc. in the biotech sector. Recommendations of the Biotech and Finance 
Forum  working  group  delivered  in  2002  on  "Financing  of  biotech  companies"  have  led  the  EIB  to  provide  an 
additional €500 million to the EIF to provide further venture capital to innovative SMEs, including for later stage 
biotech investments. 
8a  The  Commission  will  support  creation  of  a  commercial 
biotechnology  web  portal  for  Europe  that  will  help  free 
access  to  information  and  networking  available  Internet 
platforms. 
The creation of a commercial biotechnology web portal for Europe is near completion  
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8b  The Commission will develop its newly created Commission 
web  site  to  provide  a  broad  entry  platform  into  the 
Commission’s work on biotechnology. 
The Commission's central biotech web site is operational 
http://ec.europa.eu/biotechnology/index_en.htm 
9a  Member States, their regions, the Commission and the EIB will 
support  stronger interregional cooperation, e.g. through a 
network  of  biotechnology  regions.  Crossborder  and 
interregional  co operation  can  receive  funding  from  the 
Interreg programs (notably Interreg IIIB and IIIC). 
The funding of a number of networking activities between biotechnology regions under has facilitated the liaison 
between  scientists  and  business,  improving  competitiveness:  In  particular,  EU  regional  policy's  INTERREG  III 
Community Initiative has facilitated co operation across regional and national borders on a variety of biotechnology 
projects, thus fostering the development of European biotechnology regions. The INTERREG III website provides 
both  information  on  INTERREG  and  links  to  the  websites  of  individual  programmes.  See 
http://ec.europa.eu/regional_policy/interreg3/index_en.htm 
 
9b   Member States, their regions, the Commission and the EIB will 
support networks of biotechnology clusters. In addition, the 
Commission  will  organize  a  European  competition  between 
Biotechnology Innovation clusters, to highlight their capability 
to develop a cluster with a focus of excellence in a specific 
scientific field. 
Networks  have  largely  focused  on  the  exchange  of  best  practise  on  regional  development  (i.e.  of  cluster 
management, incubator development, factors for attracting investment, etc). A few strategic initiatives (such as the 
"ScanBalt  Competence  Region")  aim  at  developing  common  strategies  and  activities  within  a  network  of 
bioregions/clusters with the objective of increasing overall competitiveness of the network 
10a  The  Commission  will  establish  a  competitiveness 
monitoring function and a contact network with Member 
States  ministries  with  responsibility  for  competitiveness 
in biotechnology. Monitoring should include impact on 
European competitiveness of legislation and policy measures. 
The contact network with Member States ministries with responsibility for competitiveness in biotechnology was set 
up in 2003. 
10b  The  Commission  will  establish  a  Competitiveness  in 
Biotechnology advisory 
Group with industry and academia to assist in identification of 
issues  affecting  European  competitiveness.  The  Group  will 
provide  input  into  the  Commission’s  regular  reports  on  Life 
Sciences and Biotechnology. 
The Competitiveness in Biotechnology  Advisory Group  with industry and academia was set up in 2003. It  has 
delivered three reports in 2004, 2005 and 2006 with relevant policy advice on competitiveness issues that have 
served as input for the Commission’s annual progress reports on the biotechnology strategy and action plan. 
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11  Transparency in the administrative process: 
d The Commission and Member States should aid applicants, 
especially  from  start up  companies  and  SME’s,  requesting 
approval through the regulatory process. 
Tthe  Commission  should  issue  a  guide  to  Community 
regulation for users and for entrepreneurs who have limited 
staff and expertise in the regulatory and legal fields. Such a 
guide  should  also  benefit  non EU  (e.g.  developing  world) 
applicants and the general public. 
With the 2005 reform of EMEA, the drug development process has been simplified, facilitating the role of SMEs. 
Together with the recently published User Guide to European Regulation in Biotechnology, transparency in the way 
this area is regulated has been improved. 
 The 2005 reform (Regulation (EC) No 726/2004 and Regulation (EC) No 2049/2005) of the European Medicines 
Agency (EMEA) has meant a number of improvements including reinforced scientific advice in the drug development 
process; the creation of an SME office to help SME applicants and new fee waivers and deferrals. 
 The  Commission  has  in  collaboration  with  a  consultant  developed  a  User  Guide  to  European  Regulation  in 
Biotechnology, which was finalised and published in 2006.  
(http://ec.europa.eu/enterprise/phabiocom/docs/user_guide_biotech.pdf) 
12   In collaboration with the involved actors, the Commission will 
benchmark  good  practices  in  clustering  biotech 
companies  and  in  the  work  of  business  incubators  and 
disseminate results. 
d The  Commission  will  establish  with  Member  States  a 
program  for  benchmarking  relevant  elements  of 
biotechnology policies, in addition to existing benchmarking 
structures. 
A  programme for  benchmarking of  biotechnology  policies  has  been  started  by  the  Commission.  A  first  round  of 
benchmarking  of  national  policies  took  place  in  2004  in  close  collaboration  between  the  Commission  and  MS 
governments and was published in 2005. 
13a   The  Commission  will  propose  a framework  for  a  process  of 
dialogue and follow-up with stakeholders as a result of the 
European  strategy  for  life  sciences  and  biotechnology.  The 
framework will notably include a broadly based Stakeholders’ 
Forum. 
The Commission has organised various scientific meetings and workshops to raise awareness for the state of the 
art and existing challenges regarding measurements in life sciences and biotechnology  
 
13b  the  Commission  will  promote  awareness  of  key  scientific 
paradigms  underlying  regulatory  oversight,  within  their 
respective fields, the European Food Safety Authority and 
the European Agency for the Evaluation of the Medicinal 
Products  will  play  an  important  role  in  general  risk 
communication 
 
The Commission has adopted a series of actions in its orientation debate of 12 April 2006. The Commission will 
discuss its proposals with the Member States in the Council, and with EFSA, in the coming months with the objective 
of building greater consensus and transparency in this area of Community policy. 
The Commission has created an advisory group on the food chain and animal and plant health. (Commission 
Decision 2004/613/EC of 6 August 2004) that ix consulted on health and consumer's protection work programmes 
and measures  in the  areas  of  food  safety,  labelling,  human  nutrition,  animal  health  and  welfare  and  plants  and 
pesticides.   
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13c  the  Commission  encourage  public  debates  on 
biotechnology between scientists, industry and civil society 
 
In  the  field  of  Community  research  and  development  policies,  the  Commission  has  developed  a  number  of 
activities in the field of governance, notably regarding the participation of civil society to decision making processes, 
the collection and use of expertise and scientific advice: 
 Civil Society Organization and NGOs increasing participation in the advisory groups for the implementation of the 
various thematic priorities under Research FPs. (http://europa.eu/press_room/presspacks/sustdev/index_en.htm) 
 In order to communicate developments in Life Sciences and biotechnology more widely, the Biosociety web site 
was created on the Europa website: http://ec.europa.eu/research/biosociety/index_en.htm 
 Gender equality in the communication of research policy objectives and results is a key objective of EU’s research 
policy. 
 initiatives have been taken to involve for example consumer and patient organisations in research projects from 
the very beginning  
 Specific projects regarding the process of governance were supported, addressing issues of scientific advice, risk 
governance and participation of civil society, notably in the field of GMOs, stem cells, etc. 
http://ec.europa.eu/research/science-society/page_en.cfm?id=3132 
14  The Commission will 
-Strengthen and focus Community support for research into 
socio-economic  and  ethical  issues  and  dissemination  of 
results,  including  criteria  for  assessing  the  benefits  of  using 
biotechnology  in  agrifood  production,  to  facilitate  future 
reporting and to provide a good basis for societal decisions on 
the application of biotechnology and life sciences. d program 
research support to a more systematic 
Mapping of benefits and disadvantages/risks which should 
include a strong component for dissemination of information 
and debate.  
-Ensure that ethical, legal and social implications are taken into 
account  at  the  earliest  possible  stages  of  Community 
supported research by means of 
Funding bioethics research and of providing an ethical review 
of research proposals received. 
the Commission has taken a number of actions, under FP6 including: 
–  Defining  an  ethical  framework  and  ethical  standards  for  FP6  http://ec.europa.eu/research/science-
society/page_en.cfm?id=3199  
–  Reinforcement of the ethical review of project proposals that raise sensitive ethical issues or where ethical 
issues have not been properly addressed as part of the funding evaluation process, which is carried out by 
independent external experts. 
–  Encouraging the participation of social scientists and ethicists in research projects as well as integration of the 
analyses of the ethical, legal and social aspects into research projects funded under Priority 1 and 5  
–  Encouraging  participation  of stakeholders  including  NGOs  in  research  projects  and  dialogue  with the  wider 
public communication in the research strategy; 
–  Supporting specific actions to promote the debate on ethical, legal, social and wider cultural aspects of Life 
Sciences  and  Biotechnology,  as  well  as  monitoring  and  evaluating  consequences 
http://ec.europa.eu/research/science-society/page_en.cfm?id=3120 
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15  The Commission will 
-Propose  to  enhance  the  role  of  the  European  Group  on 
Ethics  
-Launch  a  separate  consultation  of  the  other  Community 
institutions  on  possible  structural  and  procedural 
improvements  promote  collaboration  between  Community, 
national and local levels by promoting networking of national 
and local ethical bodies and elected representatives organize 
a  network  of  academic  and  professional  experts  for  ad hoc 
advice on specific socioeconomic aspects. 
A Forum of National Ethics Councils (NEC Forum) established in 2003 involves now all 25  Member States. It 
consists of the chairpersons and the secretaries of the national ethics councils. 
(http://ec.europa.eu/research/science-society/page_en.cfm?id=3161) 
16  The Commission 
-Will develop, jointly with the European Parliament, outreach 
measures to inform about the analysis ethical issues at the 
EU level. 
 
-Will  work  with public and private partners, to identify areas 
where  it  is  possible  to  establish  consensus  on  ethical 
guidelines/standards  or  best  practice.  Areas  might  include 
stem  cell  research,  biobanks,  xenotransplantation,  genetic 
testing and use of animals in research. Such guidelines could, 
when appropriate, take the form of self regulatory initiatives in 
the scientific community and industry. 
The Commission is closely following the regulatory developments in Member States regarding biobanks, stem cell 
research and genetic testing (http://ec.europa.eu/research/biosociety/bioethics/documents_en.htm).  
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17  To develop research and pilot projects to clarify the need, and 
possible  options,  for  agronomic  and  other  measures  to 
ensure the viability of conventional and organic farming 
and their sustainable  co-existence  with genetically modified 
crops. 
 To  launch  a  new  action  program  for  the  conservation, 
characterization, collection and utilization of genetic resources 
in agriculture in the Community. 
The Commission continued to assess national co existence measures that were notified to the Commission under 
the procedure of Directive 98/34/EC of the European Parliament and of the Council of 22 June 1998 laying down a 
procedure for the provision of information in the field of technical standards and regulations 
In March 2006 the Commission adopted a report on the implementation of national measures on the co existence of 
genetically modified crops with conventional and organic farming (COM(2006)104 final).  
the Commission has organised jointly with the Austrian Presidency of the Council the conference "Co existence of 
genetically modified, conventional and organic crops – freedom of choice" that allowed an exchange of information 
and positions on co existence among policy makers, scientists, and a broad range of stakeholders, such as farmers 
and  consumers  associations,  NGOs,  seed  producers,  importers,  food  and  feed  processors,  etc. 
(http://ec.europa.eu/agriculture/events/vienna2006/index_en.htm) 
In 2006 the Council adopted conclusions on co existence, which include general considerations on this issue as well 
as proposals for future actions by the Commission. 
The coordination network on co existence, COEX NET, has been created to enhance the exchange of information 
among Member States on regulatory approaches and practical experiences with co existence.  
New case studies on the co existence of GM and non GM crops in European agriculture were published by the 
Commission in January 2006 (http://www.jrc.es/home/pages/detail.cfm?prs=1345) 
The Commission has developed 9 new sets of certified reference materials for the identification and quantification of 
genetically modified crops.  
Concerning the conservation of genetic resources in agriculture, two calls for proposals were launched on 26 July 
2005 and on 28 April 2006. Following the two calls for proposals, 17 actions were selected for co funding, and the 
corresponding grant agreements, involving 17 coordinators and 162 partners in 25 Member States and 12 countries 
outside the EU have been signed. 
 
18  To speed up the adoption of the three legislative proposals, 
revising the Community pharmaceutical legislation 
 
EMEA has reinforced and made easier scientific advice in the 2004 revision of the Pharmaceutical legislation. The 
EMEA  has  also  put  in  place  a  ‘New  Framework  for  Scientific  Advice  & Protocol  Assistance’,  which  introduces 
significant changes to the way the  Agency provides scientific advice on the research and development of new 
medicines .http://www.emea.eu.int/pdfs/human/press/pr/16597406en.pdf 
An accelerated procedure has been introduced in the 2005 revision of the Pharmaceutical legislation. When an 
application is submitted for a medicinal product that is of major public health interest and in particular from the 
viewpoint of therapeutic innovation, the assessment time may be reduced from 210 to 150 days.  
a Regulation on the conditional marketing authorisation for medicinal products for human use falling within the scope 
of the 'centralised procedure' (e.g. biotech products) has been adopted in March 2006 
http://ec.europa.eu/enterprise/pharmaceuticals/eudralex/vol-1/reg_2006_507/reg_2006_507_en.pdf  
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19  To  speed  up  the  adoption  of  the  two  following  legislative 
proposals: 
-  Proposal for a European Parliament and Council Regulation 
on  Traceability  and  Labelling  of  Genetically  Modified 
Organisms  and  Traceability  of  Food  and  Feed  derived 
from Genetically Modified Organism 
  Proposal for a European Parliament and Council Regulation 
on Genetically Modified Food and Feed. 
In 2006 the Commission issued to the Council and the European Parliament reports on the implementation of 
Regulations (EC) No. 1829/2003, 1830/2003 and Directive 2001/18/EC. 
 
20  To finalize the legislative proposals which have already been 
announced,  such  as  initiatives  concerning  GM  plant 
propagating  material,  environmental  liability  and  the 
implementation of the Biosafety protocol. 
The  Biosafety  Protocol  has  been  ratified  and  implemented  (http://www.biodiv.org/biosafety/default.aspx),  lastly 
through  Regulation  (EC)  No  1946/2003  of  15  July  2003  on  transboundary  movements  of  genetically  modified 
organisms.  Directive  2004/35/CE  of  21  April  2004  on  environmental  liability  with  regard  to  the  prevention  and 
remedying  of  environmental  damage  has  also  been  adopted.  There  is  no  planned  legislation  on  GM  plant 
propagating material on top of GMO legislation. 
21  To ensure that legislation is enforced in a uniform and effective 
way  across  the  Community  and  to  adopt  appropriate 
implementing measures required under relevant legislation, 
including the necessary guidance for detection and sampling 
methodology 
 To  establish  a  molecular  register  that  is  accessible  to  the 
public,  containing  information  on  events  of  genetic 
modification. 
 
An updated list of the implementing measure of Directive 2001/18/EC and Regulation (EC) No. 1830/2003 has been 
published  (http://ec.europa.eu/environment/biotechnology/index_en.htm).  Reports  on  the  implementation  of  the 
above mentioned legislation are published on a regular basis. Aside from this strictly regulatory approach, detailed 
information  has  been  provided  by  the  JRC  on  reference  material  and  activities  of  the  Community  Reference 
Laboratory (http://gmo-crl.jrc.it/). 
All  Member  States  apart  from  France  have  notified  to  the  Commission  their  transposition  acts  of  Directive 
2001/18/EC. The conformity check on these acts is currently ongoing.  
The Commission is also checking the legality of the co existence measures of Member States as notified under the 
procedure of Directive 98/34/EC. 
In addition to the regulatory work on GM Food and Feed (Regulation 1829/2003) and on traceability and labelling 
(Regulation  1830/2003),  the  Commission  has  issued  Commission  Recommendation  2004/787/EC  of  4  October 
2004 on technical guidance for sampling and detection of genetically modified organisms and material produced 
from genetically modified organisms as or in products in the context of Regulation 1830/2003 
The uniform implementation and monitoring of the EU legislation on GMOs has been supported by the development, 
production and distribution of new generations of matrix reference materials which are widely used by Member State 
laboratories and worldwide for the calibration and  quality assurance to fulfil regulations EC 1829/2003 and EC 
1830/2003.  Commission  Regulation  378/2005  on  detailed  rules  for  the  implementation  of  Regulation  (EC)  No 
1831/2003 as regards the duties and tasks of the Community Reference Laboratory concerning applications for 
authorisations of feed additives, provides guidance on the operational procedures of the Community Reference 
Laboratory (CRL) operated by DG JRC (http://gmo-crl.jrc.it/).  
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22   To report on the feasibility of options to improve further the 
consistency  and  efficiency  of  the  framework  for 
authorizing  GMO’s  for  deliberate  release  into  the 
environment, including a centralized Community authorization 
procedure. 
The so called "one door one key" procedure under Regulation 1829/2003 has entered into force. The Commission will 
issue a report on the implementation of Directive 2001/18/EC in 2007, where it will make reference to the prospects of 
a centralised Community authorisation procedure. 
23   To support the development of methodologies for monitoring 
potential  long-term  environmental  impacts  of  GMO’s  as 
compared with conventional crops, and methodologies for the 
monitoring of effects of genetically modified food and feed 
as  compared  with  conventional  food  and  feed.  With  the 
establishment of the European Food Safety Authority, the work 
on the early identification of emerging risks will be reinforced 
and upgraded. 
Under FP6 several research projects have started on GM traceability and safety of which the most important ones 
are SAFEFOODS and NOFORISK. On a regular base EFSA and Commission services are informed about the 
progress of these projects. 
EFSA has established a self tasking working group to study requirements for Post Market Environmental Monitoring 
(PMEM WG) in order to produce guidance for both applicants and regulatory authorities. Based on its mandate, the 
PMEM WG initiated a series of consultation workshops with different stakeholders (applicants, environmental NGOs 
and scientific institutes, experts from Member States) to establish a rationale and general framework for General 
Surveillance as a component of Post Market Environmental Monitoring. 
 
24  The  Commission  should continue  to  play  a  leading  role  in 
developing  international  guidelines,  standards  and 
recommendations in relevant sectors, based on international 
scientific consensus and, in particular, push for the 
Development  of  a  consistent,  science based,  focused, 
transparent,  inclusive  and  integrated  international  system 
dealing with food safety issues. 
 
The Commission actively participates in the meetings of the Codex Task Force on Biotechnology. , which has 
produced  guidelines  for  the  food  safety  assessment  of  plants  and  micro organisms  derived  from  modern 
biotechnology. Work is ongoing in order to develop a similar guidance document for the food safety assessment of 
recombinant DNA animals and plants modified for nutritional or health benefit. 
The  Commission  has  contributed  significantly  to  the  development  of  international  guidelines  and  standards  for 
bioanalysis  with  a  lead  technical  role  in  a  number  of  international  bodies  that  are  responsible  for  setting  the 
standards  such  as  CEN,  the  European  Committee  for  Standardisation;  ISO,  the  International  Organization  for 
Standardization and Codex Alimentarius. 
The Commission chairs the European Network of GMO Laboratories, which is a consortium of all 25 EU enforcement 
laboratories (plus Norway, Switzerland). In addition to providing support to the Community Reference Laboratory for 
GM Food and Feed, this network contributes to the harmonisation and standardisation of GMO detection protocols. 
 
25a  The  Commission  will  in  cooperation  with  Member  States 
support  the  redefining  of  national  research  towards  an 
appropriate  mix  of  traditional  techniques  and  new 
technologies,  based  on  priorities  developed  with  local 
farmers. 
 
The Commission has played a key role in the elaboration and entry into force of the Cartagena Protocol on Biosafety 
(http://www.biodiv.org/biosafety/default.aspx
 ), and continues to be one of the driving forces in its further development 
(for example in the field of identification of GMOs or in reflection on possible liability regimes).  
EN  87     EN 
N°  DESCRIPTION  ACHIEVEMENTS 
25b  The  Commission  will  in  cooperation  with  Member  States 
support the establishment of effective research partnerships 
between  public  and  private  research  organizations  in 
developing  countries  and  in  the  EU,  and  the  adequate 
capacity  and  infrastructure  for  developing  countries  to 
enter into such partnerships, in accordance with international 
commitments under the Conventions. 
 
The  INCO  programme  has  launched  two  calls  aiming  at  promoting  international  research  with  the  Developing 
Countries on "Bio diverse, bio safe and value added crops" which is a research area of the 'food security' priority. 
Calls were also launched on “Health of livestock populations” largely focused on the livestock health protection 
through the development and use of diagnostic tools and vaccines. 
The Commission is also engaged in the selection of research proposals from the CGIAR and in particular of co 
funding the Generation Challenge Programme. This programme aims at unlocking the genetic diversity of crops for 
the resource poor (http://www.cgiar.org/). 
A number of projects involving partners from developing and "emerging" countries have been implemented under 
the thematic priority "Food quality and safety". 
 
25c  The  Commission  will  in  cooperation  with  Member  States 
support  sub-regional,  regional  and  international 
organizations,  in  particular  the  International  Agricultural 
Research Centers. 
 
The Commission has supported the development of research partnerships at national, sub regional, regional and at 
global level through the implementation of Competitive Regional Research Programmes and through the CGIAR 
Global Challenge Programmes, in collaboration with Member States through EIARD.  
EC provides support to ARD at regional level, through EDF regional envelopes. Examples include the support given 
to  sub  regional  organisations  (SRO)  such  as  ASARECA for  East  and  Central  Africa,  CORAF  for Western  and 
Central Africa and SADC for Southern Africa. 
26 
(a),(b), 
(c) 
The  Commission  and  the  Member  States  will  support  the 
conservation and sustainable use of genetic resources in 
developing  countries  and  their  equitablesharing  of  benefits 
arising from their use by: 
    supporting  the  development  and  enforcement  of  effective 
measures to conserve, to use sustainably and to provide 
access to genetic resources and 
Traditional  knowledge,  as  well  as  to  share  equitably  the 
benefit  arising  from  them,  including  income  generated  by 
intellectual property protection. Support for local communities 
is  vital  to  conserve  indigenous  knowledge  and  genetic 
resources. 
-  supporting the participation of delegates from developing 
countries  in  the  negotiations  of  relevant  International 
Conventions. 
-   supporting  measures  to  promote  greater  regional  co-
ordination  in  legislation  to  minimize  disparities  in  access, 
benefits  and  also  trade  in  products  derived  from  genetic 
resources, in accordance with international commitments. 
At the WTO, the Commission actively participated in the review of Article 27.3.b of the TRIPs and examination of the 
relationship between the TRIPS Agreement and the CBD. In 2002 the Commission presented a submission that was 
well received by developing countries (http://www.wto.org/english/tratop_e/trips_e/trips_e.htm). 
In the CBD, the Commission and the Member States were active negotiators of the Bonn Guidelines on Access and 
Benefit Sharing adopted in 2002. The Commission is actively engaged in negotiations of an International Regime on 
Access  and  Benefit sharing.  The  negotiations  are  supposed  to  be  completed  at  the  latest  in  2010. 
(http://www.biodiv.org/default.shtml). 
 
At WIPO, in 2004 the EU submitted a proposal that if accepted would introduce a mandatory requirement to disclose 
the country of origin or source of genetic resources in patent applications. (http://www.wipo.int/portal/index.html.en). 
 
At the FAO, the European Community and 22 Member States have ratified the International Treaty on Plant Genetic 
Resources. The Commission and the Member States have been active negotiators in its implementation, including 
the recently adopted standard Material Transfer Agreement (http://www.fao.org/).  
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27  The Commission and the Member States should work with the 
international  community  to  concretize  the  commitment  to 
research to combat HIV/AIDS, 
Malaria, TB and other main poverty-related diseases and 
also  identify  effective  measures  to  support  developing 
countries  in  establishing  the  structures  needed  to  deploy  a 
health policy. 
 
Under FP6, poverty related diseases section, numerous projects focused on developing promising and innovative 
interventions (vaccines, drugs and microbicides) against HIV/AIDS, TB and malaria have been funded. 
The European and Developing Countries Clinical Trials Partnership (EDCTP) initiative was officially launched at the 
beginning of 2004 and an African Office of the EDCTP was opened in Cape Town (South Africa) in July 2004. 
(http://www.edctp.org/). 
In 2004, the operational basis for the networking and coordination of National Programmes was set up through the 
establishment of the European Network of National programmes (ENNP). 
A project supporting the construction of new infrastructures for studying highly contagious diseases (“EUTRICOD”) 
including viral hemorrhagic fevers was initiated involving the Republic of Ghana and Uganda.  
During 2004, additional funds were also made available to support North/South collaborative research projects on 
further “neglected tropical diseases”, on child survival, on reproductive health and on “health systems research”. 
A number of initiatives on capacity building on ethics in developing and emerging countries are being supported by 
the  Commission.  Four  African  institutions  together  with  two  European  organizations  and  the  World  Health 
Organization have come together to foster networking of medical research ethics committees in Africa: Networking 
for Ethics on Biomedical Research in Africa (NEBRA). As a first step, the project will identify existing ethics review 
capacity and needs in 15 African countries. A series of training and capacity building workshops on ethical review of 
clinical trials have been launched in several developing countries through the project “European and Developing 
Countries  Ethics  Partnership”.  The  European  Group  on  Ethics  issued  Opinion  (N°17)  on  the  ethics  of  clinical 
research in developing countries (http://ec.europa.eu/european_group_ethics/docs/avis17_en.pdf). 
28 
(a),(b),
(c), 
(d),(e) 
 
To support: 
The safe and effective use of modern biotechnologies in 
developing countries, based on their autonomous choice and 
on their national development strategies. 
Measures to increase the capacity of developing countries to 
assess  and  manage  risk  for  man  and  the  environment,  under 
conditions prevailing in the country.  
The  development  of  appropriate  administrative,  legislative  and 
regulatory measures in the developing countries, for the proper 
implementation of the Cartagena Protocol. 
That  international  research  on  social,  economical  and 
environmental  impacts  are  effectively  adapted to  take  into 
account conditions prevailing in developing countries and that 
the  findings  are  subsequently  disseminated  to  them  in  an 
appropriate format. 
That  the  international  regulatory  requirements  remain 
manageable  by  developing countries, so  as  not  to  impede their 
trade and production prospects. 
The Commission has published in March 2005 “Guidelines for Green, White, Blue and Red Biotechnologies”, on the 
potential future of “biotechnologies” in the Developing Countries. As a follow up of this study, Commission is working 
on a Biotech policy document for the Developing Countries. 
With  support  from  international  Community,  West  African  countries  and  Regional  Economic  Communities 
(ECOWAS, WAEMU) have identified their needs and gaps to deal with biotechnologies / challenges and appreciate 
opportunities. The Commission will co finance WAEMU programme with World Bank, Global Environment Fund and 
Member States. 
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29a  The Commission will enhance: 
the general foresight function across Commission services, 
and  in  particular  its  role  in  technology  foresight  through  its 
Institute for Prospective Technological Studies (IPTS), for early 
identification of newly emerging issues and of elements of a 
policy response 
 
The Commission has adopted the "Bio4EU" study http://bio4eu.jrc.es/ 
The Commission has engaged in substantial prospective work on: 
  Genetic testing; 
  Biobanks; 
  Pharmacogenetics; 
  Other emerging issues such as human tissues or nano biotechnology. 
29b  Its monitoring and review function to assess 
  the relevance, coherence and effectiveness of legislation and 
policy 
   the  extent  to  which  policy  objectives  are  achieved  and 
legislation enforced 
  the societal and economic impact of legislation and policy 
measures  In  pursuit  of  these  objectives  and  to  further 
strengthen policy coherence, the Commission 
The Commission has already published three progress reports on the Life Sciences and Biotechnology Strategy, 
which have provided for a thorough reporting on the implementation of the Strategy. Furthermore, several relevant 
reports from the Commission are providing a regular update on  the implementation of the relevant Community 
legislation (such as the reports on Directive 2001/18/EC or Regulation 1829/2003). In addition to this, the College is 
holding regular orientation debates on Biotechnology, which are an opportunity to reassess the pertinence of the 
legislation and policy orientations, which have so far always been confirmed. 
(http://ec.europa.eu/biotechnology/progress_reports_en.htm) 
29c  Will  reinforce  continuous  co ordination  between  its  services 
and  calls  upon  Member  States  to  also  provide  enhanced 
foresight/review  functions  and  a  coordinated  interface  for  a 
dialogue on these issues. 
Establishment  in  2003  of  the  "Biotechnology  Steering  Committee",  an  internal  coordination  group  involving 
Commission's cabinets and services involved in the field of Life Sciences and Biotechnology. 
30  The  Commission  will  present  a  regular  Report  on  Life 
Sciences  and  Biotechnology  to  monitor  progress  and 
indicate  possible  specific  proposals  to  ensure  policy  and 
legislative coherence. The report will draw on the conclusions 
under actions 10 and 29. 
Progress reports have so far been produced on a yearly basis. 
(http://ec.europa.eu/biotechnology/progress_reports_en.htm) 
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Annex III: Summary of recommendations from the contact network with Member 
States’ ministries with responsibility for competitiveness in biotechnology 2006 
The network’s report was prepared for the use of the European Commission, but do not 
necessarily represent the Commission's official position. 
The network has developed concrete recommendations in four thematic fields:  
–  Regulation; 
–  Access to finance; 
–  Plant science and the knowledge-based bio economy; 
–  Communication with the public. 
(1)  Regulation 
–  Study ways to improve the harmonisation of the implementation of EU 
legislation; 
–  Identify areas of inconsistent national implementation of EU legislation; 
–  Identify best practices in national follow-up of the effects and correct 
implementation of legislation, e.g. a monitoring body for the national 
impact  of  Directive  98/44/EC  on  the  legal  protection  of 
biotechnological inventions;  
–  Compare the stringency of legislation in the EU and in other countries 
(benchmark impact and costs); 
–  Consider using Regulation instead of Directive (where the benefits of 
harmonization are greater than the advantages of subsidiarity; for future 
legislation); 
–  Identify  what  legislation  could  be  considered  under  a  regulatory 
simplification agenda. Competitiveness Network to draw up a list of 
proposals; 
–  Consider  setting  up  a  Task  Force  on  Regulatory  Simplification,  to 
enable  a  discussion  between  Member  States,  industry  and  the 
Commission; 
(2)  Access to finance 
(a)  Making companies more attractive to investors: 
–  Fiscal  incentives  may  increase  R&D  expenditure  and  encourage 
employment by reducing the tax wedge; 
–  Promote the Young Innovative Company scheme across Europe;  
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–  Explain and promote the possibilities offered by the new EC framework 
for state aid to R&D&I; 
–  Study  the  possibility  of  introducing  advantages  for  SMEs  at  the 
European Patent Office; 
–  Argue for an EU agreement on an effective Community Patent; 
–  Increase  critical  mass  of  early-stage  companies  (e.g.  business  plan, 
funding, product pipeline, management skills) by:  
•  improving  support  services  and  advice  from  seed  capital 
schemes; 
•  encouraging  the  creation  of  technological  incubators  for 
launching high-tech enterprises; 
•  Identifying best practices in national business assistance, e.g. a 
one-stop-shop for start-ups which provides business advice, co-
financing, and an interface with other investors. 
(b)  Increasing the investment capital available for European biotech companies: 
–  Increase  public  funding  and  leverage  private  funding  through  public 
funding; 
–  Increase spending of institutional investors in the biotech companies; 
–  Encourage the creation of a pan-European seed fund; 
–  Encourage the creation of a European Incubator Capital Fund; 
–  Propose fiscal incentives for risk capital investments. 
(3)  Plant science and the knowledge-based bio economy 
–  Strive for coherence of all policies impacting on the knowledge-based 
bio economy (KBBE); integration and coordination of activities; 
–  A limiting factor is the absence of scientifically validated measurement 
techniques  for  the  impact  of  bio-based  products.  Support  to  the 
development of measurement techniques is necessary; 
–  Support the development of a harmonised statistical approach, e.g. by 
OECD,  to  measure  e.g.  R&D  investments,  employment,  innovation, 
products, and the value of the KBBE; 
–  Support  innovation  in  plant  and  industrial  biotechnology;  coordinate 
national and EU finance instruments; 
–  Support  the  setting  up  of  demonstration/pilot  projects  and  integrated 
bio-refineries, which are flexible installations at pilot or industrial scale  
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for the production of biofuels and other biomaterials, based on a variety 
of  feedstock.  Giving  support  to  demonstration  projects  is  important 
since SMEs active in this area do not have the resources to set up a real 
proof-of-concept. It would also help to test logistical solutions and form 
value chain coalitions between actors; 
–  Support of the entire KBBE value chain: increase and ensure the supply 
raw  materials  at  a  competitive  price,  stimulate  users  to  switch  to 
sustainable bio-processes, stimulate the demand for bio-based products 
by considering specific labelling of bio-based products and by adapting 
procurement practices, and consider a fast-track regulatory procedures 
for eco-friendly products; 
–  Ensure access to finance for industrial biotechnology and particularly 
for SMEs (industrial biotech are not working under the same conditions 
as healthcare biotech); 
–  Develop a communication strategy; raise political and public awareness 
about the KBBE. 
(4)  Communication with the public 
Communication may offer valuable support in order to:  
–  create transparency; 
–  open or continue a dialogue with the public; 
–  open or continue an inter-institutional dialogue; 
–  accompany the mid-term review of the biotechnology strategy; 
–  Contribute to policy coherence. 
Further observations of the role of communication, which: 
–  is  a  necessary  element  of  successful  policy  making,  is  vital  for 
marketing and must be science-based; 
–  should be carefully tailored to meet specific goals and target groups; 
–  should  use  all  pathways  (TV,  web  sites,  publications,  competitions, 
events etc); 
–  should make adequate use of multipliers such as journalists, teachers, 
scientists, members of political parties or parliament, NGOs etc; 
–  needs a clear strategy to support future biotech products and markets; 
–  Is a common, but shared responsibility of every stakeholder, where the 
scientific  community  and  industry  should  contribute  to  a  balanced 
debate  by  demonstrating  the  benefits  of  scientific  discoveries  and  
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innovation,  and  where  policy  makers  should  explain  the  regulatory 
framework at both national, EU and international level. 